Both groups deserve a straight answer. So let me give you the one I wish every patient walked in already knowing — because the truth about POTS is genuinely two things at once, and you need both halves.

It is real, badly under-recognized, and physically debilitating for the people who have it. And it is also over-attributed — a label increasingly stretched over symptoms that sometimes have a different, and often more fixable, cause. Understanding the difference is how you get actual help instead of a wrong turn.

What POTS actually is

POTS stands for Postural Orthostatic Tachycardia Syndrome, and once you understand the physiology, the whole thing makes sense.

Every time you stand up, gravity pulls roughly a pint of your blood downward into your legs and belly. In a healthy body, the autonomic nervous system — the automatic controller of heart rate, blood pressure, and blood vessel tone — reacts in seconds: it tightens the blood vessels in your lower body to push blood back up, and nudges your heart rate up a little to keep your brain supplied.

In POTS, that first step fails. The blood vessels don’t clamp down the way they should, so blood keeps pooling below. To compensate and keep blood reaching your brain, your heart does the only thing left to it: it races. Not a little — a lot. And critically, your blood pressure usually does not crash. That combination — a heart pounding hard on standing, without a big blood-pressure drop — is the signature of POTS.

That’s why the symptoms are what they are: lightheadedness and near-fainting when upright, a racing or pounding heart, crushing fatigue, exercise intolerance, and the “brain fog” that makes it hard to think clearly. Many patients also have nausea, bloating, headaches, poor sleep, and trouble regulating temperature. It can touch nearly every system in the body — even though the heart, gut, and nerves usually look structurally normal on standard tests. That normalcy is exactly why so many patients get told nothing is wrong, when something very much is.

Why it exploded — and who it hits

POTS overwhelmingly affects women — about 90% of cases — with onset most often between ages 13 and 29. It’s estimated to affect somewhere between 1 in 1,000 and 1 in 100 Americans, and that number has almost certainly climbed.

The reason is infection. In a large share of cases, POTS begins within about three months of a viral illness — and COVID changed everything here. Long COVID drove a real, documented surge; by some estimates, nearly a third of people with severe long COVID meet the criteria for POTS. Epstein-Barr, influenza, and other infections can trigger it too, as can major physical stressors like surgery, trauma, or pregnancy. It also travels with certain other conditions — joint hypermobility (including Ehlers-Danlos syndrome), mast cell issues, and migraines.

I want to say one thing as plainly as I can, because too many women have been told the opposite: POTS is not anxiety, and it is not “all in your head.” It is a measurable malfunction of the autonomic nervous system. Living with an uncontrollable racing heart and bone-deep fatigue certainly causes stress — but that stress is the consequence, not the cause. The average patient waits around two years for a diagnosis, often after being brushed off repeatedly. That delay is a failure of medicine, not of the patient.

So how do you actually know if you have it?

Here is the part that answers the question I get most — and it’s more objective and more reassuring than most people expect. POTS is not a vague feeling. It has clear, measurable diagnostic criteria, and the core test is simple enough to start at home.

The four things that define it:

First, chronic symptoms of orthostatic intolerance — worse when upright, better when lying down — lasting at least three months. Second, a sustained heart-rate rise of at least 30 beats per minute within ten minutes of standing (or at least 40 bpm if you’re between 12 and 19). Third, no significant drop in blood pressure when you stand — if your pressure crashes, that’s a different condition. And fourth, no other cause that better explains it.

The practical version, the “stand test,” is something any clinic can do and you can even trial yourself: lie down quietly for at least five minutes and record your heart rate and blood pressure. Then stand, and record both again at intervals for up to ten minutes, noting how you feel. A reproducible jump of 30-plus beats per minute with real symptoms — and no big pressure drop — is the finding that matters.

When it deserves a workup — and when the answer is somewhere else

This is where honesty matters most, and where I try to help my patients rather than just label them.

A racing heart when you stand up is a real symptom. But it is not automatically POTS. Several common, often more treatable things produce the exact same feeling, and a good doctor rules them out before settling on POTS:

Simple deconditioning — a loss of cardiovascular fitness after illness or a long stretch of inactivity — can cause a big heart-rate jump on standing that mimics POTS closely. Dehydration and low blood volume do it too. So do thyroid disease, anemia, adrenal problems, and certain medications — stimulants, some antidepressants, diuretics. Occasionally a genuine heart, lung, or rare hormonal condition is hiding underneath.

So the honest answer to “does this deserve a workup” is: if you have three-plus months of orthostatic symptoms and a real heart-rate rise on standing, yes — get the simple stand test, an ECG, and basic blood work (blood count, electrolytes, thyroid). That’s low-cost, low-risk, and it either confirms POTS or, just as valuably, points you toward the thing that’s actually causing your symptoms. What you don’t need, in most cases, is an immediate cascade of expensive specialist testing — tilt-table studies, Holter monitors, echocardiograms are for atypical or complex cases, not the starting point.

The goal isn’t to collect a fashionable diagnosis. It’s to find the true reason your body feels the way it does. Sometimes that’s POTS. Sometimes it’s something else entirely — and finding that is the win, because it may be more fixable than POTS is.

When — and how — it’s treated

Here’s the encouraging part: for most people who truly have POTS, the first and most effective treatments aren’t drugs at all. They deserve to be tried first, and many patients improve substantially on them alone.

The foundation is expanding your blood volume: more fluids across the day, and — this surprises people — significantly more salt, because salt helps your body hold onto that fluid and fill the tank the pooling keeps draining. This is done with a doctor’s guidance and individualized, since it’s not right for everyone (especially with high blood pressure or kidney issues). Next, lower-body compression garments — ideally waist-high — physically stop the blood from pooling. Avoiding triggers helps: heat, prolonged standing, big heavy meals, alcohol, dehydration.

And then the one that’s hardest but matters most: structured, gradual exercise — started lying down or seated (a recumbent bike, rowing, swimming) to take gravity out of the equation, then slowly progressed over weeks. Formal programs exist for exactly this. The catch, and it’s important: pacing is everything. Pushing too hard, especially if you have overlapping post-viral fatigue, can trigger a crash that sets you back. Slow and consistent beats aggressive and inconsistent, every time.

Medications come in only when these measures aren’t enough to let you function — and they’re aimed at symptoms, not a cure. Options a specialist may use include drugs to slow the racing heart, drugs to tighten blood vessels, or drugs to help retain fluid. Started low, adjusted slowly. No pill cures POTS; the honest goal is to restore your life, measured by what you can do — not by chasing a perfect heart-rate number.

What I want you to take from this

If you’re one of the women wondering whether this is you: you are not imagining your symptoms, and you’re right to want answers. Do the simple stand test. Get the basic bloodwork. Start the fluids, salt, and compression now, while you seek care — they’re safe, and they help many people before any diagnosis is even confirmed. And find a clinician who takes you seriously enough to do the honest workup: to confirm POTS if it’s there, and to keep looking if it isn’t.

Because being taken seriously cuts both ways. It means never being dismissed with “it’s just anxiety.” And it also means not being handed a label that stops the search before the real cause is found. You deserve the truth about your own body — and for most people, with the right approach, real improvement is genuinely possible.

I write clear, honest explanations of the conditions my patients actually struggle with — the science, the nuance, and the practical steps, without hype or dismissal. If you want medicine explained straight, come join me.

Blessings,

Afshine “Ash” Emrani, M.D., F.A.C.C. Assistant Clinical Professor, UCLA David Geffen School of Medicine

🏅 Castle-Connolly Nationwide Top Doctor (Since 2008) 🌟 Los Angeles Magazine Super Doctor (Since 2010) 🇺🇸 LA Style Magazine Top 100 Doctors in America (2024)

📬 Subscribe: substack.com/@afshineemrani 📚 Books: Amazon Author Profil

For all of history, medicine has been built around the average patient: the average dose printed on a label, the average risk calculated from a population study, the standard treatment that works for most people in the middle of the curve. This was never a philosophical choice. It was a limitation. We simply did not have the tools to read and rewrite biology at the level of a single individual, so we treated everyone according to the average and adjusted by trial and error.

That limitation is now falling away. The common thread running through all four of this week’s announcements is that we are gaining the ability to build medicine for one specific person — to read an individual’s biology precisely, and increasingly to reprogram it. This article explains each breakthrough in plain terms, how each one actually works, and how they connect into a single trend. I’ll keep it accurate rather than dramatic, and I’ll be clear about what is proven and what is still early.

Let’s take them one at a time.

1. A personalized cancer vaccine passed a major clinical trial

What it is. A cancer “vaccine” that is custom-manufactured for one patient, based on the specific mutations in that patient’s own tumor. Note the word “vaccine” is somewhat misleading here: this does not prevent cancer the way a flu shot prevents flu. It is a treatment, given after surgery, to stop an existing cancer from coming back.

How it works, step by step. This is the part worth understanding, because it’s genuinely different from older cancer treatment.

First, surgeons remove the tumor. Scientists then sequence the tumor’s DNA and compare it, letter by letter, to the DNA of the patient’s healthy cells. Cancer arises from accumulated genetic mutations, and those mutations cause the cancer cells to produce abnormal proteins — called neoantigens — that appear on cancer cells and essentially nowhere else in the body. These are, in effect, molecular flags unique to that person’s cancer. No other patient’s tumor carries the same set.

Next, a computer algorithm analyzes those mutations and selects up to about 34 of them that the patient’s immune system is most likely to be able to recognize and attack. Those selected targets are encoded into a strand of messenger RNA (mRNA) — the same class of molecule used in the COVID vaccines — wrapped in a tiny fat particle called a lipid nanoparticle, and injected. The patient’s own cells read the mRNA and briefly display the cancer’s molecular flags, which trains the immune system’s T-cells to recognize and destroy any cell carrying them. The vaccine is given together with a second drug (Keytruda, a checkpoint inhibitor) that removes a molecular “brake” cancers use to hide from the immune system, so the newly trained T-cells can finish the job.

The result. In a Phase 3 trial of 1,137 patients with high-risk, surgically removed melanoma, the personalized vaccine plus Keytruda outperformed Keytruda alone: it reduced the rate of cancer recurrence and reduced the rate of spread to distant organs. This is the first time in medical history that an mRNA-based cancer therapy has succeeded in a Phase 3 trial. Earlier-stage data had shown roughly a 49% reduction in the risk of recurrence or death. Trials in lung, bladder, and kidney cancers are already underway.

The honest limits. The trial measured whether the cancer returned, not yet whether patients ultimately live longer overall — that longer-term survival data is still being collected. The full statistical details (exact hazard ratios and confidence intervals) have not yet been published. And the therapy is complex and expensive to manufacture individually. But the core proof-of-concept — that a made-to-order immune therapy can beat the standard of care in a large randomized trial — is now established.

2. A one-time treatment for high cholesterol that doesn’t permanently change your DNA

What it is. An experimental treatment (from a company called Scribe) intended to lower “bad” cholesterol (LDL) with a single dose that lasts for years, aimed at the world’s leading cause of death: cardiovascular disease.

The background you need. A gene called PCSK9 helps control how much LDL cholesterol stays in your blood. Turn that gene down, and LDL drops substantially. We already know this works — there are two approved drugs (Repatha and Leqvio) that block PCSK9. What’s new here is not the target. It’s the method and the durability.

How it works, and why it’s different from ordinary CRISPR. You may have heard of CRISPR as “gene editing” — molecular scissors that cut DNA to change it. Cutting DNA is powerful, but permanent and risky: mistakes can’t be undone. This treatment does not cut DNA. It uses a deactivated version of CRISPR — the targeting system without the scissors — to place a chemical “off switch” on the PCSK9 gene. This is called epigenetic silencing: the underlying DNA sequence is left completely intact, but a chemical tag tells the cell to stop reading that gene. Because the DNA itself isn’t altered, the effect is designed to be potentially reversible. The whole package — the instructions for the silencing machinery plus a guide that steers it to PCSK9 — is delivered to the liver using the same lipid-nanoparticle technology used in mRNA vaccines.

The result. In non-human primates (monkeys), a single dose lowered LDL cholesterol by more than 50%, and the effect lasted nearly two years and was still ongoing. Higher doses reduced LDL by as much as 67–68%. Liver function stayed normal.

Why this matters. Today, preventing heart disease means taking pills every day, often for decades. But roughly half of patients stop taking their cholesterol medication within a year — and every gap allows more plaque to build in the arteries. This “adherence gap” is a major, well-documented cause of preventable heart attacks. A single treatment that holds cholesterol down for years would bypass that problem entirely.

The honest limits — and these are big. This is still animal data. The therapy is only now entering its first human trial, which is designed primarily to test safety, not to prove it works in people. Many treatments that look excellent in monkeys disappoint in humans. So this is a promising direction, not a proven therapy. It is the least clinically advanced of the four breakthroughs here — but potentially one of the most consequential if it holds up.

3. Artificial intelligence designed working proteins — confirmed in a real laboratory

What it is. AI models (from Anthropic — the company that also makes the assistant this article was drafted with; the results were independently verified by outside labs) were used to design brand-new proteins from scratch, and those designs were then physically built and tested.

What a “protein binder” is, and why it’s important. Many modern drugs work by binding — latching tightly onto a specific target molecule in the body to block it, activate it, or change what it does. A “binder” is a small protein engineered to grip a chosen target. Designing a good one from scratch (called de novo design) has traditionally required a trained protein engineer months of painstaking work per target. It is one of the foundational, rate-limiting steps in developing new medicines.

What actually happened. The AI was given a set of 15 biological targets and tasked with designing binders for all of them, working largely on its own — researching each target, choosing where to bind, running specialized design tools, and ranking its best candidates. Then two independent contract laboratories, Adaptyv Bio and Twist Bioscience, physically synthesized the AI’s designs and tested them in the lab, without modification.

The result. The designs successfully bound their targets in 14 of the 15 cases, with an overall success rate around 27% — more than double the 10–15% typical of standard industry campaigns. On one difficult target, the AI achieved a 40% success rate, compared with under 4% for human entrants in a prior competition on the same target.

Why it matters, and the honest limit. The significance is speed: a step that used to take months can now be compressed into an afternoon, and the results survived real-world laboratory testing rather than existing only on a screen. The important caveat is that a protein that binds its target is only the first step toward a drug. It still has to prove it is safe, stable, and effective inside a living body — the long and difficult part. But the design bottleneck that gated everything downstream is easing dramatically.

4. The monitoring layer: tracking microscopic disease in a tube of blood

What it is. A quieter set of advances — companies integrating genetic sequencing, artificial intelligence, and “liquid biopsy” into single platforms. This got less attention, but it is what makes the other three usable in practice.

The problem it solves. Suppose you can now build a personalized cancer vaccine or a one-time gene therapy. You still need a way to know, in real time, whether it’s actually working — ideally long before a tumor grows large enough to appear on a scan. You need a way to see inside the body between doctor visits.

How it works. A liquid biopsy is a blood test sensitive enough to detect the faint genetic traces that cancer cells shed into the bloodstream. By first building a genetic “fingerprint” of a patient’s specific tumor, doctors can then scan the blood at each follow-up for that exact signature — sometimes catching a recurrence months earlier than imaging could. If the signal reappears, treatment can begin while the disease is still microscopic and most treatable.

Why it matters. Precision therapy needs precision surveillance. A powerful personalized treatment is far more useful when paired with a sensitive way to measure whether it’s working and to catch any return early. This monitoring layer is what turns a one-time treatment from a gamble into a managed, trackable process.

How these four connect — the actual point

Individually, each of these is interesting. Together, they reveal a single trend, and it comes down to a shared toolkit.

Every one of these breakthroughs is built from the same handful of technologies that also made the rapid COVID vaccines possible: messenger RNA (programmable instructions for cells), lipid nanoparticles (a delivery system to get those instructions into the body), fast genetic sequencing (the ability to read biology cheaply and quickly), CRISPR (the ability to target and now rewrite or silence specific genes), and artificial intelligence (the ability to design biological molecules and interpret complex data). These five capabilities matured at roughly the same time, over the past decade, and this week we saw them applied — separately but simultaneously — to the two conditions that kill more people than anything else on Earth: cancer and cardiovascular disease.

The deeper shift is in the strategy of medicine itself:

• In cancer: moving from “remove the tumor, then apply broad treatments and hope” toward “read the tumor’s specific mutations, train the immune system against them, and monitor the blood for any return.”

• In cardiovascular disease: moving from “take pills every day for the rest of your life” toward the possibility of a single, durable treatment that addresses a root genetic driver.

• In drug development: moving from years of laboratory trial-and-error toward AI-assisted design that produces viable candidates faster, then synthesizing and testing them quickly.

In each case, the direction is the same: from reacting to disease after it appears, toward reading and reprogramming biology to prevent or intercept it — and from treatments designed for the population average toward treatments built for the individual. That is why four “stock stories” are really one story.

What to actually conclude — with appropriate caution

It would be a mistake to read this and conclude that cancer and heart disease are solved. They are not, and honest framing matters.

The personalized cancer vaccine is the most advanced of the four, with a genuine Phase 3 success — but it still owes us long-term survival data and full published statistics, and it is complex to manufacture. The one-time cholesterol therapy is striking but has been demonstrated only in animals so far, and is just now entering its first human safety trial; it could still fail in people, as many promising therapies do. The AI-designed proteins are an impressive and independently verified first step, but binding a target is a long way from an approved drug. And the monitoring tools, while real, are still being validated and integrated into routine care.

In this field, enthusiasm routinely runs ahead of proof, and some of these efforts will stumble. That is normal, and it is worth stating plainly.

But the underlying direction is no longer in question. The tools to read and rewrite biology at the level of the individual now exist and are working, and they are being pointed directly at the diseases that cause the most human death. The wall between “average medicine” and “medicine designed for a specific person” has been breached. What happened this week is not the finish line. It is credible, measurable evidence that the shift is real and already underway.

follow me on X to read more

I write plain-language explanations of what’s actually happening at the frontier of medicine — the science, the mechanisms, and an honest accounting of what’s proven versus what’s still early — without the hype and without the jargon. Subscribe for clear, accurate coverage of the changes that are going to shape how you and the people you love are treated.

Blessings.

Afshine Ash Emrani, M.D., F.A.C.C.
Assistant Clinical Professor, UCLA
David Geffen School of Medicine

Join Our new website

Castle-Connolly Nationwide Top Doctor (Since 2008)
Los Angeles Magazine Super Doctor (Since 2010)
LA Style Magazine Top 100 Doctors in America (2024)

Subscribe to mynewsletter: substack.com/@afshineemrani
Explore my books: Amazon Author Profile

For the first time in history, doctors can take a biopsy of your specific tumor, read its unique DNA mutations — the exact fingerprint no other cancer on earth shares — and build a custom mRNA blueprint written for one human being. Yours. It doesn’t poison the cancer. It doesn’t burn it. It teaches your own immune system exactly what to hunt.

And this week, a Phase 3 trial confirmed it works.

I’ve spent my life as a physician, and I did not expect to see this so soon. Let me show you what actually happened, how the thing is built — because the how is the most astonishing part — and then, at the end, let me answer the hard and fair questions you have every right to ask about anything with “mRNA” in its name.

But first, the wonder. Because it is real, and it is enormous.

What just happened

Added to the best immunotherapy we already had, this individualized cancer vaccine has been dramatically cutting the odds that high-risk melanoma comes back. In the earlier trial, the combination reduced the risk of recurrence or death by 49%, and the risk of the cancer spreading to distant organs by 62%, compared to the standard treatment alone.

This week, the large Phase 3 trial — over a thousand patients — met its goal. It significantly delayed recurrence and slowed the spread of cancer to distant organs, once again beating the current gold standard. It is the first time in all of medical history that an mRNA-based cancer therapy has won a Phase 3 trial.

That is not a modest tweak. That is a different trajectory for a human life.

And melanoma is only the first door. The very same approach is now being tested across lung, bladder, and kidney cancers — a whole program of trials, racing forward at once. What you are watching is not a single drug. It’s a platform — a repeatable method that could, in principle, be pointed at one cancer after another.

How the magic is actually made

This is the part that gave me chills as a doctor, and I want you to feel it too, because it sounds like science fiction and it’s happening in real laboratories right now.

Step one: read the enemy. Surgeons remove the tumor. Scientists then sequence its DNA and compare it, letter by letter, to the DNA of your healthy cells. The differences — the mutations the cancer accumulated as it grew — are its signature. And here is the key: those mutations produce abnormal proteins, called neoantigens, that appear on cancer cells and essentially nowhere else in your body. They are the cancer’s fingerprints, and they are unique to you. No other person’s tumor has the same set.

Step two: choose the targets. An algorithm sifts through those mutations and predicts which of them your particular immune system is best equipped to recognize and attack. From potentially hundreds, it selects up to a few dozen of the most promising — a personalized most-wanted list.

Step three: write the instructions. Those chosen targets are encoded into a strand of messenger RNA — the same molecular language your cells use every second of every day to make proteins. The mRNA is wrapped in a microscopic bubble of fat, a lipid nanoparticle, that carries it safely into your cells. Start to finish, this bespoke medicine is designed and manufactured for one person in a matter of weeks.

Step four: train the hunter. Injected into your body, the mRNA instructs your own cells to briefly display the cancer’s fingerprints — like handing your immune system a photograph of the criminal. Your T cells learn the face. And then they patrol, for months, hunting down any cancer cell that wears it. The vaccine doesn’t fight the cancer itself. It turns you into the thing that fights it.

Pair that with an immunotherapy drug that takes the brakes off the immune system, and you get what the trials are showing: a body newly able to find and destroy the microscopic cancer cells that surgery inevitably leaves behind — the ones that, left alone, become the recurrence that kills.

Why this is bigger than one disease

Understand what this means, because it reaches far past melanoma.

For all of history, we fought cancer with blunt weapons. Cut it out. Burn it with radiation. Flood the entire body with chemotherapy and pray the cancer dies before the patient does. We were swinging a hammer in the dark, and the hammer hit everything — the tumor and the person holding it.

This is a blueprint instead of a hammer. A therapy designed, in effect, atom by atom for one individual’s disease, that recruits their own biology to do the hunting with a precision no drug flooding the whole bloodstream could ever match. We are watching medicine shift, in real time, from managing cancer to hunting it. From reacting to a disease after it declares itself to teaching the body to hold the line before it ever spreads.

We were told, for decades, that personalized cancer vaccines were a thirty-year dream — always just over the horizon, never quite here. They are here. In real patients. With real data. In our lifetime. I say this as a doctor who knows precisely how rare these moments are, and how many false dawns the history of oncology contains: this is one of the most genuinely hopeful things to happen in the entire history of the field.

To be alive at the hour when human beings learned to teach the body to cure itself is a gift I don’t take lightly.

The questions you’re right to ask

Now — because I promised you honesty alongside the wonder, and because hope without honesty is just marketing — let me answer the hard questions directly. Not to dampen any of the above, but because a breakthrough this real can withstand real scrutiny, and the people asking these questions are being rigorous, not difficult.

Who is behind it, and how large is the evidence? This therapy is jointly developed by two pharmaceutical companies, Merck and Moderna. Industry funds the trials — a fair thing to keep in mind, and a reason to insist on independent, peer-reviewed data rather than press releases before anything becomes routine. The evidence was built in stages, each larger than the last: a Phase 1 in roughly 140 patients established safety, a Phase 2b of 157 produced the striking recurrence numbers, and the new Phase 3 randomized 1,137 patients with high-risk melanoma — and met its endpoints at a prespecified interim analysis, with a safety profile consistent with the earlier studies and no new safety signals.

How solid are the numbers, honestly? In the smaller Phase 2b trial, the benefit was real but the confidence intervals were wide — because 157 people is a small group, and small trials speak with less certainty. That is exactly why the Phase 3 existed: to see whether a dazzling early signal held up in a far larger population. It did. But the full Phase 3 details — the exact hazard ratios and p-values — haven’t been published yet; they’re coming at a medical meeting and in peer review. And these trials measured whether cancer came back, not yet whether people ultimately live longer overall. Delaying recurrence is a strong, encouraging sign that usually points toward longer survival, but the overall-survival data are still maturing. I’d rather tell you that than let you believe more than the evidence yet supports.

What about safety — where does it go in the body, and what does it do? Honest pharmacology, in plain terms: the lipid nanoparticle concentrates first at the injection site, then drains to the nearby lymph nodes — which is exactly where you want it, because that’s where the immune system is trained. The particles that reach the bloodstream distribute mostly to the liver, and to a lesser extent the spleen — which is why those are the organs researchers monitor. The mRNA itself is transient: your cells read it, make the target proteins, and then break it down within days. It does not enter the nucleus and it does not integrate into your DNA — it cannot rewrite your genome; that isn’t how the biology works. What it is, by design, is pro-inflammatory — that’s how it wakes the immune system up — and that same quality is the source of the reactions people can feel, from fever and fatigue to, rarely, more significant responses. There is also a specific risk worth naming: because the therapy trains the immune system to attack mutated proteins, there’s a theoretical risk of off-target autoimmunity if a chosen target too closely resembles a normal one. It’s minimized by heavy computational screening — but minimized is not zero, and it’s a fair thing to ask any oncologist. And the honest overarching limit: this is a new modality, so its very-long-term safety data are, by definition, still being written.

And yes — after COVID

I won’t pretend the last five years didn’t happen, or that the word “mRNA” now lands on neutral ground. It doesn’t. Many thoughtful people came out of that era with real questions, and some with real injuries. Their caution deserves respect, not a lecture.

So here is what I most want to say. Trust is the wrong frame — and it always was. No one should hand their life to a technology as an act of faith: not mRNA, not chemotherapy, not surgery, not anything. What medicine actually asks for is not trust but informed, individual consent — you, your specific situation, your own history, the real data and the real risks, and a physician who tells you the truth, together deciding whether the benefit is worth the cost for you. Someone who has had a severe reaction to something before is not being irrational to weigh that heavily; that history belongs at the very center of the decision.

And the context genuinely matters. A vaccine given to a hundred million healthy people to prevent an infection, and a therapy given to a cancer patient whose disease is likely to return and kill them, are simply not the same decision — even when they share a delivery technology. The risk you’re willing to accept changes entirely with what sits on the other side of the scale. For a healthy person, the bar should be very high, and caution is appropriate. For someone facing a high-risk cancer that may come back and spread, a 49% reduction in recurrence is weighed against a mortal threat — and that person may reasonably say yes, with full information, in a monitored setting. Another person, with a different history, may just as reasonably say no. Both are good medicine, because both are individual.

That’s the whole point. The answer to “should people trust mRNA to fight cancer” isn’t yes and isn’t no. It’s: it depends entirely on who you are, what you’re facing, and what your own body has already shown you — and no honest doctor should try to make that decision for you from a headline.

So here is where I land, holding both truths at once and dropping neither: this is a genuine scientific miracle, one of the most hopeful advances I’ve witnessed in a lifetime of practice — and it is a new, powerful therapy that deserves every hard question you can bring to it. Those two things are not enemies. Held together, they are exactly how medicine is supposed to work.

Wonder, with your eyes open. That’s the only kind worth having.

I write the version your doctor would give you if he had the time and nothing to sell — the awe and the fine print in the same breath. The deeper work lives here: the heart, longevity, the frontiers of medicine, and how to think clearly about your own body in a noisy world. Subscribe for the honest conversation — the hope with the caveats left in.

Blessings.

Afshine Ash Emrani, M.D., F.A.C.C.
Assistant Clinical Professor, UCLA
David Geffen School of Medicine

Join Our new website

Castle-Connolly Nationwide Top Doctor (Since 2008)
Los Angeles Magazine Super Doctor (Since 2010)
LA Style Magazine Top 100 Doctors in America (2024)

Subscribe to mynewsletter: substack.com/@afshineemrani
Explore my books: Amazon Author Profile

For women in midlife, it may be one of the highest-return things you can buy for pennies a day — and it works on your brain, not just your body.

Let me show you the evidence, because almost no one is telling women this.

Start with the part you might already know. In postmenopausal women, 5g of creatine monohydrate daily paired with resistance training produces small but real gains in lean mass and leg strength. The key word is paired. Without the lifting, you get almost nothing. Creatine doesn’t replace the work — it makes the work pay off more. That alone matters enormously in a decade when women are quietly losing the muscle that protects their metabolism, their bones, and their independence.

But here’s the part most women have never heard.

Your brain runs on ATP — cellular energy. And when estrogen drops in perimenopause, brain energy metabolism takes a hit. That’s a real, physical driver of the “brain fog,” the slower recall, the walking-into-a-room-and-forgetting. It was never just stress or “getting older.” Your brain’s power supply changed.

Creatine helps regenerate that energy fast. And it shines brightest exactly when the brain is under strain — poor sleep, mental fatigue, aging, hormonal transition. Which is a precise description of the midlife window.

The first dedicated menopause brain trial just landed — 36 peri- and menopausal women, 8 weeks. The creatine group improved reaction time by 6.6% (placebo: 1.2%), raised the creatine level in their frontal lobe by 16.4%, and trended toward fewer mood swings. First human imaging proof that creatine actually reaches and fuels the menopausal brain.

And here’s the part that caught my eye as a cardiologist: it also nudged their cholesterol profile in a favorable direction. A supplement being studied for brain fog quietly helped the heart too. That’s the kind of two-for-one I spend my career looking for.

Why women specifically? Two reasons. Women start with lower natural creatine stores than men. And the estrogen decline disrupts brain energy on top of that. So women may have the most to gain from the one cheap, safe tool that directly raises brain creatine and backs up ATP when the tank is running low.

Be clear-eyed: this won’t make you a genius overnight. The effects are modest, and they’re clearest when your brain is under load. Creatine builds up over weeks — the clarity isn’t a switch, it’s a slope. But stack the muscle, the strength, and the cognitive edge together, keep it consistent for months, and it’s one of the highest-ROI habits available to a woman in this chapter.

The protocol is almost insultingly simple:

5g of creatine monohydrate. Every day. No loading phase needed. Pair it with progressive lifting. Give it months, not days. Monohydrate is the most-studied, cheapest, most practical form — don’t overthink the fancy versions.

It’s safe for healthy women, with side effects no different from placebo. Check with your doctor first if you have kidney issues.

So stop letting the word “creatine” conjure a bro in a tank top.

It’s a midlife tool for the body and the brain. It helps you keep the muscle, keep the strength, and keep the sharpness that this decade tries to quietly take.

Take the 5 grams. Lift. Stay consistent.

Keep what’s yours.

Blessings.

Afshine Ash Emrani, M.D., F.A.C.C.
Assistant Clinical Professor, UCLA
David Geffen School of Medicine

Join Our new website

Castle-Connolly Nationwide Top Doctor (Since 2008)
Los Angeles Magazine Super Doctor (Since 2010)
LA Style Magazine Top 100 Doctors in America (2024)

Subscribe to mynewsletter: substack.com/@afshineemrani
Explore my books: Amazon Author Profile

For as long as I’ve practiced — twenty-five years now — medicine has treated men’s sexual health as a problem to solve and women’s as a mystery to shrug at. Men got research, drugs, dignity, and a diagnosis. Women got a hand on the shoulder and some version of: it’s stress, it’s your hormones, it’s just your age, it’s probably in your head.

That was never good enough. And it was never true.

About 40% of women report a sexual concern. Roughly 12% live with one distressing enough to genuinely affect their lives. That’s not a rare malfunction in a few unlucky women. That’s an enormous number of people being quietly told to accept something that, in most cases, can be understood, supported, and changed.

So here is the guide I wish every woman had been handed decades ago. The science, the tools that actually have evidence, the medical options no one mentioned — and the honesty the rest of it has been missing. I’m going to be direct and clinical, because you deserve information, not euphemism.

Let’s begin where the truth begins.

Your body is a system, not a mystery

The first thing almost no one explains: female sexual response isn’t one thing. It’s four.

Desire — the wanting. Arousal — physical and mental readiness, including blood flow and lubrication. Orgasm. Satisfaction — the whole experience landing as genuinely good.

Each runs on its own machinery — hormones, blood flow, the pelvic floor, neurotransmitters, sleep, stress, the relationship, the medications you take. Break one link and the whole chain can feel broken, but each breaks for entirely different reasons. Treat the wrong one and you’ll do everything “right” and feel nothing change.

And unlike male sexuality, a woman’s response is far more context-dependent and multifactorial. That is not a flaw to be fixed. It’s the design. Which is exactly why the “just take a pill” model was never going to fit — and why its failure to fit got blamed on women instead of on the model.

The real approach was always going to be layered: build the foundations, then add targeted tools. Consistency beats any single hack. And before anything else, a good clinician rules out the physical causes that love to masquerade as low desire — thyroid problems, anemia, diabetes, depression, and the genital tissue changes of menopause. So much “I just don’t want it” is actually untreated pain, exhaustion, or a fixable medical issue wearing desire’s clothing.

Now the map.

Foundation one: sleep is a sex drug

The single most powerful thing you can do for your sex life costs nothing, needs no prescription, and almost no one connects to the bedroom.

Sleep.

Poor sleep — insomnia, short nights, untreated apnea — is strongly linked to lower desire, harder arousal, more difficulty reaching orgasm, and more sexual distress. It isn’t subtle, and it isn’t your imagination. The exhausted body deprioritizes sex, because from a pure survival standpoint, sleep is mandatory and sex is optional.

Here’s the number that stops people cold: one extra hour of sleep has been associated with roughly a 14% increase in the odds of being sexually active the next day. One hour. Not a supplement, not a device — just giving your body what it was already begging for.

So aim for seven to nine hours. Women often need slightly more than men, thanks to hormonal and recovery demands. Hold your bedtime and wake time steady, because your hormones run on that clock. Dim the lights an hour before bed, get the screens out of your face, and build a real wind-down — breathing, a little stretching. Magnesium glycinate or tart cherry help some women. And be honest about alcohol: it feels relaxing, but it fragments sleep and flattens arousal.

And if you snore, wake unrefreshed, or a partner has watched you stop breathing at night — get evaluated for sleep apnea. Treating it can directly improve sexual function, and it protects your heart at the same time. Women’s apnea is wildly underdiagnosed, because it rarely looks like the male stereotype.

Foundation two: the muscle no one told you to train

There is a muscle group that governs arousal, lubrication, orgasm intensity, and whether sex hurts or feels wonderful. Almost no one trains it on purpose. Most women were never even told it could be trained.

The pelvic floor.

A stronger, better-controlled pelvic floor improves arousal, lubrication, orgasm intensity and control, and satisfaction — while reducing the pain and incontinence that quietly sabotage sex. This is among the best-supported non-drug interventions in all of women’s health; the reviews and meta-analyses are clear.

To find the muscles, squeeze as if you’re holding back gas. That’s the pelvic floor. The most common mistake is tensing the abs, glutes, or thighs instead — if those are firing, you’re missing the real muscle. Contract for three to five seconds, then fully relax for three to five; the relaxation matters as much as the squeeze. Build toward ten-second holds, three sets of ten, two or three times a day, and add quick one-second flicks for the fast-twitch fibers. Progress from lying to sitting to standing, and exhale as you contract. Smart biofeedback trainers with apps genuinely help technique and consistency.

Give it eight to twelve weeks. That’s when the change shows up.

But here is the caveat a responsible physician always adds: if you have pelvic pain, or a floor that is already too tight, more squeezing is exactly the wrong medicine — Kegels can make it worse. If you have pain, or no improvement after twelve weeks, see a pelvic floor physical therapist. That specialty is one of the most underused resources in women’s health, and it changes lives. Strength is not the only goal. Control and release are too.

The cardiologist’s secret: arousal is a blood-flow event

Here’s why a heart doctor, of all people, belongs in this conversation.

Arousal is, in large part, a blood-flow event — engorgement, lubrication, sensitivity, all driven by blood rushing to the genital tissue. And blood flow is my entire field. The same vascular system I watch to predict heart attacks is the one that decides whether a woman’s body can respond. They run on the same endothelium — the delicate, one-cell-thick lining inside every vessel you own.

When that lining thrives, arousal comes more easily. When it struggles — from high blood pressure, high blood sugar, smoking, inactivity — arousal quietly gets harder. Same plumbing, same rules as the heart.

Which leads to a genuinely liberating truth: the “sexual” fixes and the “heart” fixes are the same fixes. Aerobic exercise — 150 minutes a week of brisk walking, cycling, or swimming — improves blood flow, hormones, mood, and body image, and the meta-analyses show it lifts female sexual function across every single domain. Even short fifteen-to-twenty-minute sessions show acute benefits for desire. You are not choosing between a healthy heart and a good sex life. They are the same project.

This is also why medicine is now testing blood-flow tools directly in women — topical sildenafil cream, the Viagra molecule applied locally, is showing promise in trials for arousal disorder, with fewer whole-body effects. The logic is identical to the one we’ve used in men for decades. We were simply slower to study it in women, as usual.

And one more thing you need to hear as a cardiologist’s patient, not just a reader: if your arousal has changed, that can be a vascular signal — an early readout of the same system that decides your cardiac future. Women’s heart disease is more underdiagnosed than men’s, not less. So take it seriously. Know your blood pressure and your blood sugar. Treat your circulation as though your sex life and your life both depend on it. Because they do.

The anatomy lesson most women never got

Most women were handed decades of shame and almost no accurate information about their own body. So let me give you the version that is simply true.

The clitoris has far more nerve endings than the vagina. For most women, it is the main event, not the warm-up. This single fact rewrites an enormous amount of unnecessary frustration: if penetration alone rarely gets you there, nothing is wrong with you — that is the statistical norm. Most women need direct clitoral stimulation to reach orgasm. The cultural script that said otherwise was written without the anatomy in front of it.

So the technique that actually works is unhurried: full-body arousal first, building sensation gradually, before narrowing to the genitals — because rushing to the finish fights your own biology. Then clitoral focus with light pressure and a consistent rhythm, responsive to feedback, with internal or G-spot stimulation added if you enjoy it. Some women love it, some don’t; both are entirely normal.

Devices belong here without a flicker of embarrassment. Vibrators — wand, bullet, air-pulse and suction styles — are linked in research to better arousal, orgasm, satisfaction, and lower distress. They are not a crutch; they reliably deliver the kind of stimulation the anatomy actually wants. Choose body-safe materials, clean them properly, and treat good lubricant as a pleasure upgrade rather than evidence that anything is wrong.

And the most important instruction, the one that quietly transforms relationships: explore solo first. You cannot guide someone to a place you have never mapped yourself. Learning your own responses is the fastest route to better partnered sex — and then communicating them, in real time, not as criticism but as a gift. “There, like that” is one of the most generous sentences you can say in a bed.

It’s not “all in your head” — but your head is a lever

For generations, “it’s all in your head” was used to dismiss women. Here is the honest version: your mind is a real, powerful, physiological part of your sexual response — not as an insult, but as a lever you can actually pull.

Stress, anxiety, body image, and relationship strain aren’t soft secondary factors. They are often the main ones. The nervous system that governs arousal cannot fully engage while it’s braced for threat — and modern life keeps it braced. You cannot relax into pleasure with your foot on the alarm. This is biology, not weakness.

And this is where the evidence gets genuinely strong. Mindfulness-based cognitive behavioral therapy and sex therapy have robust data for improving desire, arousal, and orgasm — not vague relaxation, but structured, studied methods for retraining how attention and pressure operate during intimacy. For many women this outperforms every supplement in existence. The core of it: lower the performance pressure, because the goal is presence, not a perfect response; use breath to shift out of alert mode; and place your attention on sensation instead of monitoring yourself from the outside. That self-watching — is this working, do I look okay, is it taking too long — is the single most common arousal-killer there is.

The relationship is part of the medicine too. Desire lives in safety, trust, and feeling wanted, not only in hormones. So if talking, mindfulness, or therapy is what you need, that is not the consolation prize after the “real” options. For a great many women, it is the real treatment. Seek it without a shred of shame.

The medical options no one told you existed

Most women with genuine, distressing low desire have never been told that real, studied medical treatments exist. They do — and you deserve to know the whole list.

There are options FDA-approved specifically for low desire. Flibanserin (Addyi) is a daily pill that adjusts the brain’s serotonin, dopamine, and norepinephrine, with a modest but real increase in satisfying encounters and desire and less distress; it’s now approved for pre- and postmenopausal women under 65, with cautions around drowsiness and alcohol. Bremelanotide (Vyleesi) is an on-demand option that works on the brain’s “wanting” circuitry rather than on blood flow; nausea is the common effect, and because it’s an injectable prescription with cardiovascular considerations, it’s genuinely a physician conversation.

Then the off-label tools that often work beautifully. Bupropion — an antidepressant that, unlike SSRIs, tends to raise desire, arousal, and orgasm — is frequently the answer when an antidepressant is what killed the libido in the first place. And that point deserves emphasis: if you’re on an SSRI and your desire vanished, that is a known, common, fixable effect, not a life sentence. Talk to your doctor about switching or adding something; don’t suffer it in silence.

And the hormonal options, individualized and supervised. Testosterone therapy for postmenopausal women — transdermal, dosed to normal premenopausal levels, properly monitored — has real evidence for improving desire, arousal, orgasm, and satisfying encounters, and is backed by consensus statements even though it isn’t yet formally FDA-approved for women in the US. For the dryness and pain of menopause, local vaginal estrogen, vaginal DHEA, and ospemifene are highly effective at restoring tissue health — and here is the part that matters most: fixing the pain often revives desire that was never actually gone, only guarding against hurt.

The through-line for all of it: these belong with a knowledgeable clinician — a gynecologist or sexual-medicine specialist — who evaluates you, weighs your history, and monitors you. Not an internet order. But the headline is pure hope: distressing low desire is a real medical condition with real treatments. You were failed by a system that never mentioned them — not by your own body.

Menopause is not the end of desire

Somewhere along the way, women were sold a lie: that menopause ends a sex life. I want to demolish that clearly.

What changes at menopause is largely mechanical and largely treatable. Falling estrogen thins and dries the genital tissue, which makes sex uncomfortable or painful. And here is the crucial chain: pain doesn’t only hurt — it teaches the body to avoid. Desire fades because your nervous system is protecting you from anticipated pain, not because wanting has died. Which means that fixing the tissue — with local estrogen, vaginal DHEA, or ospemifene — very often brings the desire back with it. When sex stops hurting, the desire that “disappeared” frequently walks right back in.

Beyond the tissue, the desire circuitry itself can be supported — testosterone where appropriate, and flibanserin, now approved for postmenopausal women under 65. And everything else in this guide applies with even more force after menopause: sleep, aerobic exercise for blood flow, pelvic floor training, good lubricants, mindful presence. Menopause is a transition, not a terminus. With the right combination, a great many women describe this chapter as freer and better — not worse. Find a menopause-literate clinician. They exist.

The whole plan, in order

If you want the map in one glance, here is the order I’d walk a patient through.

Start with the free foundations, and give them eight to twelve weeks: fix sleep first, add aerobic exercise three to five times a week, train the pelvic floor daily. Most women see meaningful gains from this layer alone. Then the accessible add-ons: good lubricant, a vibrator without embarrassment, solo exploration and honest communication, and mindfulness or sex therapy if stress is the driver — the evidence there is strong. Then, optionally, evidence-based supplements — ashwagandha for stress-driven issues, maca around menopause, tribulus for overall function — third-party tested, given a fair trial, cleared with your doctor, understood as modest help rather than miracles. And finally, if distress persists past about three months of real foundational work, the medical evaluation: a gynecologist or sexual-medicine specialist to rule out thyroid, anemia, diabetes, depression, and menopausal tissue changes, and to open up the prescription and hormonal options above.

Track the whole way with a simple journal — desire, ease of arousal and orgasm, satisfaction — because data beats guessing. And don’t wait through the layers if you have pain, sudden changes, or significant distress; those get seen now.

The truth under all of it

This was never about chasing some idealized, airbrushed “perfect” response. It’s about reclaiming pleasure and connection in the body you actually have — the one that carried you this far and is still, right now, capable of far more than medicine ever bothered to tell you.

Your sexuality is not a mystery, and it is not broken. It is a system. And now you have the map.

I’ve spent my life at the border between the body and the soul, and I’ve come to believe that pleasure is not a frivolous thing. It is one of the ways a body says it is alive, safe, and still reaching for another person. To reclaim it is not indulgence. It’s a kind of homecoming.

Most women improve. Patience, honesty, and good guidance do the rest.

Go be well. And go be alive in the body you have.

If this told you something no one else would, understand that it’s the free version of how I think — the real science, with the shame and the hype both stripped out. The deeper work lives on my Substack: the heart, longevity, desire, and how the body and the soul actually speak to one another, longer and quieter, with no algorithm deciding what you’re allowed to see. Subscribe for the full report — the honest conversation about your body that medicine keeps forgetting to have with you.

Share this with a woman who was told it was all in her head. It wasn’t.

Blessings.

Afshine Ash Emrani, M.D., F.A.C.C.
Assistant Clinical Professor, UCLA
David Geffen School of Medicine

Join Our new website

Castle-Connolly Nationwide Top Doctor (Since 2008)
Los Angeles Magazine Super Doctor (Since 2010)
LA Style Magazine Top 100 Doctors in America (2024)

Subscribe to mynewsletter: substack.com/@afshineemrani
Explore my books: Amazon Author Profile

Minoxidil? It started as a blood-pressure pill. We noticed patients growing hair in places they didn’t ask for, and dermatology never looked back. Spironolactone — one of the best options for women — is a drug I still prescribe for heart failure and high blood pressure. Even finasteride touches the same hormonal machinery I think about every day.

So no, hair loss isn’t my clinical specialty. But I understand these molecules from the inside out. I know how they move through the body, what they do to blood pressure and potassium, and where the real risks hide versus where the internet just likes to panic.

And here’s what I’ve learned watching this from the cardiology chair: most people fail at hair loss not because the treatments don’t work, but because they start too late, quit too early, or chase gadgets instead of using the handful of things that are actually proven.

This is the no-nonsense guide I’d give a friend. Every major option, real dosage examples, and clear do’s and don’ts. Results take patience — usually three to twelve months. And one rule before we start: this is education, not a prescription. Get a real diagnosis and bloodwork before you touch any of it.

First: figure out why you’re losing it

Not all hair loss is the same, and treating the wrong cause is how people waste a year.

The most common culprit by far is androgenetic alopecia — pattern loss driven by genetics and your follicles’ sensitivity to DHT, a hormone that slowly shrinks them. But shedding can also come from stress (telogen effluvium), iron or vitamin D deficiency, thyroid disease, postpartum shifts, medications, or autoimmune conditions like alopecia areata.

Before spending a dollar on treatment, do this:

• See a dermatologist or trichologist. Rule out the reversible causes first.

• Get bloodwork: ferritin (iron stores — a huge one in women), vitamin D, thyroid panel, and hormones.

• Take baseline photos in consistent lighting. You cannot trust your memory on this; you can trust the camera.

• Move fast. A miniaturized follicle can be revived. A dead one cannot. Early is everything.

If your loss is sudden, patchy, or scarring — don’t wait. That needs urgent evaluation.

The only two drugs with full FDA approval

Everything else you’ll read about is used off-label. These two have earned the top-line stamp:

Topical minoxidil (Rogaine or generic) — over the counter, 2% or 5%, for both men and women. It works by widening blood vessels, extending the growth phase of the hair cycle, and likely nudging growth factors.

Dosage example: Men — 1 mL of 5% solution, or half a capful of foam, on a dry scalp twice daily. Women — the same, or once daily (2–5%). Foam tends to irritate less (less propylene glycol). Expect an alarming shed in weeks 2–8 — that’s the old hair making room, not a failure. Visible results in 3–6 months. Stop, and the gains reverse.

Oral finasteride 1 mg (Propecia) — men only, because it’s dangerous in pregnancy. It blocks the enzyme that makes scalp DHT, cutting it by 60–70%. On average, slightly stronger than topical minoxidil alone.

Dosage example: 1 mg once daily. Judge results at 6–12 months. Side effects are uncommon — sexual or mood changes in a small minority — and topical versions exist that lower whole-body exposure. Have an honest risk/benefit talk with your doctor rather than fearing it or dismissing it.

There’s also low-level laser therapy — FDA-cleared caps and combs, a modest add-on, roughly three sessions a week.

The heart-drug secret: low-dose oral minoxidil

This is where my world and the hair world overlap, and it’s the most important shift in the field in years.

We’ve prescribed oral minoxidil for blood pressure for decades. It turns out that at tiny doses — a fraction of the cardiac dose — it grows hair beautifully, with far better adherence than a messy topical you have to remember twice a day. For a lot of people it works as well or better than the liquid, simply because they actually take it.

It’s off-label and needs a prescription (often compounded to get the low doses exactly right). Here are the expert-consensus protocols from the international Delphi panel and clinical reviews:

• Women: start 0.625–1.25 mg once daily (a quarter or half of a 2.5 mg tablet). Maintenance usually 0.625–2.5 mg/day. Titrate up by 0.625–1.25 mg every 1–3 months if needed and tolerated.

• Men: start 1.25–2.5 mg once daily. Target 2.5–5 mg/day.

• Adolescents, low-weight, or cardiac-risk patients: start at the bottom (0.625 mg women, 1.25 mg men).

• Take it at night to blunt any dip in blood pressure.

Now the part I care about as a cardiologist — the monitoring, which too many people skip:

• Check a baseline blood pressure and heart rate. Recheck at 1–4 weeks and after dose increases, especially if you have low blood pressure, arrhythmia, or take other BP meds.

• Healthy patients don’t need routine labs or EKGs.

• The most common side effect is extra body or facial hair — dose-dependent, more common in women, and reversible if you lower the dose.

• Mild fluid retention (1–10%), a temporary shed, and rare fast heartbeat can happen. Serious cardiac events at these micro-doses are extremely rare.

• Don’t use it in pregnancy, uncontrolled hypertension, or pericardial disease. If you have heart risk factors, loop in a cardiologist. (Happy to be that voice in the room.)

Most people see something by month 2–6, with the real payoff later. Newer extended-release versions in trials are posting strong density gains with reassuring safety.

The DHT blockers — and going a step stronger

If pattern loss is DHT-driven, blocking DHT is the lever.

• Dutasteride — a stronger, dual-action blocker. Men: 0.5 mg daily, or 2–3 times a week. More effective than finasteride in head-to-head analyses, with a similar side-effect profile.

• Topical finasteride — 0.1–0.25% solution or spray, once or twice daily, with much lower absorption into the bloodstream.

The through-line in all the best data: combination beats monotherapy. A DHT blocker plus a growth stimulator plus a simple adjunct will always outperform any single hero product.

Women: this is a different game

Female hair loss deserves its own plan, not a hand-me-down of the male protocol.

• Minoxidil is first-line — topical, or low-dose oral.

• Spironolactone (my old heart-and-blood-pressure friend) is excellent when there’s androgen excess or PCOS. Start 25–50 mg daily and titrate to 50–200 mg, watching potassium and kidney function. Bonus: its mild diuretic effect offsets the fluid retention oral minoxidil can cause, which is why the two pair so well.

• Oral finasteride is generally avoided before menopause; spironolactone is preferred, and strict contraception is non-negotiable on any anti-androgen because of birth-defect risk.

• Post-menopausal women get more anti-androgen flexibility.

• A hormonal workup matters more here than in men. Don’t skip it.

The cheap adjuncts that punch way above their price

You don’t need a boutique clinic for these, and the evidence is real.

Ketoconazole shampoo (1% or 2%, e.g., Nizoral) is one of the best-supported things on any drugstore shelf. It’s a powerful antifungal that calms the scalp inflammation tied to dandruff and seborrheic dermatitis, and it mildly blocks DHT locally — lowering scalp DHT by roughly 12–16%. In studies, including one head-to-head with 2% minoxidil, it improved density and shaft thickness as an adjunct.

How to use it: Lather the whole scalp, leave it on 3–5 minutes, rinse. Two to three times a week when you’re actively treating, once a week for maintenance. Alternate with your normal shampoo. Barely any gets into your bloodstream.

Microneedling — 1 to 1.5 mm depth, once a week or every couple of weeks. On its own it’s fine; combined with minoxidil it’s a multiplier, with studies showing several-fold higher hair counts. Keep the device clean and don’t overdo it.

Rosemary oil — one randomized trial found it non-inferior to 2% minoxidil. Dilute it in a carrier oil and apply a few times a week. Not magic, but a legitimate entry point.

Caffeine shampoos, topical melatonin (mostly European data), and plain consistent scalp massage round out the supportive tier.

Procedures, when you want volume back

• PRP injections — your own growth factors, 3–4 monthly sessions then maintenance. Best as an adjunct.

• Hair transplant — FUE (tiny dot scars, faster recovery, preferred for most) or FUT (strip method, more grafts per session, a linear scar). With a skilled surgeon, 90–95% of grafts survive; 1,500–4,000+ per session; full results at 12–18 months. Critical: keep taking your meds afterward to protect the hair you were born with, and only use board-certified, experienced surgeons.

Supplements: the honest truth

I’ll be blunt, because your wallet deserves it. Supplements mostly help when they’re fixing a genuine deficiency — not as blanket growth boosters.

• Iron/ferritin, vitamin D, zinc — worth correcting if your labs are low.

• Pumpkin seed oil (~400 mg), saw palmetto (320 mg), tocotrienols, and some multi-ingredient formulas (like Nutrafol) showed modest gains in a few trials.

• Biotin — rarely useful unless you’re deficient, and high doses can distort your lab results.

Test first. Don’t megadose on faith.

The do’s and don’ts, in one screenshot

DO:

• Get diagnosed, get baseline labs, take photos.

• Start an evidence-based combo early. Men: finasteride 1 mg + minoxidil (5% topical or 2.5 mg oral) + ketoconazole 2–3×/week + weekly microneedling. Women: minoxidil (0.625–1.25 mg oral or topical) ± spironolactone 25–50 mg + ketoconazole.

• Titrate oral minoxidil slowly and check your blood pressure early.

• Commit a full 6–12 months before judging anything.

• Protect the basics: protein, sleep, stress, scalp health.

• Layer procedures (microneedling, PRP, laser) for synergy.

DON’T:

• Wait, hoping it “stops on its own.” It usually doesn’t.

• Rely on biotin, onion juice, castor oil, or the remedy that went viral last week.

• Wear tight, pulling hairstyles or ignore an inflamed scalp.

• Panic and quit during the early minoxidil shed.

• Self-dose high anti-androgens or ignore pregnancy risk.

• Buy every new clinic gadget without evidence behind it.

• Assume “natural” means safer or better — that belief delays real care every day.

The bottom line

For most pattern hair loss, the highest-return path hasn’t changed: start early, combine treatments, and stay consistent. Minoxidil — topical or precisely dosed oral — plus the right DHT blocker, plus cheap adjuncts like ketoconazole and microneedling. Procedures and transplants shine when you need real volume back. Supplements play a supporting role, at best.

I’ve watched people spend years and thousands chasing the next miracle while walking past the boring, proven protocol that would have worked. Your future density is decided by what you do now — not by the perfect plan you keep meaning to start.

Diagnose it. Build the foundation. Give it a year.

The follicles you save are the ones you act on today.

This is educational, not personalized medical advice. Discuss every option, risk, and monitoring plan with your own physician.

Blessings,

Afshine “Ash” Emrani, M.D., F.A.C.C. Assistant Clinical Professor, UCLA David Geffen School of Medicine

🏅 Castle-Connolly Nationwide Top Doctor (since 2008) 🌟 Los Angeles Magazine Super Doctor (since 2010) 🇺🇸 LA Style Magazine Top 100 Doctors in America (2024)

📬 Subscribe to my newsletter: substack.com/@afshineemrani 📚 Explore my books: Amazon Author Profile

Two medicines were built to lower blood sugar. They keep quietly saving lives instead — and a cardiologist explains what that really means for you

Some of the most important discoveries in medicine were never the thing we were looking for.

Penicillin was a contaminated petri dish. The pacemaker began as a wiring mistake. And right now, in real time, we are living through another one — except this time the accident isn’t a mold or a miswired circuit. It’s two entire classes of drugs, designed to do one modest job, that turned out to do something their inventors never promised:

They help people live longer.

I have spent twenty-five years as a cardiologist watching the longevity world chase immortality through mouse studies, supplement stacks, and molecules that look dazzling in a petri dish and vanish in a human being. And the whole time, the two drugs with the strongest evidence for extending healthy human life were sitting in the diabetes aisle, wearing name tags that said something else entirely.

Let me tell you what they are, what the data actually shows, and — because I am a physician and not a salesman — exactly where the hype outruns the truth.

The difference that matters: mouse hope vs. human proof

First, a rule I want you to carry through this entire essay, because it separates real medicine from beautiful fiction.

Almost everything marketed as a “longevity compound” rests on one of two thin foundations: it made mice live longer, or it correlated with something good in an observational study. Rapamycin. Metformin. Acarbose. Lithium. Fascinating molecules, every one. But their human longevity evidence is weak, indirect, or purely preclinical. They are promises, not proof.

The two drugs I’m about to describe are different in kind, not degree. They earned their place at the top of the evidence rankings the hard way — through enormous randomized controlled trials measuring the only endpoints that can’t be spun: death, heart failure, kidney failure. Tens of thousands of real human beings, followed for years, with a placebo group to keep everyone honest.

That is the gold standard. And these two cleared it while no one was looking for longevity at all.

Drug class #1: SGLT2 inhibitors — the calorie-restriction mimic in a pill

You may know them by their names: empagliflozin, dapagliflozin, canagliflozin. They were built for one purpose — to lower blood sugar in type 2 diabetes — and they do it through one of the strangest mechanisms in pharmacology.

They make you urinate out your sugar.

By blocking a transporter in the kidney, an SGLT2 inhibitor causes you to spill roughly 60 to 90 grams of glucose into your urine every day. That’s 240 to 360 calories of sugar, flushed away. In effect, the drug creates a mild, continuous caloric-restriction and light-ketosis state — and caloric restriction is the single most reproducible life-extending intervention in the history of biology.

But here’s where it stops being interesting and starts being astonishing. When researchers ran the big outcome trials — EMPA-REG, DECLARE, DAPA-HF, EMPEROR-Reduced, DAPA-CKD, EMPA-KIDNEY — they found something no one had promised:

• Pooled analyses show around a 14% relative reduction in all-cause mortality in the populations studied. Not sugar numbers. Death.

• Sharp reductions in cardiovascular death, heart-failure hospitalizations, and the progression of chronic kidney disease.

• And — this is the part that rewrote guidelines — those benefits held up in people who don’t even have diabetes. In several of the landmark heart-failure and kidney trials, a third to half of the participants weren’t diabetic at all. The drug was protecting hearts and kidneys through some pathway that had nothing to do with blood sugar.

So cardiologists like me started asking the obvious question: if the benefit isn’t really about glucose, what is it about?

Why it looks like aging itself

The mechanisms that emerged read like a checklist of the biology of aging:

AMPK activation — the cellular “energy sensor” that also gets switched on by exercise and fasting, and that governs how cells repair and recycle themselves. Mild ketosis, which appears to be a cleaner, more efficient fuel for a stressed heart. Improved mitochondrial function — better power plants in your cells. Reduced systemic inflammation, including the low-grade “inflammaging” that smolders under nearly every age-related disease. Upregulated autophagy — the cell’s self-cleaning process, hauling out damaged parts before they accumulate. There are even early signals of senolytic activity: helping the immune system clear out “senescent” cells, the aged, dysfunctional cells that linger and poison the tissue around them. And in one small trial, a signal of telomere lengthening — the protective caps on our chromosomes that normally fray with time.

Male mice on these drugs live longer. The human healthspan trials — the ones designed specifically to test aging as the endpoint — are still pending. But you do not need to wait for those to appreciate the point: we already have hard mortality data in humans. That is more than almost any “longevity drug” on earth can say.

Drug class #2: GLP-1 receptor agonists — the ones you’ve already heard about

Semaglutide. Liraglutide. Tirzepatide. Ozempic, Wegovy, Mounjaro. You cannot open a phone without meeting them. Everyone knows them as weight-loss drugs, and before that, diabetes drugs. Almost no one is talking about the part that matters most to a cardiologist.

SELECT was the trial that changed the conversation. It took people who were overweight or obese and had established cardiovascular disease — but did not have diabetes — and gave them semaglutide or placebo. The result: roughly a 20% reduction in major adverse cardiovascular events — heart attack, stroke, cardiovascular death. In a population that wasn’t taking it for diabetes at all.

FLOW looked at the kidneys, in people with type 2 diabetes and chronic kidney disease, and found about a 24% reduction in major kidney events, along with mortality signals pointing the right way.

Zoom out to the broader meta-analyses and the pattern holds: reductions in cardiovascular events on the order of 13 to 14%, fewer strokes, fewer heart-failure hospitalizations, lower all-cause death in high-risk groups, and measurable kidney protection. And now the frontier signals — the ones still early, still small, but worth watching: lower dementia risk in some cohorts, and slower “epigenetic aging clocks” in early studies, including one HIV cohort where a biological-aging measure slowed by roughly 9%.

Crucially, a meaningful share of the cardiovascular benefit appears to be partly independent of the weight loss itself. Something else protective is happening — likely the anti-inflammatory and direct vascular effects — beyond simply carrying fewer pounds.

Now the part the influencers skip: the honest risks

Here is where I have to be a doctor, because the internet will sell you the upside and bury the fine print, and my job is the opposite.

Muscle loss is real, and it’s the big one. GLP-1 drugs cause weight loss, and a portion of what’s lost is not fat — it’s muscle. For an older adult, muscle is not vanity; it is survival. It’s your metabolism, your balance, your defense against a fall that starts the last chapter of too many lives. Losing weight while losing muscle can trade one aging problem for a worse one. This is why I will not discuss these drugs without saying, in the same breath: adequate protein and resistance training are not optional add-ons. They are part of the prescription.

Gastrointestinal effects — nausea, and in some people significant slowing of the gut — are common, especially early.

Rare but serious signals deserve honesty: pancreatitis, and a debated but real ongoing discussion around NAION, a form of “eye stroke,” where the evidence is still being sorted out. I raise these not to frighten you but because you deserve the whole ledger.

And the quiet structural problem: for most people, these are lifelong drugs. Stop them, and the weight — and often the metabolic risk — tends to return. That is a very different life decision than a short course of anything, and it deserves to be made with clear eyes.

For SGLT2 inhibitors the risk profile is different and generally gentler, but not zero — a specific type of dehydration, genital yeast infections from all that urinary sugar, and a rare metabolic complication that a knowledgeable physician watches for.

None of this cancels the benefits. It contextualizes them. A drug can extend life and still demand respect.

Head to head: which does what

If you want the cardiologist’s cheat sheet:

SGLT2 inhibitors shine brightest on heart failure and on the broad protection of the kidneys — and they carry the strongest all-cause mortality signal of the two. If I had to rank them by the weight of hard human endpoints, they sit at number one.

GLP-1 agonists shine on atherosclerotic events and stroke, and of course on the metabolic transformation that comes with substantial weight loss. Number two — an extraordinary number two.

And the most tantalizing data of all suggests the two classes may be additive — that using both, in the right person, could project more years free of cardiovascular and kidney events than either alone. We are only beginning to map that combination.

What I actually want you to take from this

Let me be very clear about what this essay is and is not.

It is not a prescription. It is not permission to order anything off the internet, and it is emphatically not a suggestion that healthy people should reach for powerful metabolic drugs as a shortcut to living forever. These medicines were studied in specific populations — people with diabetes, established heart disease, obesity, kidney disease — and that is where the evidence lives. The person they help most is not the biohacker chasing an extra decade. It’s the ordinary patient sitting across from me with a struggling heart or a failing kidney, whose life these drugs can measurably lengthen.

Whether they belong in your life is a decision for you and a physician who knows your history, checks your labs, watches for the risks I listed, and treats you as a whole human being rather than a set of numbers to optimize. The longevity clinics selling these as lifestyle enhancements are running ahead of the evidence. The cardiologists prescribing them to the right patients are practicing some of the best medicine of our era. The difference between those two things is everything.

But step back and feel the largeness of what’s happening here. We set out to lower blood sugar, and we stumbled into medicines that protect the heart, guard the kidneys, cool the fires of inflammation, and — in the populations we’ve studied — hold death itself at a small but real distance. We were looking for a better glucose number and found, by accident, a longer life.

The last word

I have stood at more bedsides than I can count, and I have learned that the goal of medicine was never simply more time. A longer life spent afraid, sedentary, and disconnected is not the prize. The prize is more good years — more mornings with the people you love, more strength in your legs, more clarity behind your eyes, more of you.

These accidental drugs are a gift, but they are not the point. They buy time. What you do with the time is the actual work — the walking, the eating well, the sleeping, the loving, the staying connected, the small daily faithfulness to a body you were only ever loaned.

The pill can hold death at a distance. Only you can fill the years it gives back.

So talk to your doctor. Read the whole ledger. And then go live in a way that would make the extra decade worth having.

Blessings.

Afshine Ash Emrani, M.D., F.A.C.C.
Assistant Clinical Professor, UCLA
David Geffen School of Medicine

Join Our new website

Castle-Connolly Nationwide Top Doctor (Since 2008)
Los Angeles Magazine Super Doctor (Since 2010)
LA Style Magazine Top 100 Doctors in America (2024)

Subscribe to mynewsletter: substack.com/@afshineemrani
Explore my books: Amazon Author Profile

You can hold your face together in a boardroom. You can smile through a diagnosis, a funeral, a marriage quietly coming apart. The body is a diplomat almost everywhere it goes.

But not in bed. In bed, the body finally tells the truth — about your hormones, your nerves, your blood vessels, and, though almost no one is listening, about your heart.

I have practiced cardiology for twenty-five years. I have watched the entire architecture of a man’s health announce itself, first and most honestly, in the one place he was least prepared to hear it. And I have come to believe that “sexmaxing” — the internet’s new obsession with optimizing sexual function — is asking the right question with the wrong map.

Because the men chasing a better night are ignoring the most sensitive early-warning system in all of medicine. It has been running the whole time. They simply never learned to read it.

This is the long version — everything I’d tell you if you were sitting across from me and we had the afternoon. Let me teach you to read your own body.

Part I — The mistake almost everyone makes

We talk about sex as if it were a single event that either works or doesn’t. On or off. Hard or soft. Pass or fail.

It isn’t. An erection — real sexual function — is four separate systems firing in sequence, each with its own biology, each capable of failing for completely different reasons:

Desire — the brain. The do I even want this. Arousal — the nervous system. The wiring that carries the signal from mind to body. Blood flow — the vessels. The plumbing that makes the mechanics possible. Orgasm and bonding — the hormones. The intensity of the finish, and the closeness after.

Break any one link and the entire chain feels broken. But the reason it broke — and the fix — lives in a different system each time. Treat the wrong one and you’ll do everything “right” and still feel like a stranger in your own body.

Hold that four-part map in your head. Almost everything that follows is an argument that the little blue pill fixes exactly one of them and quietly markets itself as the whole answer.

Part II — Viagra solved a quarter of the problem, and sold it as the whole thing

Viagra and Cialis are genuinely great drugs. I prescribe them. They belong to a class called PDE5 inhibitors, and their mechanism is elegant: they block an enzyme that would otherwise break down the chemical signal that dilates blood vessels. Stop the breakdown, and the signal to open stays switched on. The result is more flow, on demand. It is one of the great pharmacologic discoveries of the last century.

But notice where it acts. Blood flow. Step three. The plumbing. That is all it touches.

If your problem is desire, or arousal, or the hollow, disconnected quality of the finish, a PDE5 pill does nothing for you. It floods a house whose lights were never turned on. This is why so many men take the pill, watch the hydraulics work perfectly — and still feel nothing. No hunger. No pull. No reason to cross the room.

That is not a broken drug, and it is not a broken man. It is a category error. You treated a brain problem with a blood-vessel tool and then blamed yourself when the emptiness didn’t lift.

The interesting science — the actual frontier — is all upstream of the plumbing. There are three frontiers, and no pill on your nightstand has reached any of them.

Part III — The three frontiers

1. Kisspeptin — the master switch

Deep at the top of your hormonal cascade sits a molecule that functions like the master switch for the entire sexual system. It gives the command that begins the whole program — long before a single blood vessel is involved. Its name is kisspeptin.

For years it was a fertility-lab curiosity, known mostly as the trigger that ignites puberty and drives the reproductive hormones. Endocrinologists cared; nobody else did. Then researchers asked a sharper question: what if the problem for so many people isn’t the plumbing at all, but the command that’s supposed to switch everything on?

So they ran the trial. In 2023, a research team gave kisspeptin to men with low sexual desire — not classic erectile dysfunction, but the harder, quieter, more shameful problem of simply not wanting. The results turned heads. On functional brain imaging, kisspeptin lit up the brain’s entire sexual-processing network — the circuits that assign meaning and generate pull. Penile arousal response climbed by more than half — up to 56% — over placebo. And the men reported feeling more, not merely functioning more. A parallel trial in women with low desire showed the same kind of thing: modulation of the brain’s sexual and attraction circuitry, and women reporting they felt more drawn, less averse. Both trials were well tolerated.

Sit with what that means. Desire — the thing we always dismissed as mood, psychology, “just how you feel” — behaved like a real, measurable, reachable target. A switch you could actually find and flip. That is not a small upgrade to Viagra. That is a different category of medicine, and it is still early enough to feel like the opening chapter of something. It is research, not a product on a pharmacy shelf — but it is the strongest signal we have ever had that “I just don’t want it anymore” has a genuine biological address.

2. The melanocortin pathway — where wanting itself is born

Here is a truth that quietly haunts a great many men, and almost no one explains it kindly:

You can be fully capable in bed and feel no hunger for it at all. Everything works. You don’t care. And you lie there wondering what is wrong with you.

Nothing is wrong with you. Deep in the hypothalamus runs a circuit called the melanocortin pathway, and its entire job is to generate wanting — not the mechanical ability, but the pull, the reaching-toward, the appetite that makes you cross the room in the first place. It works by nudging the brain’s dopamine and reward machinery. Desire and function are two different machines. You can own a flawless engine and a dead ignition.

This is precisely the circuit Viagra never touches. PDE5 drugs work in the vessels; this works in the brain’s motivation system, and the two do not overlap. That single fact explains one of the most common and most private disappointments in men’s health: the pill worked, and the wanting still wasn’t there.

Modern research has produced molecules that act on this melanocortin pathway directly — creating arousal and desire from the top down, in the brain, rather than routing through the bloodstream. The first of them reached the market having been studied in women whose desire had gone silent, and there is real off-label experience in men, including men who never responded to PDE5 drugs at all. It comes with real trade-offs — flushing and nausea chief among them — which is exactly why it belongs in the hands of a physician and not a group chat. But the headline isn’t any single drug. The headline is that wanting is finally something science can aim at.

3. Oxytocin — the most underrated molecule in sex

Everyone calls oxytocin the “cuddle hormone,” and in doing so they insult it. That nickname makes it sound optional — soft, a garnish, a nice-to-have.

It is none of those things. Oxytocin surges at the moment of orgasm. It drives the intensity of the peak itself, and then the wave of disarmed closeness that follows — the deep, tethered, unguarded feeling after real intimacy. It is the molecular difference between a transaction and a connection, between sex that relieves one person and sex that binds two. Research on intranasal oxytocin in couples found greater orgasm intensity and greater contentment afterward, with some of the strongest effects in men. The effect is modest, but it is real, and it points at something large: the finish and the bond are their own system, with their own chemistry, that you can actually influence.

And here the blue pill has nothing at all to offer. It manages friction and ignores meaning entirely. We optimized the mechanics of sex and abandoned the part that actually makes it matter over the course of a life.

There is a cardiologist’s footnote here too, and it’s not small: oxytocin lowers stress and blood pressure and buffers the heart against chronic strain. Connection is not merely good for your relationship. It is measurably good for the organ keeping you alive. Intimacy is cardiac medicine we almost never think to prescribe.

Part IV — The whole map, in one place

Before I turn to the part I actually came to tell you, let me lay the board out cleanly, because this is the picture I wish every man had before he ever swallowed his first pill:

• Desire → kisspeptin territory. The master switch at the top of the cascade.

• Wanting / arousal → melanocortin territory. The circuit that generates hunger itself.

• Blood flow → PDE5 territory. Viagra, Cialis — the one part they own, and the one wired straight into your heart.

• Orgasm and bonding → oxytocin territory. The peak and the afterglow.

Four systems. Four different machines. One drug class that handles a single quarter of the problem while presenting itself as the entire answer.

Learn all four and you stop misdiagnosing yourself. You stop treating a desire problem with a plumbing pill and wondering why you still feel empty. You get better — and gentler with yourself — in every one of them.

And you never forget that System Three is doing double duty. Because it isn’t only the plumbing of sex. It is the early-warning system for your heart.

Part V — The turn: your erection is a stress test

You could stop reading here and be better informed than most men alive about the science of desire. But I am a cardiologist, and I would be failing you if I let you leave with only that.

Here is what keeps me up at night:

Your erection is a stress test. You take it constantly, for free, with no treadmill and no electrodes. You have simply never read the result.

Let me give you the number almost no man has ever heard. The arteries that feed an erection are roughly one to two millimeters across. The coronary arteries feeding your heart are three to four millimeters. Same body. Same blood. Same disease process when plaque begins to build.

But plaque clogs the narrow pipes first. It is simple physics applied to your own anatomy.

The tiny penile arteries choke on buildup years before the larger coronary ones show a single symptom. Which means erectile decline is often the very first visible sign of vascular disease anywhere in the body — appearing, on average, three to five years before a heart attack.

Read that again. Three to five years of advance warning. A head start most of my cardiac patients would trade almost anything to have had. And most men spend that priceless window embarrassed, hiding, or quietly ordering pills off the internet — silencing the alarm instead of answering the door.

Because that is what it is. A door. Your body knows you will ignore fatigue. It knows you will wave off “I’m just getting older.” So it delivers the message somewhere you cannot possibly miss it, at the one door a man will actually open. That is not a malfunction. That is mercy — if you are willing to receive it.

One organ, fingertips to heart

There is a reason all of this connects, and its name is the endothelium — the single-cell lining inside every blood vessel you own. One continuous sheet, unbroken, running from the tips of your fingers to the chambers of your heart to the tissue that makes an erection possible. It weighs more than your liver. It is not passive plumbing; it actively governs how vessels open, relax, and stay clean.

And it is one organ. So when it begins to fail — from high blood pressure, high blood sugar, smoking, inflammation, ruined sleep — it does not fail in one isolated spot. It fails everywhere at once. The whole lining stiffens and misfires together. The bedroom is simply where a man notices first, because the penile vessels are the smallest and least forgiving, the tissue with the least margin for error.

Erectile decline, then, is not an isolated embarrassment. It is your endothelium sending up its first flare — a live readout of the exact tissue that determines whether you have a heart attack. And here is the hopeful part: the endothelium heals. It responds, sometimes remarkably fast, to the unglamorous things. Fix the lining and you repair both rooms at once — the bedroom and the chest — because they were never separate to begin with.

Part VI — What happens in my office

Let me tell you how this actually plays out, because no advertisement will ever show it to you.

A man comes to me for his sex life. He is embarrassed. He has rehearsed the conversation in the car. He wants a prescription and a quick exit.

I do not reach for the prescription pad. I reach for his numbers. Blood pressure. Cholesterol. Blood sugar. Sleep. Stress. Family history. Because he did not actually bring me a bedroom complaint. He brought me a vascular one — he just doesn’t know it yet.

I refuse to treat the erection in isolation, and here is why. The vessels that failed in the bedroom are made of the same lining, fed by the same blood, threatened by the same plaque as the vessels feeding his heart — and the small ones always fail first. His symptom is a window. It would be negligent to paper over it with a pill and send him home.

So every so often, I find it. The blood pressure that has been quietly cooking his arteries for a decade. The cholesterol nobody flagged. The early coronary disease with a three-to-five-year fuse already lit. I find the thing that would have dropped him on a treadmill, or in his sleep, or on a Tuesday afternoon — because his erection knocked on the only door he would answer.

And then comes the moment I have never gotten used to. He came in for his sex life. He leaves having had his life extended. Sometimes he understands what just happened. Sometimes he never fully does. The bedroom saved him, and he thought he was there for something else entirely.

If you are that man — rehearsing the awkward conversation in the car right now — come in anyway. And when you do, do not ask only for the pill. Ask for the workup. Ask what your erection is telling you about your heart. That is the question that saves lives. I have watched it save them.

Part VII — How to actually read the report

Stop treating your sex life as a performance to pass or fail. Start reading it as a report your body is filing on itself, in real time, in a language you were never taught. Once you can read it, everything changes.

Desire that has gone quiet is a brain signal. It can mean hormones, dopamine, stress, sleep debt, a medication, or the early vascular changes that starve a brain of good blood flow. “I just don’t want it anymore” is data, not a verdict. It deserves a workup, not a shrug.

Arousal that won’t come is a nervous-system signal. The wiring between brain and body isn’t firing cleanly. Anxiety, nerve health, blood sugar, and circulation all live here. It is rarely “all in your head” in the cruel way people imply. It is in the wiring — and wiring can be checked.

An erection that fades is a vascular signal — and this is the loudest one. It is often the earliest warning your heart will ever hand you. This is the signal you never, ever ignore.

A finish that feels hollow — no intensity, no closeness after — is a bonding signal. That is the oxytocin layer, the part that decides whether sex connects you to someone or merely discharges tension. A lifetime of intimacy is built there, not on hardness.

Four signals. Four systems. One body, telling you the truth in the only room where it can’t lie.

Part VIII — What actually helps

This is the part the internet gets dangerously wrong. It will sell you a vial and a dosing protocol and call it optimization. I have spent a quarter century watching what that road does to hearts. Here are the levers with real evidence behind them — in the order I would pull them, the order I would give my own brother.

Move your body. This is the most underrated sexual drug on earth. Exercise repairs the endothelium directly, raises nitric oxide, lowers blood pressure, sharpens insulin sensitivity, and lifts testosterone and mood. Men who train regularly have measurably lower rates of erectile dysfunction. No pill does all of that at once.

Sleep — and get tested for apnea. Most of your testosterone is manufactured during deep sleep; wreck the sleep and you wreck the hormone. Untreated sleep apnea quietly destroys both erections and hearts, hammering the vessels all night long. If you snore, wake exhausted, and your desire has vanished, that is not a coincidence. Get a sleep study.

Eat like your vessels depend on it — because they do. A Mediterranean pattern is one of the few eating styles actually shown to improve erectile function and cut cardiac risk: olive oil, fish, plants, nuts; far less sugar and processed junk. Nitric oxide — the very molecule Viagra’s mechanism depends on — is built by a well-fed, well-exercised endothelium. Feed the machine.

Supplements with real mechanism, not magic. L-citrulline (in the range of 3–6 grams) raises nitric oxide and mildly improves blood flow through the same pathway as the pills, more gently; L-arginine works alongside it. These are legitimate and food-adjacent. Skip the “male enhancement” blends — they are mostly caffeine, hope, and occasionally hidden pharmaceuticals that can be dangerous precisely because you don’t know they’re there.

The pills — used intelligently, not secretly. Tadalafil is the most useful PDE5 inhibitor for many men because of its long duration, and a daily low dose also eases prostate and urinary symptoms, with genuine interest in what steady vascular support does over time. But the rule is absolute: a PDE5 pill should be a decision made with a physician who has checked your heart first — never a thing you order around the workup. The pill can mask the very warning this entire essay is asking you to hear.

The honest order of operations: get evaluated → fix sleep, movement, diet, blood pressure, and blood sugar → add the food-based support → then, only if needed, the right medication under real guidance. That sequence treats the whole man. It also happens to protect the one organ trying to keep him alive.

Everything above belongs with a doctor who understands the whole system, who draws baseline labs and checks your blood pressure, who is treating a man and not a symptom. The newer frontiers — the peptides and central agonists everyone is whispering about online — are real science, but they carry real cardiovascular effects, real interactions, and in some cases no approval for this use at all. They are not something to source from a stranger and inject on a hunch. This essay is education, not a prescription, and the internet is not your cardiologist.

Part IX — The last thing, and the real thing

I have spent a lifetime standing at the border between the body and the soul, and I have never found that border as sharp as we pretend it is.

The bedroom is the most honest room in your life not only because the vessels can’t fake it, but because intimacy strips away the performance we wear everywhere else. It asks the truest questions a body can ask: Do I want. Can I connect. Am I well. Am I still here.

When the answer falters, the temptation is to name it failure and reach for the fastest fix — a pill, a vial, a silence. But your body is not failing you when it speaks. It is loving you in the only language it has. The fading erection is not your enemy. It may be the most faithful messenger you will ever receive, carrying — years in advance — the one piece of news that could save your life.

So optimize. Chase the upgrade. Learn all four systems; it will make you better, and more merciful with yourself, in every one of them.

But read the whole report. Because the most powerful thing your body does in the dark is not perform.

It is warn you. It is tell you the truth. It is knock, patiently, on the only door you will answer — and wait to see whether you will finally open it.

Open it.

If this changed how you see your own body, understand that it is only the free sample. The deeper work — the science of the heart, longevity, desire, and how the body and the soul actually speak to each other — lives here, longer and quieter, with no algorithm deciding what you’re allowed to see. Subscribe for the full report, not just the headlines.

And one more thing. Every word above was written about men, because that is where the questions came in. But the science of desire, arousal, bonding, and vascular health is every bit as real in women — and their cardiac risk is more underdiagnosed, not less. The kisspeptin trials ran in women too. So did the desire research. So does the warning. If you want the version of this written for you — the desire science, the arousal biology, the bonding chemistry, and the cardiac signs medicine keeps missing in women specifically — tell me in the comments. If enough of you ask, that is the next essay.

Blessings.

Afshine Ash Emrani, M.D., F.A.C.C.
Assistant Clinical Professor, UCLA
David Geffen School of Medicine

Join Our new website

Castle-Connolly Nationwide Top Doctor (Since 2008)
Los Angeles Magazine Super Doctor (Since 2010)
LA Style Magazine Top 100 Doctors in America (2024)

Subscribe to mynewsletter: substack.com/@afshineemrani
Explore my books: Amazon Author Profile

“I thought it was just protein powder.”

It was not protein powder. It was a vial of research-grade peptide, ordered online, shipped in a plastic bag with a label reading “for research use only — not for human consumption,” reconstituted with bacteriostatic water bought from the same website, and injected into her sixteen-year-old son’s shoulder in his bedroom.

He is fine. Many are not.

There are documented cases of teenagers developing infections from contaminated vials severe enough to require skin grafts. There have been amputations. There have been cardiac events, severe allergic reactions, and hormonal disruption in young people whose bodies were still under construction.

Some of these kids started at twelve or thirteen.

I am a cardiologist. I do not treat many adolescents. But I treat the adults those adolescents become, and I have spent enough time reading this literature and hearing from worried parents that I think this needs to be said plainly, by a physician, in language a teenager will actually read.

So this article is written for two audiences at once.

Parents: here is what is happening, what to look for, and how to have the conversation.

And if you’re the teenager who found this yourself — because you’re doing your own research before you buy something, which is genuinely smart — I want to talk to you directly too. Not to lecture. To tell you what these compounds actually do inside a body your age, and what will get you the result you’re actually after, faster and permanently.

PART ONE: WHAT IS ACTUALLY HAPPENING

Teenagers are buying compounds like BPC-157, TB-500, CJC-1295, ipamorelin, and various “recovery” or growth stacks — from websites, from Instagram and Discord sellers, and from people at their gym.

They are mixing them at home. They are injecting them. And they are doing it on the basis of social media claims about faster recovery, more muscle, better skin, and “anti-aging.”

In a fifteen-year-old.

Here is what is absent from that entire chain: no physician. No baseline bloodwork. No monitoring. No sterile technique training. No quality control. No dosing standard. No adverse event reporting. And no idea whether the substance in the vial is even the substance on the label.

Over forty percent of gray-market peptide samples fail basic purity or dose testing. Wrong content. Under-dosed. Misidentified entirely. Bacterial endotoxins. Heavy metals.

And that “not for human consumption” label? It is not a warning about quality. It is legal protection for the seller — a phrase that lets a company sell an injectable substance without meeting any pharmaceutical standard whatsoever. It works. That is precisely why every one of these vendors uses it.

PART TWO: WHY A TEENAGE BODY IS THE WORST POSSIBLE PLACE FOR THIS

This is the section I most want a teenager to read, because it is not a moral argument. It is physiology.

During adolescence, your body is still under construction. And that is not a figure of speech — specific, irreversible construction is happening on a schedule.

Your growth plates are still open. These are zones of cartilage at the ends of your long bones where growth actually occurs. When they close, you stop growing. Permanently. There is no reopening them.

Your natural growth hormone and IGF-1 levels are already at the highest they will ever be in your life. Higher than any adult you know. Higher than the professional athletes you follow.

Think about that for a moment. You are already running the most powerful anabolic program your body will ever run. There is no deficiency to correct. There is no missing signal to supply. You are, hormonally, at peak.

And your reproductive and hormonal systems are still calibrating — the feedback loops that will govern your testosterone, your fertility, and your metabolism for the rest of your life are being set right now.

Introducing external compounds that push growth, healing, or hormone signaling into that system is not optimization. It is interference with a process that is already running correctly and cannot be re-run.

What can go wrong

Disrupted puberty timing.

Premature closure of the growth plates — which means you end up shorter than you would have been. Permanently. I want to state that as bluntly as possible, because for a teenager chasing physical development, this is the specific irony: you can take something to look bigger and end up shorter for the rest of your life.

Insulin resistance and blood sugar dysregulation. Growth hormone pathways and insulin pathways are intertwined; pushing one affects the other.

Fluid retention, joint problems, and cardiovascular strain.

Unknown effects on mood and brain chemistry during the years your brain is undergoing its most significant remodeling since infancy.

Immune reactions — your immune system can recognize these molecules as foreign and mount a response, and the impurities in gray-market product make that considerably more likely.

And the honest summary: there is essentially no long-term safety data in healthy young people. Nobody knows what happens at thirty-five to someone who started injecting these at fourteen. Not because it’s fine. Because nobody has studied it, and nobody will for decades.

PART THREE: “BUT PEPTIDES AREN’T STEROIDS”

This is the argument I see most often, and it contains a grain of truth wrapped around a serious error.

What’s true: peptides are different molecules operating through different pathways, and many do not suppress natural testosterone the way anabolic steroids do. That is a real distinction.

What’s false: the conclusion that this makes them safe for a developing body.

Let me lay out what we know about steroids in teenagers, because we have decades of data there:

Stunted height from premature growth plate closure. Testicular shrinkage, reduced sperm count, and fertility problems in boys. Breast tissue development in boys. Facial hair, voice deepening, and menstrual disruption in girls. Severe acne. Hair loss. Liver damage and liver tumors. High blood pressure and adverse cholesterol changes that raise cardiac risk decades later. Mood swings, aggression, and depression. And dependency.

Steroid use among high school students remains relatively low — under one percent in recent surveys — but the documented costs are severe and frequently permanent.

Now here is the reasoning error.

We know steroids are dangerous in teenagers because they have been used long enough for the damage to be documented. The evidence exists because the harm accumulated over decades and researchers went looking for it.

Peptides have not been used long enough or studied enough in adolescents for that evidence to exist.

Absence of evidence is not evidence of safety. It is simply absence.

And peptides still interfere with growth signaling, healing pathways, and hormone regulation in a body that has not finished developing. Add contamination risk and dosing errors from unregulated product, and treating them as “the safer new steroids” is a genuine mistake.

Both are shortcuts during the exact years your body is supposed to finish building itself.

PART FOUR: WHO THESE ARE ACTUALLY FOR

There is a legitimate conversation happening about certain peptides in adults — and I want to be fair about it, because dismissing it entirely is neither honest nor persuasive.

Adults in their forties, fifties, and beyond who already have accumulated damage — degenerative joint disease, cardiovascular disease, metabolic dysfunction, poor healing capacity, age-related hormonal decline — are exploring some of these compounds under medical supervision. The FDA is currently considering pathways for lawful compounding of several.

That is a completely different situation.

Those adults have something to restore. Declining function. Impaired healing. Measurable deficiency.

A healthy fifteen-year-old has none of that. Their natural systems are running at maximum capacity. Their healing is the fastest it will ever be. Their hormonal output is at peak.

There is nothing to fix. There is only something to disrupt.

PART FIVE: WHAT ACTUALLY WORKS — AND WORKS BETTER

Now the part I most want the teenager reading this to take seriously, because I am not going to spend two thousand words saying no and then offer nothing.

Here is the honest truth from someone who has studied human physiology for twenty-five years:

You are currently in possession of the most powerful anabolic environment you will ever have. Nothing you can buy will match it. The only question is whether you’re going to use it.

Most teenagers chasing peptides are doing so while sleeping six hours, eating largely processed food, drinking on weekends, training inconsistently, and skipping protein.

They are looking for a shortcut past a road they have never actually walked.

Here is the road.

Sleep — the most powerful anabolic tool you own

Eight to ten hours a night. Not seven. Teenagers genuinely need more than adults, and almost none get it.

Here is why this matters more than any injection: the large majority of your daily growth hormone is released during deep sleep, in pulses concentrated in the first few hours. Testosterone is produced predominantly during sleep. Muscle protein synthesis, tissue repair, and memory consolidation all happen at night.

A teenager sleeping six hours has voluntarily shut down the most powerful growth pathway in their own body — and then goes online to buy a compound that tries to imitate it.

You cannot supplement your way out of that. You can only sleep your way into it.

Consistent bed and wake times, including weekends. Dark, cool room. Phone out of the bedroom — and I mean physically out, not face-down, because the mere presence of it measurably reduces sleep quality and attention.

Fix this first. It is free, it is the highest-leverage thing available to you, and nothing else on this list works as well without it.

Eat like you’re building something, because you are

Protein at every meal. Roughly 1.6 to 2.2 grams per kilogram of body weight daily for someone training hard. Distribute it — about 30-40 grams per meal, because muscle protein synthesis responds to the per-meal dose, not just the daily total.

Eggs, meat, fish, dairy, legumes. Real food first.

Eat enough total calories. This is the single most common reason teenagers fail to build muscle. You cannot construct tissue from a deficit. If you are training hard and not growing, the answer is almost always that you are not eating enough — not that you need a peptide.

Cut the ultra-processed food and added sugar. Not because of purity culture, but because of what they actually do: drive insulin resistance, inflammation, and poor recovery, and displace the nutrients you need to build tissue. A diet built on packaged food and sugary drinks is a diet that fights your training.

Eat real food. Vegetables, fruit, whole grains, quality protein, olive oil, nuts. Boring, unglamorous, and it is what every well-built body is actually made of.

Train properly — and progressively

Resistance training three to five times weekly, built around compound movements: squat, hinge, push, pull, carry.

Progressive overload is the entire mechanism. Add weight or reps over time. Keep a log. The log is what turns intention into progress.

And understand the timeline honestly: meaningful muscle development takes years, not months. Everyone you follow who looks impressive has either been training consistently for a very long time, is using something, or both. The compressed timelines you see online are largely fiction, and comparing your six months to someone’s six years is how good training programs get abandoned.

No alcohol. No drugs. No vaping.

Alcohol suppresses testosterone, blunts muscle protein synthesis, wrecks sleep architecture, and impairs recovery for days after a single episode of heavy drinking.

The adolescent brain is undergoing its most significant remodeling since infancy. Alcohol, cannabis, and nicotine all interfere with that process, and the earlier the exposure, the more consequential it is.

Nicotine and vaping constrict blood vessels, impair recovery, and create dependency in a developing brain faster than in an adult one.

If you are serious about building your body, this is not a moral position. It is the single easiest performance decision available to you.

Manage stress, and move outside

Chronic stress elevates cortisol, which directly opposes muscle building and impairs recovery. Time outdoors, daily movement, real friendships, and something you do that isn’t optimization.

The honest promise

Do those five things consistently — sleep, protein, real food, progressive training, and no substances — for two years, and you will have a better body than any peptide protocol would have given you.

You will also have it permanently, without hormonal disruption, without infection risk, and without an unanswerable question about what you did to yourself at fifteen.

The basics are not the slow path. They are the only path. Everything else is decoration on top of them — and for a teenager, dangerous decoration.

PART SIX: FOR PARENTS — WHAT TO LOOK FOR AND WHAT TO SAY

Warning signs

Packages arriving that your teen intercepts, particularly small padded envelopes.

Small glass vials, syringes, alcohol swabs, or bacteriostatic water — that last one is worth searching for specifically, because there is no innocent explanation for it in a teenager’s room.

Sharps or needle caps in the trash.

Unusually rapid physical change, or dramatic swings in mood, appetite, or sleep.

New injection marks, particularly on the abdomen, shoulders, or thighs.

Sudden expertise in vocabulary — dosing, reconstitution, “stacking,” “cycling,” “research chemicals,” specific compound names.

Unexplained spending or requests for gift cards and crypto, which is how a great deal of this is purchased.

And a heavy focus on “looksmaxxing,” body optimization content, or fitness influencers in what they consume.

How to have the conversation

Do not lead with punishment. If your teenager believes disclosure means losing their phone and their gym membership, they will simply get better at hiding it — and the danger here is contamination and dosing, both of which get worse in secret.

Lead with curiosity. “I’ve been reading about the peptide stuff kids are buying online. What are you seeing about it?” You will learn more in five minutes of that than in an hour of interrogation.

Take the underlying motivation seriously. They are not doing this because they are reckless. They are doing this because they want to look a certain way, because that pressure is genuinely intense, and because their entire feed is telling them that everyone else has an edge. Dismissing that will end the conversation instantly.

Use the physiology, not the morality. “Your growth plates are still open and you already have more growth hormone than you’ll ever have again” lands considerably better with a sixteen-year-old than “drugs are bad.” Teenagers respond to being treated as intelligent.

And use the specific fear that actually works: the risk of ending up shorter. For a teenager chasing physical development, permanent height loss is the consequence that registers.

Involve a physician early if you suspect use. Not for punishment — for baseline bloodwork, for an honest conversation with someone who is not their parent, and because if there has been injection with unregulated product, infection risk needs to be assessed.

And examine what’s driving it. Body dysmorphia, disordered eating, and appearance-related anxiety are dramatically underdiagnosed in adolescent boys specifically, because we screen girls and assume boys are fine. If the drive here is distress rather than curiosity, that deserves real attention.

THE BOTTOM LINE

Peptides may eventually have a legitimate role in adults with real medical need, under real medical supervision, once the trials exist. That is a genuine conversation and I have written about it at length.

For teenagers, the answer is not complicated.

There is no deficiency to correct. The natural systems are running at peak capacity. The long-term risks are unknown and unknowable for decades. The products are frequently contaminated. And the specific window being interfered with — growth plates, puberty, hormonal calibration, brain development — closes permanently and does not reopen.

You can take something to look bigger at fifteen and end up shorter at twenty-five.

To the teenager who read this far: you already have the most powerful anabolic environment of your entire life running right now, for free, every night while you sleep.

Sleep eight to ten hours. Eat real food and enough of it. Lift progressively for years. Stay away from alcohol and drugs. Be patient.

That is not the boring alternative to the shortcut.

That is the thing the shortcut is a bad imitation of.

Protect the years when your body is still building itself. You only get them once, and nothing you can buy will give them back.

Parents: share this with another parent. Most have no idea this is happening, and it is happening in a lot of houses. And if your teenager will read it, that may matter more than anything you say — sometimes the same information lands differently from a doctor than from a father.

This article is educational and not personalized medical advice. If you suspect a young person is using these compounds, involve a physician promptly — particularly if there is any sign of infection at an injection site, which can escalate rapidly.

Follow me on X: @afshineemrani — daily on cardiology, metabolic health, longevity, and the research most people never hear about until it is already standard of care.

Subscribe to this newsletter — completely free. No paywall. No supplement line. Nothing to sell you. Just a cardiologist writing what I would want my own children to know.

Subscribe: substack.com/@afshineemrani

Blessings.

Afshine Ash Emrani, M.D., F.A.C.C. Assistant Clinical Professor, UCLA David Geffen School of Medicine

Join our new website: doctoremrani.com

Castle-Connolly Nationwide Top Doctor (Since 2008) Los Angeles Magazine Super Doctor (Since 2010) LA Style Magazine Top 100 Doctors in America (2024)

Explore my books: Amazon Author Profile

During those years it damages arteries. It fills the liver with fat. It disrupts fertility. It changes how the brain regulates hunger. It elevates cancer risk. And it does all of this while your blood glucose stays perfectly normal and your physician tells you your labs look fine.

It is insulin resistance. And the reason it goes undetected is not that we lack a test.

It is that the test that finds it early is not part of your annual physical, and almost nobody orders it unless you ask by name.

I am a cardiologist, and I treat the downstream consequences of this condition every single day — the heart attacks, the strokes, the heart failure, the arterial disease. By the time these patients reach me, the process that caused their disease has typically been running for two decades.

This handbook is my attempt to move that timeline forward. What insulin resistance actually is, what it is not, how it presents in people who do not fit the picture, exactly how to get diagnosed, and the complete protocol for reversing it.

The central message is simple and I want it stated at the top:

By the time your glucose is abnormal, you are late. The window for easy reversal is the decade before that — and you can find it, if you know what to ask for.

PART ONE: WHAT INSULIN RESISTANCE ACTUALLY IS

Insulin has two primary jobs. It moves glucose out of your bloodstream and into cells for energy or storage. And it signals your liver to stop producing additional glucose.

In insulin resistance, cells stop responding properly to that signal.

And here is the crucial compensation that hides the entire disease: your pancreas responds by producing more insulin. More signal, same result. Glucose stays in the normal range.

Not because you are metabolically healthy. Because your pancreas is working progressively harder to keep you looking that way.

That compensation can hold for a decade or considerably longer. Eventually the pancreatic beta cells begin to fail, insulin production can no longer keep pace, and glucose finally rises. At that point you are diagnosed with prediabetes or type 2 diabetes.

The diagnosis marks the failure of compensation — not the beginning of the disease.

This is why I tell patients that a normal fasting glucose is one of the most misleading reassurances in medicine. It tells you the compensation is still working. It says nothing about how hard your pancreas is working to achieve it.

PART TWO: WHY YOU CAN BE HUNGRY AND GAINING WEIGHT AT THE SAME TIME

This section explains something millions of people have experienced and been blamed for, and it deserves to be understood properly.

Different tissues become insulin resistant at different rates. This is the key insight, and it changes how the whole condition makes sense.

Muscle cells become resistant relatively early. They take up less glucose, which means less fuel entering the tissue that should be burning it.

Liver cells become resistant to the signal telling them to stop producing glucose. So your liver continues dumping glucose into circulation even when there is already plenty.

Fat cells, however, often remain insulin-sensitive longer. They are still receiving the message clearly — and insulin’s message to a fat cell is store.

So the picture becomes: high circulating insulin, muscle that cannot efficiently use fuel, a liver adding glucose it should be withholding, and fat tissue enthusiastically storing everything available. Preferentially as visceral fat, packed around the organs.

And then there is the brain

Insulin also acts in the brain, where it participates in satiety signaling and supports cerebral glucose metabolism.

When the brain becomes insulin resistant, you remain hungry despite enormous quantities of insulin circulating. And brain glucose metabolism can drop, which likely contributes to the fog, the low energy, and the mood changes people describe but struggle to articulate.

There is a genuine paradox here worth naming: chronically elevated peripheral insulin can result in relatively lower effective insulin action in the brain.

What this means, and I want to be emphatic

The lived experience becomes: constantly hungry, persistently low energy, steadily gaining fat around the middle — and being told, by doctors and family and the culture, to try harder.

That is not a willpower failure. It is a signaling failure.

The signal telling you that you have eaten enough has stopped arriving. The signal telling your fat cells to store is being received perfectly.

If you have been shamed about your weight while experiencing exactly this, I want you to read that paragraph twice. You were not weak. You were fighting a hormone.

PART THREE: WHAT INSULIN RESISTANCE IS NOT

It is not the same as type 1 diabetes, which results from autoimmune destruction of insulin-producing beta cells. Entirely different disease, entirely different mechanism.

It is not simply “eating too much sugar.” Diet matters enormously, and refined carbohydrate is a major driver. But genetics, sleep, circadian disruption, chronic stress, medications, hormonal conditions, muscle mass, and inflammation all contribute substantially.

It is not always accompanied by obesity. This is one of the most consequential misconceptions in medicine.

There is a well-described phenotype — sometimes called TOFI, “thin outside, fat inside,” or metabolically obese normal weight — in which a person of entirely normal body weight carries high visceral and hepatic fat, low muscle mass, and marked insulin resistance.

These people are massively underdiagnosed, precisely because they do not look the part and therefore nobody checks.

It is not a moral or character failure. See Part Two. This is hormonal signaling, and the signaling is measurable.

And critically: it is not irreversible. For the great majority of people, substantial improvement is achievable — which is exactly why detecting it early matters so much.

One more: a high fasting insulin does not mean you have diabetes. And a normal glucose does not rule out insulin resistance. Those two facts, held together, explain most of the diagnostic failure in this field.

PART FOUR: WHAT CAUSES IT

Visceral and ectopic fat. Not fat under the skin, but fat stored around organs and inside the liver and muscle. This is why waist circumference is more informative than weight, and why a lean person can be metabolically ill.

Physical inactivity and low muscle mass. Skeletal muscle is your largest glucose disposal organ. Less muscle means fewer places for glucose to go and greater demand on insulin to force it there.

Chronic caloric surplus, particularly from refined carbohydrate and ultra-processed food in susceptible individuals.

Sleep deprivation and circadian disruption. This one is more dramatic than people expect — even a few nights of restricted sleep measurably worsens insulin sensitivity in previously healthy people. Shift work is a genuine metabolic risk factor.

Chronic stress. Cortisol directly opposes insulin action. This is physiology, not weakness.

Genetics and family history. Real, substantial, and not your fault.

Medications — glucocorticoids most notably, along with certain antipsychotics and some antiretrovirals.

Aging and menopause. The menopausal transition drives genuine shifts in insulin sensitivity and fat distribution, and it begins in perimenopause — years before periods stop.

Inflammation and oxidative stress, which function as both cause and consequence, creating a self-reinforcing loop.

In women specifically: polycystic ovary syndrome, a history of gestational diabetes, and in some cases hormonal contraceptives.

PART FIVE: HOW IT PRESENTS — THE SIGNS PEOPLE MISS

Early insulin resistance can be entirely silent. But there are signals, and most of them get attributed to something else.

Fatigue after meals — the post-lunch crash that feels like you need to lie down. This is one of the earliest and most commonly dismissed signs.

Carbohydrate cravings that feel compulsive rather than casual.

Weight gain concentrated around the midsection, or an inability to lose it despite genuine, sustained effort.

Acanthosis nigricans — dark, velvety patches of skin on the neck, in the armpits, or in the groin. This finding is nearly diagnostic of insulin resistance, and it is constantly mistaken for dirt or poor hygiene, including by patients themselves. It is neither. It is a hormonal skin change.

Skin tags, often clustered in the same regions.

High triglycerides, low HDL, and rising blood pressure — the metabolic syndrome cluster, which frequently appears on a standard panel before anyone connects the dots.

Fatty liver, often discovered incidentally on an ultrasound ordered for something else entirely.

PART SIX: YOUNG WOMEN — THE MOST MISSED GROUP IN MEDICINE

In young women, insulin resistance very frequently presents as polycystic ovary syndrome — and it is often the underlying driver rather than an incidental finding.

How it shows up:

Irregular or absent menstrual periods. Anovulation and difficulty conceiving. Hyperandrogenism — acne, unwanted facial or body hair, scalp hair thinning in a male pattern. Central weight gain or difficulty losing weight. Substantially elevated risk of gestational diabetes and later type 2 diabetes. And mood symptoms — anxiety, depression — that the metabolic disruption genuinely worsens rather than merely accompanies.

And here is what gets missed constantly

Lean women with PCOS can have marked insulin resistance.

Driven by genetics and by ovarian and adrenal androgen excess rather than by excess adipose tissue.

If you are slim with irregular cycles, unexplained acne, or hair changes — you can be significantly insulin resistant, and almost nobody will check, because you do not fit the mental image the clinician is carrying.

Other presentations worth flagging in women: a history of gestational diabetes (which is insulin resistance revealing itself under metabolic load, and carries substantial future risk), rapid weight gain after starting certain medications, and sleep apnea — which is underdiagnosed in women because we present differently.

If you have PCOS, irregular cycles, or a gestational diabetes history — ask for a fasting insulin. Regardless of your weight. Especially if you are planning pregnancy.

PART SEVEN: HOW TO ACTUALLY GET DIAGNOSED

No single perfect test exists in routine practice. But the tests below, taken together, will find this years before a standard panel does.

Fasting insulin — the test that changes everything

Target: under 5 μIU/mL. Ideally 3-4.

This is the single test that identifies insulin resistance ten to fifteen years before glucose moves. Laboratory reference ranges commonly extend to 25 or higher — because those ranges describe a population that is largely metabolically unwell, not a target for health.

Almost nobody orders this. You will likely have to ask for it by name.

A fasting insulin of 12 with a normal glucose is not reassuring. It is a pancreas working overtime, and it is exactly the finding you want to catch.

HOMA-IR

Calculated from fasting insulin and fasting glucose:

(fasting glucose in mg/dL × fasting insulin in μIU/mL) ÷ 405

Target under 1.0. Above 2.5 generally indicates meaningful insulin resistance. You can calculate this yourself the moment you have both values.

Triglyceride-to-HDL ratio

Free. Calculated from any standard lipid panel you already have.

Under 2 is good. Under 1 is excellent. Above 3 is a red flag regardless of what your total cholesterol says. It is one of the best available proxies for insulin resistance and for the presence of small dense LDL particles.

The supporting panel

HbA1c — optimal under 5.4%, not merely under the 5.7% prediabetes threshold. Note that A1c can read falsely low with rapid red cell turnover and falsely high in iron deficiency, so interpret it alongside the rest.

Fasting glucose — under 90 is optimal. The standard cutoff of 100 is late.

Waist circumference — more informative than weight or BMI for metabolic risk.

ALT and AST — for fatty liver. And note the reinterpretation: standard ranges extending to 40 were derived from populations full of undiagnosed fatty liver. Optimal ALT is likely under 25 in men and under 20 in women.

Full lipid panel and blood pressure.

More informative, if available

An oral glucose tolerance test with insulin levels measured — not just glucose. This reveals the compensation your fasting numbers may still be hiding, and it is considerably more sensitive.

Continuous glucose monitoring can reveal post-meal excursion patterns invisible on fasting labs.

The hyperinsulinemic-euglycemic clamp remains the research gold standard but is not a clinical test.

PART EIGHT: THE PROTOCOL — WHAT ACTUALLY REVERSES IT

Lifestyle is not the consolation prize here. For insulin resistance, it is the most powerful intervention that exists, and it works faster than most people expect.

1. Build muscle — the highest-leverage intervention

Skeletal muscle is your largest glucose disposal tissue. More muscle means more capacity to absorb glucose and less demand on insulin to force it there.

Resistance training two to four times weekly. Build sessions around compound movements: squat pattern, hinge pattern, push, pull, and carry. Progressive overload is the entire point — add weight or reps over time, and keep a log.

This becomes more important with age and through the menopausal transition, not less. Muscle mass is metabolic insurance.

2. Walk after meals

Ten to fifteen minutes after eating. This blunts post-meal glucose excursions more effectively than almost any free intervention available, because contracting muscle can take up glucose through a pathway that does not require insulin at all.

If you do one thing from this entire handbook, do this one.

3. Cut ultra-processed food and refined carbohydrate

This is the single highest-yield dietary change for most people. Sugar-sweetened beverages first — they deliver a rapid glucose and insulin load with essentially zero satiety.

4. Protein and fiber at every meal

Fiber: 25-38 grams daily. Most patients get half that. Legumes are the single best source, followed by vegetables, whole grains, nuts, and seeds.

Protein at every meal stabilizes blood sugar, preserves muscle mass, and provides genuine satiety.

5. Stop grazing

Constant snacking keeps insulin elevated all day, and the whole problem is chronically elevated insulin.

Two or three defined meals, without grazing in between, gives your body actual low-insulin windows. This is often more impactful than changing what you eat.

6. Front-load your calories

Insulin sensitivity peaks in the morning and declines through the day. The identical meal produces meaningfully different metabolic consequences at 8am versus 8pm.

Larger breakfast and lunch. Lighter dinner. Stop eating three hours before bed.

A 10-12 hour overnight fast is achievable for nearly everyone and captures most of the benefit of time-restricted eating without extremes.

7. Sleep — and get tested for apnea

Seven to nine hours, with consistent timing. Short sleep worsens insulin resistance within days.

If you snore, wake unrefreshed, or your partner notices you stop breathing — get a sleep study. Untreated sleep apnea drives insulin resistance, hypertension, and inflammation simultaneously, and treating it can improve every other number in this handbook.

8. Manage chronic stress

Cortisol directly antagonizes insulin. Slow breathing, meditation, time outdoors, movement, and — the part nobody says — actually addressing the structural sources of stress in your life.

9. Target visceral fat specifically

Even modest visceral fat loss markedly improves insulin sensitivity. Focus on fat loss while preserving or building muscle, rather than scale weight alone. Watch your waist.

10. Correct the deficiencies

Magnesium, vitamin D, and omega-3 when genuinely low. Limit alcohol. Do not smoke.

How fast does it work?

Improvements can appear within weeks to months. Different tissues recover at different rates — liver and muscle often respond relatively quickly. Retest at eight to twelve weeks after making changes.

PART NINE: MEDICATIONS

Lifestyle remains foundational. Medications are added when lifestyle alone is insufficient, or when risk warrants faster intervention.

Metformin. First-line for many. Reduces hepatic glucose output and modestly improves peripheral insulin sensitivity. Widely used in PCOS and prediabetes, inexpensive, with decades of safety data. Note that long-term use warrants B12 monitoring.

GLP-1 receptor agonists (semaglutide, tirzepatide). Powerful for appetite regulation, weight loss, and glycemic control, improving insulin resistance both through fat loss and through additional mechanisms. Now with substantial cardiovascular and kidney outcome data. If you use these, the protein and resistance training in Part Eight become non-negotiable — otherwise a meaningful fraction of the weight you lose will be muscle.

SGLT2 inhibitors. Helpful for glucose with strong cardiac and kidney protection, plus modest weight loss.

Pioglitazone. Directly improves insulin sensitivity — genuinely, at the receptor level — with side effect considerations including weight gain, fluid retention, and bone risk.

For PCOS specifically: combined oral contraceptives, anti-androgens, and fertility treatments are frequently layered on top of metabolic therapy. Choice depends on age, fertility goals, and comorbidities.

All of these require medical supervision and individualization.

PART TEN: WHY THIS MATTERS — THE COMPLICATIONS

Untreated, insulin resistance progresses to prediabetes and type 2 diabetes. But long before that, hyperinsulinemia itself causes damage.

Cardiovascular disease. This is why a cardiologist writes about it. Insulin resistance drives small dense LDL particles, high triglycerides, low HDL, hypertension, endothelial dysfunction, and systemic inflammation. It is upstream of the disease that kills more people than anything else.

Fatty liver disease, progressing to steatohepatitis, fibrosis, and in some cases cirrhosis.

Certain cancers — endometrial, breast, colorectal among them — partly through insulin and IGF-1 growth signaling. Insulin is a growth hormone, and chronically elevated growth signaling has consequences.

Cognitive decline and elevated dementia risk, through brain insulin resistance and cerebral glucose hypometabolism.

Reproductive dysfunction and pregnancy complications.

Chronic inflammation, kidney disease risk, and worsening sleep apnea — each of which feeds back into the others.

And the mental health burden, which is real and rarely counted: the energy, the mood, the self-image, and the accumulated experience of being told it is your fault.

PART ELEVEN: THE THINGS PEOPLE MOST OFTEN MISS

Insulin resistance can exist with a completely normal weight and a completely normal fasting glucose. Both facts together are why it goes undiagnosed for a decade.

Hyperinsulinemia has independent effects beyond glucose — growth promotion, sodium retention and blood pressure elevation, and appetite dysregulation. The high insulin is itself doing harm, not merely marking it.

Recovery is tissue-specific and non-linear. Do not expect everything to improve in lockstep.

Young women with PCOS or irregular cycles should be evaluated even if slim.

Muscle is medicine — and it becomes more important, not less, with age and hormonal change.

Early intervention can delay or prevent progression for many years, and in many cases indefinitely.

And monitor more than glucose. Look at triglycerides, waist, liver enzymes, blood pressure, symptoms, and — when useful — insulin itself.

THE BOTTOM LINE

Here is what I want every person reading this to carry away.

You can have normal glucose, a normal HbA1c, a normal weight, and a physician telling you everything looks fine — while being a decade into a disease nobody has named yet.

The compensation that keeps your glucose normal is the same thing that hides the disease. And when that compensation finally fails, you receive a diagnosis for a process that has already been damaging your arteries, your liver, and your brain for years.

The test that finds it early costs almost nothing. Ask for fasting insulin by name, because you will almost certainly have to.

If it comes back elevated, understand precisely what you have been handed. Not a diagnosis — a decade of warning. A window during which this remains largely reversible, using tools that are free and available to you starting tomorrow.

Build muscle. Walk after meals. Cut the ultra-processed food. Fix your sleep. Stop grazing. Retest in three months.

Most people never get that warning. They get the diagnosis instead, twelve years later, when the easy window has closed.

Go get your number.

If this was useful, share it — particularly with anyone who has been told their labs are fine while feeling exhausted, hungry, and blamed for it. And with any young woman with PCOS or irregular cycles who has never had a fasting insulin drawn.

This handbook is educational and not personalized medical advice. Diagnosis and treatment require a qualified clinician who can interpret your labs in context, rule out other conditions, and tailor a plan — particularly for women planning pregnancy or with PCOS. If you have symptoms or risk factors, seek evaluation rather than self-diagnosing.

Follow me on X: @afshineemrani — daily on cardiology, metabolic health, longevity, and the research most people never hear about until it is already standard of care.

Subscribe to this newsletter — completely free. No paywall. No supplement line. Nothing to sell you. Just a cardiologist writing what I would want my own family to know, including the inconvenient parts and the parts my profession gets wrong.

Subscribe: substack.com/@afshineemrani

Blessings.

Afshine Ash Emrani, M.D., F.A.C.C. Assistant Clinical Professor, UCLA David Geffen School of Medicine

Join our new website: doctoremrani.com

Castle-Connolly Nationwide Top Doctor (Since 2008) Los Angeles Magazine Super Doctor (Since 2010) LA Style Magazine Top 100 Doctors in America (2024)

Explore my books: Amazon Author Profile

Los Angeles Heart Specialists 18370 Burbank Blvd., Suite #401, Tarzana, CA 91356 818-996-4100

That framing is now badly out of date, and it is costing people who could genuinely benefit — because they hear “weight loss,” decide the conversation isn’t about them, and never learn that this class reduces heart attacks, strokes, kidney failure, and possibly dementia.

Here is where we actually are.

What began as a single hormone has become a family — single, dual, and triple receptor agonists. The newest of them just produced 28.3% average weight loss in a Phase 3 trial. That is approaching bariatric surgery territory with a weekly injection.

And yet there is a serious problem almost nobody is warning patients about, one that can leave you frailer at a lower weight than you started.

This manual covers all of it: the complete map of the drug family, every documented benefit across organ systems, exactly who benefits most, who should avoid these entirely, the nutritional and training protocol that determines whether your weight loss builds you or hollows you out, and the practical details your prescriber may never mention.

I wrote a book on this subject because I got tired of the conversation being dominated by either uncritical enthusiasm or reflexive dismissal. This article is the current, condensed version of what I believe.

PART ONE: THE FAMILY TREE

Single agonists — the foundation

Semaglutide, liraglutide, dulaglutide. These activate the GLP-1 receptor, producing four effects simultaneously: slowed gastric emptying, enhanced glucose-dependent insulin release, suppressed glucagon secretion, and quieted appetite signaling in the hypothalamus.

Typical weight loss: 10-15%.

Why “glucose-dependent” matters more than people realize: insulin is released only when blood glucose is actually elevated. This is why these drugs rarely cause hypoglycemia on their own — a genuine safety advantage over older diabetes medications like sulfonylureas, which push insulin regardless of need.

Dual agonists — two receptors, synergistic effects

GLP-1 + GIP (tirzepatide). GIP adds insulin sensitivity and improved lipid handling on top of the GLP-1 effects. Weight loss up to approximately 21%.

GLP-1 + glucagon (survodutide, mazdutide). This combination is conceptually different and worth understanding. The glucagon arm raises energy expenditure and drives hepatic fat oxidation. You are not merely eating less — you are burning more. This makes them particularly powerful for liver disease.

GLP-1 + amylin (CagriSema). Amylin recruits a separate satiety pathway plus gastric effects, adding to the GLP-1 mechanism.

Triple agonists

Retatrutide activates GLP-1, GIP, and glucagon receptors simultaneously: appetite suppression, insulin sensitization, and increased energy expenditure all at once. This is the agent producing bariatric-adjacent results.

PART TWO: WHAT JUST CHANGED

Retatrutide’s Phase 3 data is in

TRIUMPH-1: 28.3% average weight loss at 80 weeks on the 12mg dose, with up to 30.3% at 104 weeks in the higher-BMI extension.

That is the largest reduction ever reported in a Phase 3 obesity trial.

It remains investigational. Filing is expected in the first quarter of 2027, with approval realistically not before 2027-2028. Anyone selling you retatrutide today is selling you something from a gray market, not a pharmacy.

The oral era arrived

Oral semaglutide 25mg was approved in December 2025 — roughly 16.6% weight loss in the OASIS 4 trial.

Then orforglipron was approved on April 1, 2026 — the first small-molecule oral GLP-1 receptor agonist. It can be taken any time of day, with no food or water restrictions, unlike the peptide-based orals that require careful fasting protocols.

Its approximately 12% weight loss trails the injectables. But focusing on that misses the point entirely: fewer than one in ten eligible patients currently take any GLP-1. The barrier has never been efficacy. It has been injections, cost, and supply.

Being a small molecule rather than a peptide, orforglipron is also far easier to manufacture at scale — which matters enormously for supply and eventually for price.

And an honest disappointment

CagriSema failed non-inferiority against tirzepatide in February — 20.2% versus 23.6% at 84 weeks in a head-to-head trial.

I include this deliberately. The field does not only produce wins, and you should be suspicious of anyone who only tells you about the successes.

PART THREE: THE CARDIOVASCULAR DATA

This is my field, and this is why I stopped calling them weight loss drugs.

SELECT

17,604 people with obesity and established cardiovascular disease, without diabetes. Semaglutide cut major adverse cardiovascular events — cardiovascular death, nonfatal heart attack, nonfatal stroke — by 20%.

Here is the detail that changed my thinking: roughly a third of that benefit appeared independent of weight loss, and cardiac protection began emerging before significant weight came off.

That tells you these drugs are doing something directly to the vasculature and to inflammation — not simply helping by shrinking people.

Across the class

13-20% reduction in major adverse cardiovascular events, with specific reductions in myocardial infarction, stroke including fatal stroke, and heart failure hospitalization. Benefits extend to peripheral arterial disease.

Heart failure with preserved ejection fraction

This deserves its own paragraph, because HFpEF is a brutal condition for which we have had almost nothing to offer.

Roughly 40% relative risk reduction in heart failure hospitalization in some analyses. And in the SUMMIT trial, tirzepatide cut cardiovascular death or worsening heart failure by 38% in patients with HFpEF and obesity.

For many of these patients, this is the first genuinely effective therapy anyone has been able to offer them.

The mechanisms

Lower hs-CRP and systemic inflammation. Lower blood pressure. Lower triglycerides. Effects on atherosclerotic plaque. And direct receptor activity in cardiac and vascular tissue — GLP-1 receptors exist in the heart and blood vessels, not merely the gut and brain.

PART FOUR: KIDNEY, LIVER, AND SLEEP

Kidney

The FLOW trial: 24% fewer serious kidney events and 20% lower all-cause mortality.

Reduced albuminuria, slower eGFR decline, and delayed progression to kidney failure — with or without diabetes.

For anyone with chronic kidney disease, this is a major development. We have had very few interventions that meaningfully alter that trajectory.

Liver

Dramatic reductions in liver fat — 60-86% with the dual and triple agonists — plus enzyme normalization and genuine fibrosis resolution signals. The ESSENCE trial resolved MASH inflammation in approximately 63% of patients.

The glucagon-containing agents excel here, which points toward something important: a patient with heavy liver fat may be better matched to a glucagon-inclusive drug than to a pure GLP-1.

That is what personalized incretin therapy will look like — matching the receptor profile to the phenotype.

Sleep apnea

Tirzepatide is now FDA-approved for moderate-to-severe obstructive sleep apnea in adults with obesity.

SURMOUNT-OSA demonstrated large reductions in apnea-hypopnea index, hypoxic burden, blood pressure, and inflammatory markers — improving sleep independent of, or additive to, CPAP.

This one matters enormously downstream. Untreated sleep apnea drives hypertension, atrial fibrillation, insulin resistance, and low testosterone. Treating it improves nearly everything else.

PART FIVE: THE SIGNALS WE ARE STILL CHASING

I want to label these clearly as promising rather than established.

Brain

Observational data and meta-analyses link GLP-1 use to roughly 30% lower dementia and Alzheimer’s risk in diabetes cohorts, with improved cognitive scores in mild cognitive impairment and early signals in Parkinson’s disease.

Preclinical work shows reduced neuroinflammation, amyloid, and tau pathology. Dedicated randomized trials using oral semaglutide are running now, and their results will matter a great deal.

Cancer

Propensity-matched analyses of obesity-related cancers show 38-50% lower likelihood of progression from stage I-III to metastatic disease among GLP-1 users, with roughly 30% signals for lower breast cancer incidence and recurrence. Higher tumor GLP-1 receptor expression correlates with better outcomes.

These are associative and require confirmatory trials. I will not overstate them. But the proposed mechanism — reduced inflammation, lower insulin and IGF-1 signaling, less visceral fat — is biologically coherent.

Also documented

Lower alcohol consumption and cravings, with reduced substance use disorder risk across categories. Fewer venous thromboembolic events. Osteoarthritis symptom relief. PCOS improvement. Better wound healing. And measurable reductions in sick days, physician visits, and emergency department utilization.

PART SIX: WHO SHOULD TAKE THESE

Let me be direct about the strongest candidates.

Type 2 diabetes, particularly with established cardiovascular disease or chronic kidney disease. Here these are arguably first-line beyond metformin, and the outcome data is robust.

Obesity with established cardiovascular disease. The SELECT population. If this is you and you are not having this conversation with your cardiologist, you should be.

Obesity with heart failure, particularly HFpEF. The SUMMIT data is genuinely important.

Chronic kidney disease with albuminuria. FLOW.

MASLD or MASH — especially with a glucagon-containing agent when available.

Obesity with moderate-to-severe obstructive sleep apnea — tirzepatide now has a specific indication.

Metabolic syndrome with a strong family history of premature cardiovascular disease.

And people who have genuinely tried. I want to say this plainly, because the moralizing around obesity remains ugly: if you have made serious, sustained attempts at lifestyle change and your biology fought you, that is not a character failure. Obesity is a chronic disease with powerful hormonal defenses of body weight. Using an effective medication for a chronic disease is not cheating. Nobody calls a statin cheating.

PART SEVEN: WHO SHOULD AVOID THEM — OR PROCEED WITH REAL CAUTION

This section is the one most articles skip, and it matters as much as everything above.

Absolute contraindications

Personal or family history of medullary thyroid carcinoma, or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). This is a boxed warning based on rodent thyroid C-cell tumor findings. The human relevance remains uncertain, but the contraindication is firm.

Known hypersensitivity to the agent or its components.

Pregnancy. These should be discontinued well before a planned pregnancy — typically at least two months before, given the long half-lives — and they are not for use while breastfeeding. Important and underdiscussed: improved fertility with weight loss and restored ovulation means unintended pregnancies happen. If you are of reproductive age, discuss contraception explicitly. Oral contraceptive absorption may also be affected by delayed gastric emptying.

Serious cautions requiring individual judgment

History of pancreatitis. Not an absolute contraindication in most guidance, but it warrants genuine caution and shared decision-making. If you have had confirmed GLP-1-associated pancreatitis, do not restart.

Gastroparesis or severe gastrointestinal motility disorders. These drugs slow gastric emptying by design. Adding that to a stomach that already empties poorly is a bad combination.

Active gallbladder disease or a history of gallstones. See the gallbladder section below — risk is genuinely elevated.

Proliferative diabetic retinopathy. Rapid glucose lowering can transiently worsen retinopathy. This requires ophthalmology involvement and careful monitoring, not avoidance necessarily — but it must be addressed before starting.

Active eating disorder, or a significant history of one. This is the one I feel most strongly about and see handled most poorly. A powerful appetite suppressant in someone with anorexia nervosa, bulimia, or a restrictive eating history can be genuinely dangerous. Screen for this honestly. If you have that history, tell your prescriber even if you would rather not.

Significant frailty or sarcopenia already present, particularly in older adults. See Part Eight — you can make a frail person frailer.

Severe renal or hepatic impairment. Requires dose adjustment and specialist input.

Planned surgery or procedures requiring anesthesia. Delayed gastric emptying raises aspiration risk. Tell your surgeon and anesthesiologist you are on a GLP-1 — guidance on holding doses before procedures exists and continues to evolve. This is a real safety issue, not a formality.

Type 1 diabetes — not an approved indication, and use requires specialist management.

And a category of caution nobody discusses

If you cannot commit to adequate protein and resistance training, particularly if you are over 60 or postmenopausal, seriously reconsider the timing.

I am not saying you cannot have the medication. I am saying the drug plus neglect produces a specific bad outcome — rapid loss of muscle and bone — and you should know that before you start rather than discover it on a DEXA scan two years later.

PART EIGHT: THE WARNING ALMOST NOBODY GIVES PATIENTS

Rapid weight loss of any kind — including with these drugs — costs you lean tissue.

If unmitigated, 20-40% of total weight lost can be lean mass.

And bone follows muscle. Studies show measurable declines in hip and spine bone mineral density — around 2% in some 52-week data — with increased bone resorption markers and observational signals of higher osteoporosis diagnosis rates in long-term users.

Fracture data is genuinely mixed. Some analyses show neutrality or even protection in diabetes cohorts. I will not overstate this. But the risk concentrates exactly where you would expect: older adults, postmenopausal women, and anyone with low baseline bone density.

The mechanism is largely secondary: reduced calorie and nutrient intake including calcium, vitamin D, and protein; loss of the muscle that mechanically loads bone; and hormonal shifts during rapid catabolism. Direct drug effects on bone appear neutral to mildly negative.

You can lose 25% of your body weight and end up frailer than when you started.

That is not theoretical. I see it. And sarcopenia and low bone density are what determine whether you spend your last decade in your own home or in a facility.

The drug is half the treatment. Here is the other half.

PART NINE: THE PROTEIN PROTOCOL

Target 1.2-1.6 grams per kilogram of body weight daily. Higher end if you are over 60 or losing rapidly. For a 90kg person, that is roughly 110-145 grams daily.

Distribute it: approximately 0.3-0.4 g/kg per meal — about 30-40 grams per sitting. Muscle protein synthesis responds to the per-meal dose, not merely the daily total. One large protein dinner does not substitute for three adequate meals.

Leucine is the trigger. Aim for roughly 2.5-3 grams per meal — approximately what is contained in 30 grams of high-quality protein. Whey, eggs, dairy, meat, and fish are leucine-rich. Plant sources generally require larger portions to reach the same threshold.

Higher protein intake correlates directly with less lean mass loss on these drugs. This is the single most important variable you control.

And here is why it is genuinely hard: the medication suppresses appetite, which is the entire point of taking it. You must eat with intention rather than waiting for hunger to arrive.

Practical approach: protein first, every meal, before anything else on the plate. A protein shake is legitimate nutrition in this context, not a shortcut — when appetite is suppressed, liquid calories that are nutrient-dense are a tool, not a compromise.

PART TEN: THE TRAINING PROTOCOL

Protein supplies the raw material. Resistance training is the signal that tells your body to keep the muscle. Without the signal, the protein has nowhere useful to go.

Two to four sessions weekly. Non-negotiable.

Build every session around compound movements that load the hips, spine, and legs — the sites that lose bone first:

Squat pattern (back squat, goblet squat, leg press, split squat) · Hinge pattern (deadlift, Romanian deadlift, hip thrust) · Push (overhead press, bench press, push-up) · Pull (row, pull-up, lat pulldown) · Carry (farmer’s walk, suitcase carry)

Rep ranges: 5-8 with a genuinely challenging load for strength and bone. 8-12 for muscle hypertrophy. Do some of each. The final two or three reps should be difficult.

Progressive overload is the entire point. Add weight, reps, or sets over time. Keep a log — the log is what makes progression actually happen rather than remaining an intention.

And add impact if your joints allow: 10-20 jumps, hops, or heel drops daily. Rope skipping counts.

Bone responds to exactly two signals: heavy loading and impact. Walking does not build bone density. It is excellent for other reasons — cardiovascular health, glucose control, mood — but it will not preserve your skeleton during rapid weight loss.

Medication plus training preserves bone mineral density substantially better than medication alone. This is the difference between losing fat and losing yourself.

PART ELEVEN: MICRONUTRIENTS AND MONITORING

Appetite suppression means you are eating less of everything, not merely fewer calories.

Calcium 1,000-1,200mg daily, food first, spread across the day for better absorption.

Vitamin D to a blood level of 40-60 ng/mL — take D3 with K2, with a fat-containing meal.

Magnesium — required to activate vitamin D and supports the bone matrix.

Plus iron, zinc, and B12 — check these, particularly if you were already marginal before starting.

What to monitor

Baseline DEXA if you are postmenopausal, over 60, of low body weight, or have a family history of osteoporosis. Repeat it during treatment.

Track strength, not just the scale. Grip strength. What you can lift. How fast you walk. If those numbers are falling while your weight falls, something is wrong with how you are losing.

Body composition beats scale weight, always. A 15% loss that is nearly all fat is a better clinical outcome than a 25% loss that took your quadriceps with it.

PART TWELVE: THREE THINGS YOUR PRESCRIBER MAY NOT MENTION

Gallbladder risk, and how to reduce it

These drugs slow gallbladder emptying through reduced cholecystokinin signaling, and rapid weight loss supersaturates bile with cholesterol. The result is meaningfully elevated gallstone risk.

Practical mitigation that almost nobody explains:

Do not do prolonged fasting windows on these drugs. Regular smaller meals stimulate gallbladder contraction and emptying. Long fasts allow bile to sit and concentrate — exactly the wrong thing when your gallbladder is already sluggish.

Do not eliminate dietary fat entirely. Fat is the primary trigger for gallbladder contraction. Very low-fat eating during rapid weight loss is a recipe for sludge and stones.

Know the warning signs: right upper quadrant pain especially after fatty meals, pale stools, dark urine, yellowing of the eyes or skin, persistent nausea.

Asymptomatic enzyme elevations are not pancreatitis

Mild rises in amylase and lipase are expected pharmacology on these drugs. The positive predictive value of an isolated asymptomatic elevation for actual clinical pancreatitis is under 1%.

Routine surveillance enzyme testing in asymptomatic patients is not recommended by FDA prescribing information, the ADA Standards of Care, or major gastroenterology and endocrine societies.

Yet patients are being taken off effective, life-extending therapy over trivial laboratory changes. I see it constantly, and it is a genuine harm.

Real pancreatitis means severe, persistent upper abdominal pain, often radiating to the back, typically with nausea and vomiting. That is a stop-immediately-and-evaluate situation. A number on a routine panel in someone who feels fine is not.

Plan for maintenance before you start

Weight regain after discontinuation is substantial in the trial data. This is chronic disease therapy, not a course of antibiotics.

Discuss the long-term plan before you begin — including what happens if insurance coverage changes, if supply tightens, or if you need to stop for surgery. Knowing the plan in advance prevents the panic and the rapid regain that follow an abrupt stop.

PART THIRTEEN: WHERE THIS IS GOING

By 2027-2028, retatrutide and the next wave should push average weight loss toward 28-30%, with substantially stronger multi-organ outcome data.

Oral small molecules will democratize access — the barrier was never efficacy, it was needles, cost, and supply.

Monthly dosing is in Phase 3. Indications will keep expanding into MASH, additional heart failure phenotypes, osteoarthritis, and possibly the first neurodegenerative approvals if the ongoing trials succeed.

And critically: combinations pairing incretins with muscle-preserving agents — activin receptor antagonists such as bimagrumab — are already in trials, targeting precisely the lean mass problem described above.

The future is matching drug to phenotype. Heavy liver fat to a glucagon-inclusive agent. Sleep apnea to tirzepatide. Adherence difficulty to an oral. Sarcopenia risk to a combination that protects muscle.

THE BOTTOM LINE

Here is how I think about this class now.

These have stopped being weight-loss medicine and become foundational cardiometabolic therapy — arguably the most important development in my field since statins.

Fewer heart attacks. Fewer strokes. Less kidney failure. Better sleep. Resolved liver inflammation. Possibly less dementia and slower cancer progression.

But the drug is only half the treatment.

Eat the protein. Lift the weights. Watch body composition, not the scale. Get the DEXA. Keep the muscle.

And know honestly whether you belong in the group who should take these — or in the group who should wait, or avoid them entirely. That conversation is worth having properly, with a physician who will discuss both columns.

Otherwise you will get the number you wanted, and lose the body you needed to carry it.

If you want the complete version

I wrote a book on this, because the public conversation kept collapsing into either uncritical enthusiasm or reflexive dismissal, and patients deserved better than both.

The GLP-1 Breakthrough: A Cardiologist’s Secrets for a Healthier Life — the full clinical picture, the protocols, the safety details, and how to have this conversation with your doctor.

If this article was useful, the book is where the rest of it lives.

Share this with someone starting a GLP-1 who has not been told about the muscle and bone piece. That conversation may matter more than any other one they have about this medication.

This article is educational and not personalized medical advice. Do not start, stop, or change any medication without your own physician. If you develop severe abdominal pain on a GLP-1 receptor agonist, seek medical attention immediately.

Follow me on X: @afshineemrani — where I post daily on cardiology, metabolic health, longevity, and the research most people never hear about until it is already standard of care.

Subscribe to this newsletter — completely free, no paywall, nothing to sell you. Just a cardiologist writing what I would want my own family to know, including the inconvenient parts and the parts my profession gets wrong.

Subscribe: substack.com/@afshineemrani

Blessings.

Afshine Ash Emrani, M.D., F.A.C.C. Assistant Clinical Professor, UCLA David Geffen School of Medicine

Join our new website: doctoremrani.com

Castle-Connolly Nationwide Top Doctor (Since 2008) Los Angeles Magazine Super Doctor (Since 2010) LA Style Magazine Top 100 Doctors in America (2024)

Explore my books: Amazon Author Profile

You are injecting something into your body. Can you prove what it is?

Not “the vendor said.” Not “it came with a certificate.” Not “my guy has been reliable.” Can you actually prove — with a document you independently verified, tied to the specific vial in your hand — that the substance you are putting under your skin is what the label claims, at the dose it claims, free of bacterial endotoxins and heavy metals?

For the overwhelming majority of people using peptides today, the honest answer is no.

Over forty percent of gray-market peptide samples fail basic purity or dose testing. Wrong content. Under-dosed. Misidentified. Contaminated.

And here is the part that should genuinely unsettle you: the people selling to you know this. They know that almost nobody verifies. They know a convincing certificate of analysis takes an afternoon in a PDF editor. They know that the phrase “not for human consumption” on the vial is legal armor for them and means nothing for you.

I am not writing this to talk you out of peptides. I have read enough dismissive medical commentary to know that it does not work and is not even honest. The hunger driving this is real, and the inference behind it is reasonable — millions of people watched a prescribed injectable transform their metabolic health and concluded that molecular medicine can change a body. They are not wrong about that.

What I object to is not the ambition. It is that an entire industry has been built on the assumption that you will not check.

So this is how you check.

PART ONE: THE QUESTION THAT DECIDES EVERYTHING ELSE

Before we get to laboratories and certificates and pharmacy licenses, answer this one:

Which of three completely different regulatory worlds are you buying from?

Most people cannot answer. And this single question determines more about your actual risk than which peptide you chose, what dose you take, or how carefully you inject it.

Tier 1 — FDA-approved finished drug products

Completed Phase 1 through 3 human trials establishing safety and efficacy for a defined indication. Manufactured under current Good Manufacturing Practices in FDA-inspected facilities. Validated purity, potency, sterility, endotoxin limits, batch-to-batch consistency. Required labeling. Established dosing. Known contraindications. Defined monitoring. Adverse event reporting. Manufacturer liability.

You know what is in the vial. You know what it does. You know what it might do to you.

Tier 2 — Lawfully compounded under prescription

Prepared by licensed 503A pharmacies or 503B outsourcing facilities under USP standards, including USP <797> for sterile compounding. Real state board oversight. A prescribing clinician. Accountability.

But the crucial limitation: compounded preparations do not undergo pre-market FDA review for the safety and efficacy of that specific preparation. The pharmacy is regulated. Whether the molecule works is an entirely separate question.

Tier 3 — “Research use only”

No manufacturing standard. No purity requirement. No sterility guarantee. No identity verification. No adverse event system. No recourse whatsoever.

And the “not for human consumption” label exists to protect the seller in court. It is not a quality designation. It is a liability shield, and it works — which is precisely why every one of these vendors uses it.

The ladder to memorize

FDA-approved finished drug > lawful compounding under prescription from a verified pharmacy > everything else.

If you take one thing from this manual, take that hierarchy. It is worth more than any dosing protocol you will ever read.

PART TWO: WHICH PEPTIDES ARE ACTUALLY APPROVED — AND WHICH AREN’T

This section makes people uncomfortable, which is why I am putting it early.

Actually FDA-approved

Metabolic: semaglutide (Ozempic, Wegovy, Rybelsus and oral forms), tirzepatide (Mounjaro, Zepbound — now also approved for obstructive sleep apnea), liraglutide (Victoza, Saxenda), and orforglipron (approved April 2026, the first small-molecule oral GLP-1).

Specific indications: tesamorelin (Egrifta) for HIV-associated lipodystrophy. Bremelanotide (Vyleesi) for hypoactive sexual desire disorder. Teriparatide and abaloparatide for osteoporosis. Insulin. Somatropin for documented growth hormone deficiency. Afamelanotide for certain porphyrias.

Sermorelin previously held approval for pediatric growth hormone deficiency; current US availability runs largely through compounding.

Not FDA-approved for any human use

BPC-157. TB-500. CJC-1295. Ipamorelin. MOTS-c. KPV. Epitalon. Semax. Melanotan II. AOD-9604.

And essentially every other compound marketed for recovery, wellness, anti-aging, or performance.

These lack completed large-scale human safety and efficacy trials. The evidence base is animal studies, cell work, small uncontrolled series, and anecdote.

That does not mean they do nothing. It means nobody has established that they do something — at what dose, by what route, with what consequences over years.

And the July 2026 vote everyone is misrepresenting

An FDA advisory committee voted to recommend adding several of these — BPC-157, TB-500, MOTS-c, KPV — to the 503A bulk substances list for compounding eligibility. The BPC-157 vote was 8 to 6, over the objection of the FDA’s own scientific staff.

Three facts:

It is non-binding. The FDA still decides.

Formal rulemaking takes twelve to twenty-four months minimum. Nothing changed legally that day.

Compounding eligibility is not FDA approval. It would mean a licensed pharmacy may lawfully prepare it under prescription. It would not mean anyone proved it works.

If someone told you “BPC-157 is approved now” — they were either confused or selling. Notice which, because it tells you what else they might be willing to tell you.

PART THREE: HOW TO READ A CERTIFICATE OF ANALYSIS

The COA is your only practical window into what is in a vial.

It is also the most commonly forged document in this industry, because a professional-looking PDF is trivial to produce and almost nobody verifies it.

Here is what a real one contains.

The exact batch or lot number printed on your physical vial. Not “representative.” Not a different lot of the same product. The one in your hand.

A named, independent laboratory — not “our third-party lab,” not the vendor’s in-house department.

Identity by mass spectrometry (MS or LC-MS), with the observed molecular weight matching the theoretical value for that peptide sequence. This is what proves the vial contains the molecule claimed. Without identity testing, purity data describes an unknown substance.

Purity by HPLC, including the actual chromatogram, integration data, and method details — column, gradient, detection wavelength. Not a round number in a box.

Net peptide content in milligrams. This one catches almost everyone: a vial can be 99% pure and contain half the stated dose. Purity and quantity are different measurements. Peptide products carry counterions, water, and residual salts that add mass without adding peptide.

For injectables: bacterial endotoxin testing (LAL assay per USP <85>), and ideally sterility data. Endotoxins are bacterial cell wall fragments that survive sterilization. Injecting them causes fever, chills, and systemic inflammatory response — and worse in significant exposure.

Plus: analysis date, referenced methods, residual solvents where relevant, analyst signature, and a unique accession number or verification key.

PART FOUR: HOW TO VERIFY IT — THE STEP ALMOST NOBODY TAKES

This is the heart of the manual.

Step 1 — Match the lot number

Vial to COA. Exactly. No match, stop.

Step 2 — Confirm the laboratory exists and is independent

Search the name, physical address, and accreditation.

ISO/IEC 17025 is the gold standard for testing laboratory competence — it means an independent accreditation body audited their methods, equipment, personnel, and quality systems.

Where to check accreditation:

• A2LA (American Association for Laboratory Accreditation) — public directory at a2la.org

• ANAB (ANSI National Accreditation Board) — searchable directory at anab.ansi.org

• PJLA (Perry Johnson Laboratory Accreditation) — pjlabs.com

If a laboratory claims ISO 17025, it will appear in one of these directories. If it doesn’t appear, the claim is false.

Step 3 — Verify through the laboratory’s own portal

This is the step that defeats nearly all fraud.

Take the accession number, QR code, sample ID, or verification hash from the COA and enter it into the laboratory’s own public verification system — not a link the vendor provides, which can point anywhere.

The original record should appear and match.

Why this works: a vendor can fabricate a beautiful PDF in an afternoon. What a vendor cannot do is insert a matching entry into an independent laboratory’s database.

If the number does not resolve on the lab’s own system, the document is worthless no matter how professional it looks.

Step 4 — Read the actual data

Look at the raw chromatogram and mass spectrum, not just the summary numbers.

Does it look like real analytical output — baseline noise, realistic peak shapes, actual retention times? Or does it look like clip art?

PART FIVE: RED FLAGS THAT MEAN WALK AWAY

No named laboratory, or a generic in-house name.

A “representative” or multi-batch COA rather than lot-specific.

Purity without identity, or identity without purity. You need both.

No net peptide content — only a purity percentage.

No endotoxin testing on an injectable.

No verification portal, or an accession number that fails to resolve.

Vendor-only contact. If you cannot reach the laboratory directly, you cannot verify anything.

Perfect round numbers. Real analytical results are untidy — 98.7%, not “99%.”

Identical results across different lots. Real manufacturing has batch variation. Identical data means one template and a text editor.

Urgency and scarcity marketing. Limited-time pricing on an injectable substance is a sales tactic, not a medical one.

And the biggest one: anyone who discourages you from verifying. A legitimate supplier is proud of their testing. Defensiveness about verification is the loudest signal in this entire manual.

PART SIX: HOW TO VET A PHARMACY

If you are going the prescription route — and you should — here is the actual diligence.

Verify the license, yourself, in two minutes

Every state maintains a searchable pharmacy license database. Find yours by searching “[your state] board of pharmacy license verification.”

The NABP (National Association of Boards of Pharmacy) maintains resources at nabp.pharmacy, including their Verified Pharmacy Program and a list of accredited digital pharmacies. Their “.pharmacy” top-level domain is only issued to verified legitimate pharmacies — a site ending in .pharmacy has passed vetting.

The FDA maintains a public list of registered 503B outsourcing facilities at fda.gov — searchable, and worth checking directly rather than taking a claim on faith.

Ask 503A or 503B — and know the difference

503A pharmacies compound for individually identified patients with a prescription. State-regulated.

503B outsourcing facilities register with the FDA and operate under cGMP — a substantially higher manufacturing standard, with FDA inspection.

When you have the choice, 503B is the better tier. Ask directly.

Ask where the API comes from

The active pharmaceutical ingredient should come from an FDA-registered facility.

If the pharmacy will not answer this question, that is your answer. Legitimate operations know their supply chain and will tell you.

Look for PCAB accreditation

PCAB (Pharmacy Compounding Accreditation Board), administered through ACHC, is a voluntary accreditation for compounding quality systems. Verify at achc.org. It is a genuine positive signal.

Ask about their testing

A quality pharmacy tests incoming API and finished preparations — potency, sterility, endotoxin. They will describe their program without hesitation. Vagueness here is disqualifying.

PART SEVEN: HOW TO VET A PROVIDER

This may matter more than the pharmacy, because the provider is who decides what goes into you.

Verify they are who they claim

Check the medical license through your state medical board — every state has a public lookup. Search “[state] medical board license verification.”

Check board certification at certificationmatters.org (ABMS) for physicians, or the equivalent for the specific credential claimed. “Board certified” gets used loosely; verify what board and in what specialty.

Check for disciplinary actions. Most state boards publish them. So does the Federation of State Medical Boards at docinfo.org — a nationwide physician lookup showing licensure and disciplinary history.

For nurse practitioners and physician assistants, verify through the state nursing or medical board, and ask specifically about their supervising physician arrangement and what oversight actually exists.

Then ask the question that separates a clinician from a salesman

Ask this, verbatim:

“Can you tell me which of these is FDA-approved, which is lawfully compounded, and which is experimental — and walk me through the evidence gaps for each?”

A good provider answers immediately, in those categories, without discomfort.

A provider who blurs those three, or bristles, or redirects to testimonials, is selling.

Six more questions worth asking

“What baseline labs will you order before I start, and what will you monitor while I’m on it?” — If the answer is “none,” walk out. Any compound worth taking is worth monitoring.

“What are the specific risks and contraindications for this compound in someone with my history?” — A real answer will be specific to you. A rehearsed answer will be generic.

“Do you or the clinic have a financial relationship with the pharmacy or supplier?” — You are entitled to know. Disclosure is normal; evasion is not.

“What would make you tell me to stop?” — A clinician has stopping criteria. A salesman does not.

“What happens if I have a reaction at 2am? Who do I call?” — If there is no answer, you are unsupported.

“How many patients have you managed on this, and what problems have you seen?” — Anyone who reports zero problems across many patients is either inexperienced or not telling the truth.

The red flags in a provider

Consultations that are essentially sales calls. Package deals and bulk discounts on injectables. Recommending a protocol before ordering any labs. Dismissing your questions about evidence. Claiming FDA approval for compounds that have none. Pressure. Testimonials in place of data. And no monitoring plan — the single clearest sign that nobody is actually practicing medicine.

PART EIGHT: THE OPTION ALMOST NOBODY USES

If you are spending real money, using something long-term, or making a high-stakes decision:

Send a sample from your own vial to an independent analytical laboratory.

Request HPLC for purity, mass spectrometry for identity, and endotoxin (LAL) testing if injectable.

Look for ISO 17025-accredited analytical laboratories that accept third-party samples — verify accreditation through A2LA, ANAB, or PJLA as described above before you send anything.

It costs a fraction of what you are already spending. And it is the only way to know what is in your vial rather than what a document claims about a batch.

I find it remarkable how many people spend four hundred dollars a month for two years and never spend a hundred and fifty dollars once to find out if it is real.

PART NINE: THE HONEST LIMITS OF ALL THIS

Here is where I have to be scrupulous, because verification enthusiasm can itself mislead you.

What a verified COA proves: chemical composition and certain purity and safety markers, at the moment of testing, for that batch.

What it does not prove: that the compound works. That it is safe over years. That your dose is right. That your route of administration has ever been studied.

Verification solves the contamination problem. It does not solve the evidence problem.

Concretely: BPC-157’s strongest published human data involves roughly thirty subjects, longest treatment about two weeks, and the routes studied barely overlap with how people actually use it. TB-500 has no completed human randomized trials.

A perfectly pure vial of something unstudied is still something unstudied.

PART TEN: MY CONCERNS AS A CARDIOLOGIST

Angiogenesis. BPC-157 appears to work partly by growing new blood vessels — plausibly why it may heal tendon. It is also why I want to know what else is growing in someone before they inject a molecule whose fundamental message is build, repair, proliferate. Nobody has studied this over years. Nobody has studied it in cancer survivors. The FDA’s own briefing materials flagged theoretical tumor concerns.

Immunogenicity. Repeated injection of a poorly characterized substance is a genuine immunologic exposure. Impurities and aggregates can drive anti-drug antibody formation. Add endotoxin and you have real systemic inflammatory risk.

The reconstitution problem. Powders are sold by weight. Doses are drawn by volume. Some syringes are marked in milliliters, others in units. The bacteriostatic water required is itself a prescription product being sourced informally.

Every one of those is a place a tenfold dosing error can happen — and I have very little confidence that most people using these compounds could state their actual delivered dose with precision.

YOUR PRE-PURCHASE CHECKLIST

□ Which tier am I in — approved, compounded under prescription, or research-use-only? □ Is there an FDA-approved alternative for my actual goal? □ Do I have a lot-matched COA for this specific vial? □ Does it include identity by MS and purity by HPLC and net peptide content? □ Endotoxin testing, if injectable? □ Is the lab named, real, and ISO 17025 accredited — verified through A2LA, ANAB, or PJLA? □ Did I verify the accession number on the lab’s own portal, not the vendor’s site? □ Pharmacy: state license verified? 503A or 503B? API source? PCAB accredited? □ Provider: license and board certification verified? Disciplinary history checked? □ Did they answer the approved/compounded/experimental question cleanly? □ Is there a written monitoring plan with baseline and follow-up labs? □ Do I know who to call at 2am, and would they answer?

THE RESOURCE LIST

Verify a laboratory’s accreditation: a2la.org · anab.ansi.org · pjlabs.com

Verify a pharmacy: your state board of pharmacy license lookup · nabp.pharmacy (NABP resources and Verified Pharmacy Program) · fda.gov registered 503B outsourcing facility list · achc.org (PCAB accreditation)

Verify a provider: your state medical board license verification · certificationmatters.org (ABMS board certification) · docinfo.org (FSMB nationwide physician lookup and disciplinary history)

Check drug approval status: accessdata.fda.gov/scripts/cder/daf (FDA Drugs@FDA database — search any drug name and see exactly what is approved, for what)

Check for ongoing trials: clinicaltrials.gov — search the compound name. If you want access to something experimental, a trial gives you monitoring, dosing expertise, and contribution to real knowledge.

Report a problem: FDA MedWatch at fda.gov/safety/medwatch. Almost nobody reports adverse events from compounded or gray-market products, which is precisely why the safety data does not exist. If something happens to you, reporting it protects the next person.

THE BOTTOM LINE

I want to be clear about where I actually stand, because I am not the physician who tells you no reflexively.

I support a regulated compounding pathway. The FDA’s earlier restrictions did not eliminate demand — they eliminated quality control and pushed an entire market into anonymous overseas suppliers and kitchen-counter reconstitution. A licensed pharmacy preparing a tested product under a real prescription is a genuine safety improvement, even for compounds whose efficacy is unproven.

But access without evidence is not liberation. It is a better-looking gamble.

Here is the manual in one paragraph:

Know which tier you are in. Match the lot. Verify the laboratory through its own portal — not the vendor’s link. Demand identity, purity, net peptide content, and endotoxin testing. Verify the pharmacy license and ask 503A or 503B. Verify the provider’s license and board certification. Ask the approved-compounded-experimental question and listen carefully to how it lands. Insist on baseline labs and a monitoring plan. And if the stakes are high, send a sample and find out for yourself.

Then be honest about what all that buys you. It substantially reduces the chance of receiving contaminated, under-dosed, or misidentified material.

It does not tell you the compound works.

The hunger to heal is real and I respect it. But the body you are trying to improve is the one irreplaceable thing you were given.

Self-sourcing unapproved injectables does not make you a biohacker. It makes you an unmonitored experimental subject — sample size of one, with nobody recording the results.

You are allowed to want more from your body.

You are also allowed to demand proof before you put something in it.

Share this with anyone in your life buying from a group chat. Everything in this manual is free, and it may prevent something serious.

This manual is educational and not personalized medical advice. Regulatory status and evidence continue to evolve. Consult a qualified licensed clinician for individualized decisions, and do not begin injectable therapy without appropriate medical supervision and monitoring.

I write everything I know — cardiology, metabolic health, hormones, cancer screening, longevity science, and the frontier research most people never hear about until it is already standard of care — on this newsletter.

Completely free. No paywall. Nothing to sell you. No supplement line, no affiliate links, no peptide vendor paying for placement. Just a cardiologist writing what I would want my own family to know.

Subscribe: substack.com/@afshineemrani

Blessings.

Afshine Ash Emrani, M.D., F.A.C.C.
Assistant Clinical Professor, UCLA
David Geffen School of Medicine

Join Our new website

Castle-Connolly Nationwide Top Doctor (Since 2008)
Los Angeles Magazine Super Doctor (Since 2010)
LA Style Magazine Top 100 Doctors in America (2024)

Subscribe to mynewsletter: substack.com/@afshineemrani
Explore my books: Amazon Author Profile

“You’re young. You’re healthy. This isn’t something you need to think about yet.”

I understand why physicians say it. Statistically, a thirty-four-year-old woman is unlikely to have a cardiac event this year, and there is a real cost to alarming people about low short-term risks.

But that sentence contains a hidden and false assumption — that heart disease is an event rather than a process.

It is a process. It begins decades before anything happens. Autopsy studies of young trauma victims have found fatty streaks in coronary arteries of people in their twenties, and established plaque in a meaningful fraction of people in their thirties. The disease is quietly assembling itself for twenty or thirty years while everyone involved is confident there is nothing to discuss.

And here is what should genuinely alarm you: cardiovascular disease in women aged 20 to 44 is projected to rise nearly 50 percent by 2050. The youngest patients in my practice keep getting younger. I have treated women in their thirties and forties who had every reason to believe they were fine.

Cardiovascular disease already kills more women than breast cancer, lung cancer, and chronic lung disease combined. It is the leading cause of death in women — and yet, culturally and clinically, we screen relentlessly for the cancers and essentially not at all for this.

So this article is written for you if you are somewhere between twenty-eight and fifty. Not because you are about to have a heart attack. Because this is the window where everything is still reversible, and almost nobody is looking.

THE CASE THAT SHOULD WORRY YOU

Let me tell you about a woman I’ll call Lisa, because the specific details matter.

At fifty, she had never smoked. Normal weight. Exercised. Ate the way we tell people to eat. No diabetes, no hypertension. Total cholesterol 221, HDL 68 — numbers that make a physician smile.

Her ten-year risk calculator returned 2.5 percent. Low risk. No treatment recommended.

Then she had a coronary calcium scan. Her score was 204 — far above the 95th percentile for her age, carrying roughly seven to eight times the event risk of a peer with identical “excellent” numbers and a clean scan.

She had established coronary disease at fifty.

Now here is the part I want you to sit with, because it is the entire reason this article is aimed at you:

That plaque did not appear at forty-nine. It accumulated across her thirties and forties, silently, during exactly the years when she was told she was too young to think about it — and during exactly the years when the process was most modifiable.

Nobody looked until fifty. By then, twenty years of opportunity had already been spent.

The only conventional clue was buried in one line of her history that no algorithm weighted properly: her mother had a heart attack at sixty-two.

WHY THE RISK CALCULATOR FAILS YOU SPECIFICALLY

Standard cardiovascular risk calculators were built around age, blood pressure, cholesterol, smoking, and diabetes — the risk profile of a middle-aged man.

They fail young women twice over.

First, they are age-weighted. Age is the single heaviest input in most risk scores, which means a young woman will be classified as low risk almost regardless of what else is true about her. A thirty-eight-year-old with genuinely dangerous biology will still return a reassuring number. The calculator is not measuring her arteries. It is mostly measuring her birthday.

Second, they omit or underweight nearly everything that actually drives cardiovascular risk in a female body: adverse pregnancy outcomes, early menopause, PCOS, autoimmune disease, and genetic factors like lipoprotein(a).

These tools were designed to answer “will this person have an event in ten years?” That is a reasonable question at sixty-five. It is the wrong question at thirty-five, where the useful question is: “what is my trajectory, and can I still change it?”

Ten-year risk is not the same as lifetime risk. And you are living the lifetime.

PART ONE: YOUR PREGNANCIES WERE A CARDIAC STRESS TEST

If you take one thing from this article, take this — and it applies to you now, in your thirties and forties, not in some distant future.

Pregnancy places extraordinary demands on the cardiovascular system. Blood volume rises forty to fifty percent. Cardiac output climbs substantially. Your vascular system is stressed harder and longer than at nearly any other point in your life.

Some women pass that test. Some don’t. And the ones who don’t are being shown something about their vasculature decades before anything else will reveal it.

Preeclampsia

The diagnosis is described as high blood pressure and organ dysfunction in pregnancy. But the underlying biology is endothelial dysfunction — impairment of the single-cell lining of your blood vessels, which is precisely the first step of atherosclerosis.

Preeclampsia is not a complication that resolves at delivery. It is a vascular stress test your body did not pass, and those are the same vessels you will carry for the next fifty years.

Women who experience it carry roughly two to four times the lifetime cardiovascular risk, with dramatically elevated risk of developing chronic hypertension, and events occurring earlier than they otherwise would.

That word — earlier — is why this matters at thirty-eight rather than sixty-eight.

Gestational diabetes

This is insulin resistance unmasking itself under metabolic load. Up to half of these women develop type 2 diabetes within a decade, with cardiovascular risk climbing alongside.

It was never “a pregnancy thing that went away.” It was a preview.

Preterm delivery, placental abruption, fetal growth restriction

Each carries independent cardiovascular risk signals, most likely because they reflect abnormal placental vasculature — and the placenta is a vascular organ. Problems there are frequently problems with your vascular biology, expressed in one place at one time.

The failure, stated plainly

Most women are discharged after a preeclamptic pregnancy with no cardiovascular follow-up plan whatsoever.

The pressure normalizes. Everyone exhales. Obstetric care ends. And nobody mentions it again for thirty years — until she arrives in an emergency department at fifty-eight with a chart that never captured the most predictive event of her life.

If you had any of these complications, your cardiovascular surveillance starts now. In your thirties and forties. Blood pressure monitored. ApoB, Lp(a), hs-CRP, and fasting insulin measured. That history recorded in your chart as a permanent risk factor.

And you may have to be the one who puts it there. Say the words: “I had preeclampsia. I understand that raises my long-term cardiovascular risk. I’d like to be evaluated accordingly.”

PART TWO: PERIMENOPAUSE IS COMING SOONER THAN YOU THINK

Most women assume menopause is a problem for their fifties. Perimenopause commonly begins in the early to mid forties, and sometimes in the late thirties — and the cardiovascular changes begin with it, years before your periods stop.

We talk about this transition as hot flashes and mood. What we almost never explain is that it is one of the most consequential vascular events of your life.

Estrogen is vasculoprotective, and it does specific measurable things. It promotes nitric oxide production, which keeps arteries dilated and the endothelium healthy. It shapes lipids favorably. It exerts anti-inflammatory effects on the vessel wall. It helps maintain insulin sensitivity. And it influences where your body stores fat.

Then it withdraws — and the changes cluster tightly around the transition itself rather than tracking gradually with age:

LDL and ApoB rise. Triglycerides rise. HDL often becomes less functional even when the number looks unchanged.

Fat redistributes from hips and thighs to the abdomen. This is not cosmetic. Visceral fat is metabolically active, inflammatory tissue — an endocrine organ producing inflammatory signals.

Insulin resistance increases, sometimes substantially — which is why women who changed nothing about diet or exercise watch their metabolic markers deteriorate anyway.

Blood pressure rises, and hypertension becomes more common in women than men after this transition.

Arterial stiffness increases measurably.

Why this section is in an article for young women

Because these changes begin in perimenopause — while your cycles are still occurring and while everyone, including your doctor, still mentally files you as premenopausal.

That is exactly the window in which they are most modifiable. And exactly the window in which nobody is looking.

If you are in your forties and noticing your energy, sleep, body composition, or labs drifting in ways that don’t match your behavior — you are not imagining it, you are not failing, and it is not simply age. It is a physiological transition with cardiovascular consequences, and it deserves measurement rather than dismissal.

Two situations that raise the stakes considerably: premature or early menopause — before forty, or before forty-five — carries meaningfully higher cardiovascular risk and warrants earlier, more aggressive evaluation. And emerging data suggests frequent or severe hot flashes may correlate with less favorable vascular measures, meaning the symptom may be a signal rather than an inconvenience.

On hormone therapy: in November 2025 the FDA began removing the black box warnings, and the FDA Commissioner called the original decision one of the greatest errors in modern medicine. Roughly fifty million women were frightened away based on a misreading of the WHI — in whose estrogen-only arm breast cancer risk was actually lower. Hormone therapy is not a cardiovascular preventive treatment and I won’t present it as one. But it deserves a real conversation rather than a reflexive refusal built on data misinterpreted twenty-four years ago.

PART THREE: THE OTHER THINGS THAT MATTER IN YOUR THIRTIES AND FORTIES

PCOS. Insulin resistance, unfavorable lipids, and elevated cardiovascular risk beginning in the twenties. If you have PCOS, you are not simply managing fertility and cycles — you are managing a metabolic condition with cardiovascular consequences, and it deserves that framing.

Autoimmune disease — lupus, rheumatoid arthritis, psoriasis, inflammatory bowel disease. Far more common in women, frequently diagnosed in the reproductive years, and chronic inflammation accelerates atherosclerosis at any age. A young woman with lupus deserves the cardiovascular vigilance we’d give a diabetic, and rarely gets it.

Migraine with aura — associated with elevated stroke risk, and directly relevant to decisions about estrogen-containing contraception. Worth an explicit conversation.

Breast cancer treatment. Certain chemotherapies and chest radiation carry cardiac consequences that emerge years afterward. Young survivors need cardiovascular surveillance built into survivorship care.

Pregnancy-related hypertension, even without full preeclampsia.

And SCAD — spontaneous coronary artery dissection. Ninety percent occurs in women, often young, fit, with no traditional risk factors, and frequently around pregnancy or the postpartum period. It is the leading cause of heart attack in women under fifty. Most physicians have never diagnosed one.

PART FOUR: THE FOUR TESTS TO GET BEFORE YOU TURN 40

These are inexpensive, widely available, and almost never ordered unless you ask by name.

1. Lp(a) — test once, then tell your family

A genetically determined particle that promotes atherosclerosis, thrombosis, and aortic valve calcification simultaneously. Set at birth. Stable across your life. Minimally influenced by diet or exercise — which means it will never show up as a consequence of anything you did or didn’t do.

Roughly one in five people carry elevated levels. The 2026 ACC/AHA guidelines now give a Class I recommendation to measure it at least once in every adult. Most never have been.

Request it in nmol/L: under 75 is lower risk, 125+ carries roughly 1.4-fold increased risk, 250+ at least doubles it.

And here is why this belongs specifically in an article for young women: midlife levels above the seventy-fifth percentile predict higher event rates over the following thirty years. A blood draw at thirty-eight forecasting your sixties.

If you’re going to be tested once in your life for something genetic, do it while there’s still time for it to change your care.

And if it’s elevated, get your parents, siblings, and children tested. It is inherited. This is one of the few times in medicine where one test protects an entire family.

2. ApoB — the number that should replace your LDL

Every atherogenic particle carries exactly one ApoB molecule, making it a direct count of the particles capable of entering your artery wall.

LDL tells you how much cholesterol your particles are carrying. ApoB tells you how many particles there are — and it’s the particle count that determines how many can enter and damage the wall.

One analysis found fifty-four percent of patients had dangerous ApoB levels that standard LDL testing missed entirely. The discordance is worst in people with insulin resistance, high triglycerides, or metabolic syndrome — which describes a great many young women with PCOS or post-gestational-diabetes metabolic changes.

Target under 80 mg/dL, and under 60 with established disease, diabetes, or elevated Lp(a).

3. hs-CRP — and the finding that should be famous

Measures the systemic inflammation that destabilizes plaque. Standard CRP is too blunt — request the high-sensitivity version. Target under 1.0 mg/L.

And here is the striking finding from long-term data in healthy women: a single midlife measurement of hs-CRP, LDL, and Lp(a) together predicts thirty-year cardiovascular risk more powerfully than any one alone.

One blood draw in your forties telling you a great deal about your seventies. There is almost nothing else in medicine with that reach.

One caution: hs-CRP rises with any infection, injury, or recent hard training. Never interpret a single elevated value while unwell.

4. Fasting insulin — the ten-year warning bell

The most valuable test almost nobody orders.

Your glucose and HbA1c can look entirely normal for ten to fifteen years while your pancreas works progressively harder to keep them there. Insulin resistance comes first; compensation hides it. By the time glucose rises, you’ve often been metabolically ill for a decade.

Target under 5 μIU/mL. Lab reference ranges extend far higher because they describe a metabolically unwell population.

For a woman in her thirties, this is the earliest actionable signal available — and it’s where PCOS, post-gestational-diabetes risk, and perimenopausal metabolic change all show up first.

Also worth having

Full lipid panel with the triglyceride-to-HDL ratio — free, calculated from numbers you already have, and one of the best proxies for insulin resistance. Under 2 is good, under 1 excellent.

HbA1c under 5.4 percent. Full thyroid panel. Vitamin D. Urine albumin-to-creatinine ratio — microalbuminuria is an early marker of vascular damage throughout the body.

PART FIVE: WHEN TO ACTUALLY LOOK AT YOUR ARTERIES

Blood tests estimate. Imaging shows.

Should a young woman get a calcium score?

Not routinely — and I want to be honest about that rather than sell you a scan.

A calcium score is most useful in intermediate-risk adults, typically over forty. In a genuinely low-risk thirty-two-year-old it will almost certainly be zero, and that zero tells you very little you didn’t already know.

But it becomes genuinely useful earlier if you have: familial hypercholesterolemia, markedly elevated Lp(a), a parent or sibling with an event before fifty-five (men) or sixty-five (women), long-standing autoimmune disease, or a significant adverse pregnancy history combined with other risk factors.

And a critically important interpretation point for young women: any calcium at all under fifty is meaningful. A score of 1 in a forty-two-year-old is not “basically zero” — it places her in a high percentile for her age and signals aggressive early disease. Always ask for your percentile, not just your score.

The trap that matters most for women

Calcification is a late finding. Soft, non-calcified plaque — the kind that ruptures — is invisible to a calcium scan.

And women calcify later than men, which means a young woman’s disease is disproportionately the type a calcium score cannot detect.

In the PROMISE trial, twenty-five percent of patients who suffered a major cardiac event had a calcium score of zero. Studies find five to nine percent or more of people with zero calcium still have non-calcified plaque, and that proportion climbs with baseline risk.

Zero calcium does not mean zero plaque. It means no calcified plaque.

CT coronary angiography

CCTA visualizes the entire coronary tree and quantifies total plaque burden, non-calcified plaque volume, and high-risk features. It detects the disease calcium scoring misses.

And the detail that matters most for us: women have events at lower absolute plaque burdens than men, partly because our coronary arteries are smaller. Less plaque, same danger.

The SCAPIS study found silent atherosclerosis in over forty percent of middle-aged adults with no known disease.

Reserved for selective use — but exactly right for the young woman with a zero calcium score and significant risk factors, elevated Lp(a), or persistent symptoms.

And a warning about stress tests

A normal stress test is not a clean bill of arterial health. It detects flow-limiting narrowing above roughly seventy percent and is largely blind to the non-obstructive soft plaque that causes most heart attacks.

It also performs less well in women, partly because women more often have microvascular disease — plaque in vessels too small for standard imaging to see. A woman can be having a heart attack with “clean” coronary arteries on catheterization. This has a name — MINOCA — and it is considerably more common in women.

If your symptoms persist despite normal testing, push for cardiac MRI, PET imaging, or coronary function testing. Do not accept “your tests are normal, it’s probably anxiety” when your body is telling you otherwise.

PART SIX: WHAT’S COMING, AND WHY YOUR TIMING IS GOOD

For four decades, Lp(a) has been the risk factor we could measure and could not treat.

That is ending — and if you are in your thirties or forties, this matters enormously to you specifically, because these drugs will exist for most of your remaining life.

Five agents in advanced development achieve seventy to ninety-five percent or greater reductions, by silencing apolipoprotein(a) production or disrupting particle assembly.

Pelacarsen — monthly injection. Phase 3 with 8,323 patients, readout expected in the second half of 2026.

Olpasiran — dosed every twelve weeks, over ninety-five percent reduction in Phase 2 with durable suppression for months after the final dose. Phase 3 with approximately 7,300 patients, results anticipated around December 2026.

Lepodisiran, zerlasiran, and the oral agent muvalaplin are advancing behind them.

Positive outcomes would be the first proof that lowering Lp(a) prevents cardiovascular events — and would transform management for one in five people.

Which is precisely why you should know your number now. When these arrive, the people who benefit will be the ones who already knew they were elevated and had spent the intervening years driving every other risk factor to the floor.

PART SEVEN: WHAT TO ACTUALLY DO

This week

Write down your complete pregnancy history. Every complication by name — preeclampsia, gestational hypertension, gestational diabetes, preterm delivery, growth restriction.

Write down your family history properly. Not “heart disease runs in my family.” Which relative, which event, at what age. An event before fifty-five in men or sixty-five in women is a genuine risk multiplier.

Note where you are hormonally, and at what age any transition began.

At your next appointment

Bring the list. Bring these words:

“I’d like an advanced cardiovascular panel — ApoB, Lp(a) once in nmol/L, hs-CRP, and fasting insulin. I know these aren’t standard, but I want to establish a baseline now rather than find out at sixty.”

And if relevant:

“I had [pregnancy complication], and I understand that raises my long-term cardiovascular risk. How should that change my monitoring?”

If your doctor says you’re too young — and some will — try: “I understand my ten-year risk is low. I’m asking about my lifetime risk, and about establishing a baseline I can trend.”

That reframe usually works, because it’s the medically correct question.

Build the foundation now, while it compounds

This is the enormous advantage of your age: everything you do in your thirties and forties compounds for decades.

Blood pressure under 130/80. Buy a home cuff — the smartest forty dollars in cardiac self-care.

Resistance training two to four times weekly. Muscle is your largest glucose disposal organ and your primary defense against the metabolic changes coming in perimenopause. It becomes more important through that transition, not less. And it builds the bone density that determines whether you’re independent at eighty.

Zone 2 cardio, 150+ minutes weekly, at a conversational pace. Cardiorespiratory fitness is among the strongest mortality predictors we have measured.

Sleep seven to nine hours, and get evaluated for apnea if you snore or wake unrefreshed. Sleep apnea is underdiagnosed in women because we present differently.

Mediterranean pattern eating, fiber twenty-five to thirty-eight grams daily, and honest attention to alcohol — the “moderate drinking is protective” finding has substantially eroded.

Don’t smoke or vape. Nothing else on this list compensates.

And protect your relationships. Loneliness carries mortality risk comparable to smoking. This is not sentiment — it is one of the most robust findings in longevity research.

Know the symptoms, because they are not what you were taught

Medicine spent decades calling women’s cardiac symptoms “atypical.” They are not atypical. They are female-typical.

Crushing fatigue. Shortness of breath. Jaw, neck, or back pain. Nausea. Sudden exhaustion during sleep. Cold sweats. A sense that something is deeply wrong.

And young women are dismissed more than anyone. You will be told it’s anxiety, or dehydration, or stress. Sometimes it is. Sometimes it isn’t, and the consequence of being wrong is not symmetrical.

If you ever have concerning symptoms, say these exact words: “I am concerned this could be my heart.” That sentence changes the workup you receive. Do not soften it. Do not apologize for it.

Call 911 rather than driving. Treatment begins in the ambulance.

THE BOTTOM LINE

Lisa’s plaque did not appear at forty-nine. It accumulated across her thirties and forties — during exactly the years she was told she was too young to think about it, and during exactly the years when it was most reversible.

That is the entire argument of this article.

You are not being told to be afraid. You are being told that you are standing in the most valuable window you will ever have, and that almost nobody is going to point it out to you.

Your risk calculator was not built for you. It is age-weighted, which means it will reassure you almost regardless of what is true about your biology.

Your pregnancy history is cardiovascular data, not obstetric history that ended at delivery.

Perimenopause starts earlier than you think, and the vascular changes begin before your periods stop.

A calcium score of zero does not mean zero plaque — especially in a woman, because we calcify later.

A normal stress test does not mean healthy arteries.

And “you’re too young to worry about this” is not a medical finding. It is a statement about probability in the next ten years, offered in response to a question about the next fifty.

Get the four tests. Know your Lp(a) once. Write down your pregnancy and family history. Build the foundation while it still has forty years to compound.

Then, if anything is elevated, act on it now — while you have every advantage of time.

The heart attack at fifty-two is decided in your thirties.

You are still deciding.

Please share this — with your sister, your friend who had preeclampsia and was never told what it meant, your daughter. This is the article I wish every woman received at thirty-five.

This article is educational and not personalized medical advice. Every decision should be made with your own physician who knows your full history. If you have concerning symptoms, seek immediate care.

I write everything I know — cardiology, women’s health, hormones, metabolic health, cancer screening, and the frontier research most people never hear about until it is already standard of care — on this newsletter.

Completely free. No paywall. Nothing to sell you. Just a cardiologist writing what I would want my own wife, mother, and daughters to know.

Subscribe: substack.com/@afshineemrani

Blessings.

Afshine Ash Emrani, M.D., F.A.C.C. Assistant Clinical Professor, UCLA David Geffen School of Medicine

Castle-Connolly Nationwide Top Doctor (Since 2008) Los Angeles Magazine Super Doctor (Since 2010) LA Style Magazine Top 100 Doctors in America (2024)

Not “what should I take” in the abstract — people can find a thousand lists for that, most of them written by someone selling the product at the bottom of the page. What patients actually want to know is narrower and more useful:

What do you actually take? And how do you take it?

So here it is. Seven supplements. The exact doses, the exact timing, and — the part almost nobody explains — the reasons the timing matters as much as the compound.

Because here is what I have learned watching thousands of patients try to do this right: most people are taking the correct supplements and absorbing a fraction of them. They swallow fat-soluble vitamins with black coffee on an empty stomach. They start vitamin D without magnesium and wonder why they feel worse. They buy the cheapest fish oil on the shelf, which has been slowly oxidizing under fluorescent light for eleven months.

The compound was never the problem. The execution was.

Before I go further, let me be clear about the frame, because I am not a supplement enthusiast and I am not selling anything.

These are not magic pills. They do not outperform sleep, resistance training, real food, blood pressure control, or human connection — and if you are taking supplements while sleeping five hours and never lifting anything heavy, you are decorating a foundation that does not exist.

What they do is fill specific, common, measurable gaps that modern food, chronic stress, and aging quietly create. That is a real and worthwhile thing. It is just a smaller thing than the industry would like you to believe.

With that said — here is exactly what I run.

THE MORNING STACK

Take these with, or immediately after, a meal containing some fat. Eggs, avocado, olive oil, full-fat yogurt, nuts — whatever you actually eat. This single detail meaningfully changes how much of it reaches your bloodstream.

1. Creatine Monohydrate — 5 grams

When: Anytime, but I take it in water first thing so it does not get forgotten. Timing is genuinely flexible for this one.

Why it is first on my list: Creatine has an image problem. Most people file it under “gym supplement for young men,” which has cost a great many older adults something valuable.

Creatine’s actual job is regenerating ATP — the energy currency of every cell you own. That includes skeletal muscle, but it also includes cardiac muscle and, importantly, brain tissue. Your brain is roughly 2% of your body weight and consumes about 20% of your energy.

The evidence base here is enormous — creatine monohydrate is among the most studied compounds in all of sports and clinical nutrition, with an exceptional safety record across decades.

What it supports: strength and lean mass preservation, which matters enormously as sarcopenia becomes the primary threat to independence after sixty. Faster recovery. And a growing body of work on cognition, with the clearest signals in older adults and in people who are sleep-deprived — which, in my practice, is nearly everyone.

Form and dose: Plain creatine monohydrate. Cheap and thoroughly studied. The exotic forms cost more and have not demonstrated superiority. Five grams daily. Skip loading protocols — consistency saturates the muscle within a few weeks regardless.

The detail nobody warns you about: Creatine raises your serum creatinine without any actual change in kidney function. Tell your physician you take it before anyone reads that lab. Healthy people have been referred to nephrology over this. If you have kidney disease or a borderline eGFR, ask for cystatin C instead — it is unaffected by muscle mass and supplementation.

2. Vitamin D3 with K2 — 2,000-5,000 IU D3 + 100-200 mcg K2

When: Morning, with a fat-containing meal. Vitamin D is fat-soluble, and taking it with fat substantially improves absorption. Taking it with black coffee accomplishes considerably less than you think.

The target that matters: A blood level of 50-80 ng/mL — not the 30 that most laboratories flag as the bottom of “normal.”

Understand what 30 actually represents. It is approximately the level required to prevent overt bone disease. It is a floor for avoiding rickets and osteomalacia, not a target for optimal function. Most people feel meaningfully different in the 55-80 range, and the associations with lower inflammation, better immune function, improved mood, and reduced cardiovascular events sit well above the minimum.

Now the part most people miss, and it is the reason this entry has two ingredients:

Vitamin D increases calcium absorption from your gut. That calcium then has to go somewhere. Vitamin K2 activates the proteins — matrix Gla protein and osteocalcin — that help direct calcium into bone rather than soft tissue. Take D3 alone at meaningful doses and you may be increasing calcium absorption without the machinery that decides where it lands.

And there is a second interaction almost nobody mentions: your body requires magnesium to convert vitamin D into its active form. If you supplement D3 while magnesium-deficient — which describes most adults — you can deepen that deficiency. This is a common and entirely avoidable cause of feeling worse after starting vitamin D.

These three are a system, not three separate pills. That is the single most useful thing in this article.

An honest note on K2, because I have been asked pointedly and the question deserves a straight answer. The trial evidence on K2 and vascular calcification is genuinely mixed — one trial found no significant effect on coronary or aortic valve calcification, while a more recent one found roughly 29% less calcium progression. Nobody has shown that K2 reduces heart attacks or deaths. The defensible rationale for pairing it with D3 is calcium partitioning, not proven plaque reversal. I take it because the logic is sound and the risk is negligible, not because it is proven to save lives.

And one absolute rule: if you take warfarin, K2 is off the table without your physician’s involvement. It directly antagonizes the drug and will destabilize your INR. This does not apply to the newer anticoagulants like apixaban or rivaroxaban.

Retest your vitamin D every 3-6 months until it is stable, and remember that levels swing substantially by season. A July value and a January value are effectively different tests.

3. CoQ10 (Ubiquinol) — 100-300 mg

When: With breakfast, with fat. Also fat-soluble.

Why a cardiologist cares: Your heart beats roughly 100,000 times a day, every day, without a break, for your entire life. That is an extraordinary energy demand, and cardiac tissue is among the most mitochondria-dense in the body.

Coenzyme Q10 sits in the electron transport chain — the final step of cellular energy production. It is also a potent antioxidant protecting mitochondrial membranes.

Two things deplete it: age, and statins.

The statin connection deserves attention. Statins block HMG-CoA reductase, which is upstream not only of cholesterol but of CoQ10 synthesis. That is a plausible mechanism for statin-associated muscle symptoms, and while the trial evidence on supplementation for that specific complaint is mixed, the biological rationale is coherent and the risk of supplementing is essentially nil.

If you take a statin, CoQ10 is the most rational supplement pairing in all of cardiology. I recommend it routinely.

Form matters here. Ubiquinol is the reduced, more bioavailable form, and absorption advantages become more relevant with age. It costs more than ubiquinone. For most people over fifty, that is worth it.

4. Omega-3 (EPA + DHA) — 1,000-2,000 mg

When: With a meal containing fat, which improves absorption significantly — particularly for ethyl ester formulations.

What it supports: Triglyceride reduction, endothelial function, inflammatory balance, membrane fluidity, and cardiac rhythm stability. DHA is a primary structural fat of the brain and retina.

The critical detail that ruins most people’s results: A great deal of retail fish oil is oxidized. It sits on shelves under warm light for months, and polyunsaturated fats are precisely the fats most prone to going rancid. Oxidized fish oil is not neutral — you are consuming lipid peroxides, which is the opposite of the intended effect.

Only buy third-party tested product — NSF or USP certified. If a capsule smells strongly fishy when you break it open, it has oxidized. Throw it out.

And a distinction that matters clinically: generic over-the-counter fish oil has largely failed to reduce cardiovascular events in outcome trials. But prescription purified EPA (icosapent ethyl) demonstrated a 25% event reduction in REDUCE-IT for the right patients — those with elevated triglycerides already on a statin. Not all omega-3 is equivalent. If your triglycerides are high, have that specific conversation with your cardiologist.

Consider measuring your omega-3 index — the percentage of EPA and DHA in your red cell membranes. Target above 8%. Most Americans sit around 4%.

5. Psyllium Husk — 1 tablespoon

When: Morning, mixed into water or yogurt, followed by additional water.

Why a supplement most people dismiss earns a place: Because the average adult consumes roughly half the fiber they need, and fiber does more than most people realize.

Soluble fiber binds bile acids in the gut, forcing your liver to pull cholesterol from circulation to manufacture more — a genuine LDL-lowering mechanism. It slows glucose absorption and blunts post-meal spikes. It feeds the gut bacteria that produce short-chain fatty acids, which support the intestinal barrier and modulate inflammation. And it increases satiety.

Target 25-38 grams of total fiber daily, from food first. Psyllium is the cheap, reliable way to close the remaining gap.

Two practical points: increase gradually or you will be uncomfortable for a week, and always take it with plenty of water. Also separate it from medications by roughly two hours — fiber can bind drugs and reduce their absorption.

THE NIGHT STACK

Take these 30-60 minutes before bed.

6. Magnesium Glycinate — 300-500 mg

When: Evening. This is the supplement I recommend more than any other, and the one patients thank me for most.

Why: Magnesium participates in over 300 enzymatic reactions. It regulates vascular smooth muscle tone, supports normal cardiac rhythm, modulates NMDA receptors and GABA signaling in the nervous system, and is required to activate vitamin D.

Up to 75% of adults have inadequate intake, largely because modern agriculture and food processing have stripped it from the food supply. Most have no idea.

What patients actually report: they stop waking at 3 a.m. The night cramps disappear. The “wired but exhausted” feeling resolves. They describe waking up calm instead of wrecked. I hear a version of this constantly, usually within one to two weeks.

Form is not a detail here — it is the whole thing. Magnesium oxide, which is what most cheap supplements contain, is poorly absorbed and will mostly give you gastrointestinal distress. Glycinate is highly bioavailable, gentle on the stomach, and the glycine component contributes its own calming effect.

Magnesium citrate is acceptable but more laxative. Magnesium L-threonate is designed to cross the blood-brain barrier and has some interesting cognitive data, though it is more expensive and the strongest trial was industry-funded.

One caution: if you have significant kidney disease, discuss magnesium supplementation with your physician. Impaired kidneys clear it poorly.

7. Glycine — 5 grams

When: In water, 30-60 minutes before bed. It has a mildly sweet taste and dissolves easily.

Why it works for sleep, mechanistically: Falling asleep requires your core body temperature to drop. Glycine promotes peripheral vasodilation, which accelerates heat dissipation and speeds that decline. Studies have shown improved subjective sleep quality, faster sleep onset, and reduced next-day fatigue.

What else it does while you sleep: Glycine is the most abundant amino acid in collagen — roughly a third of it by composition — and demand may exceed what most diets supply. It is also one of the two rate-limiting substrates for glutathione, your master antioxidant, and supports the liver’s detoxification pathways.

And it stacks beautifully with magnesium glycinate, which is itself magnesium bound to glycine. Both are working the same calming pathways from different directions.

Many patients tell me the combination gives them the sleep they had in their twenties. That is anecdote rather than trial data — but it is remarkably consistent anecdote.

THE SYNERGIES MOST PEOPLE MISS

This is the section I would keep if I could keep only one.

Vitamin D + K2 + Magnesium. D increases calcium absorption. K2 directs where that calcium goes. Magnesium activates D in the first place. Take any one alone and you are running an incomplete system.

Glycine + Magnesium Glycinate. Both promote calm and sleep through overlapping mechanisms. Together the effect is noticeably greater than either alone.

Creatine + CoQ10. Both work on cellular energy from different angles — creatine regenerates ATP, CoQ10 supports the mitochondrial machinery that produces it.

Omega-3 + everything else. Lowering the systemic inflammatory background makes every other intervention work in a less hostile environment.

THE MISTAKES THAT QUIETLY DESTROY THE BENEFIT

Taking fat-solubles on an empty stomach. Vitamin D, K2, CoQ10, and omega-3 all require dietary fat for meaningful absorption. Swallowing them with black coffee wastes a substantial portion.

Starting vitamin D without magnesium. The single most common reason people feel worse after starting D3.

Buying oxidized fish oil. If it smells strongly fishy, it is rancid. Buy third-party tested.

Magnesium oxide instead of glycinate. Poor absorption, more GI upset, less benefit.

Taking them “when I remember.” These work on consistency. An excellent protocol executed 40% of the time is a mediocre protocol.

Ignoring interactions. K2 with warfarin. Omega-3 with anticoagulants at high doses. Psyllium binding medications. Magnesium with certain antibiotics. Tell your physician everything you take — including the things you think are too minor to mention.

And never assuming “natural” means safe. Arsenic is natural. Beta-carotene supplements increased lung cancer in smokers in two large trials. High-dose vitamin E increased prostate cancer risk. Concentrated green tea extract and high-absorption turmeric have documented cases of acute liver injury. Evidence, not marketing.

WHAT TO MEASURE

Do not fly blind. Get these before and after:

Vitamin D (25-OH) — target 50-80, retest every 3-6 months until stable. Magnesium, ideally RBC magnesium rather than serum, which is a poor reflection of body stores. Omega-3 index — target above 8%. hs-CRP — inflammation, target under 1.0. A full lipid panel with ApoB, particularly if you are adding psyllium and omega-3 for cholesterol. Fasting insulin and HbA1c for the metabolic picture.

And notice how you feel. Sleep quality, energy, night cramps, and mood typically shift first — usually within one to two weeks. Those subjective changes are real data.

THE HONEST BOTTOM LINE

I take every one of these, every day. Not because I believe supplements are the center of health — they are not, and anyone who tells you otherwise is usually selling something.

They are the edges. And edges matter, but only once the center exists.

The center is sleep, resistance training, Zone 2 cardio, real food, blood pressure under 130/80, not smoking, and the relationships that make a life worth extending. If those are not in place, no capsule compensates. If they are in place, these seven close specific gaps that modern life reliably creates.

Two of them I recommend nearly universally: magnesium glycinate and vitamin D3 with K2. The patient feedback is consistent, the deficiencies are common, the cost is trivial, and the risk is minimal.

The rest are what I personally run, based on the evidence as it stands and the biology as I understand it.

Cheap. Evidence-informed. Timing optimized.

Do it properly for thirty days — with the right forms, at the right times, with food where it matters — and pay attention to your sleep, your energy, and your night cramps.

Those tend to move first.

Disclaimer: I am a physician, but I am not your physician. Supplements interact with medications and medical conditions. Talk to your own doctor before starting anything here — particularly if you have kidney disease, or take blood thinners, statins, nitrates, thyroid medication, or antibiotics. Get baseline labs where relevant. Nothing in this article is a substitute for treating actual disease.

If this was useful, share it with someone who has been taking supplements for years without ever being told how to take them.

I write everything I know — cardiology, metabolic health, hormones, cancer screening, bone and muscle, longevity science, and the frontier research most people never hear about until it is already standard of care — on this newsletter.

Completely free. No paywall. No supplement line, no affiliate links, nothing to sell you. Just a cardiologist writing what I would want my own family to know.

Subscribe: substack.com/@afshineemrani

Blessings.

Afshine Ash Emrani, M.D., F.A.C.C. Assistant Clinical Professor, UCLA David Geffen School of Medicine

Castle-Connolly Nationwide Top Doctor (Since 2008) Los Angeles Magazine Super Doctor (Since 2010) LA Style Magazine Top 100 Doctors in America (2024)

"I'm 63. If I could be 25 again, here's what I'd tell myself."

Nine truths followed.

They hit harder than anything I'd read that week, and it took me a while to understand why. It wasn't that the advice was new. It was that I recognized every single one of them from a different source entirely — from Marcus Aurelius, from Epictetus, from Seneca. Men who had solved these exact problems two thousand years earlier, on the assumption that human beings would keep making the same mistakes forever.

They were right about that.

And there was a third recognition, the one that actually kept me awake. I have spent more than twenty years as a cardiologist, and a significant part of that has been sitting with people in their final hours. I have heard what people say when the monitor starts to slow and there is no longer any reason to perform.

Nobody dies wishing they had worked more. They die wishing they had acted more.

Said the thing. Made the call. Taken the risk. Forgiven someone while both of them were still breathing. Been present for the life that was already happening while they waited for a better one to start.

So I took Carrey's nine truths, ran them through Stoic philosophy, and translated each one into something you can actually do — today, tomorrow, and the day after.

This is not motivational content. Motivation is a feeling, and feelings are unreliable narrators. This is an operating system.

Read it once through. Then pick one.

1. Action Is the Only Cure for Anxiety

The Stoic principle. Anxiety lives in the gap between what you can control and what you cannot. Epictetus taught that your power lies in exactly three places — your judgments, your desires, and your actions. Everything else is borrowed, temporary, and not yours to command.

Thinking has never once freed anyone. Rumination is anxiety wearing the costume of problem-solving. It feels productive. It produces nothing.

And here I'll add the physician's note, because the body agrees with the philosophy in a way that shows up in bloodwork.

Chronic worry keeps your sympathetic nervous system switched on. Cortisol stays elevated. Blood pressure climbs. Inflammation smolders in the vessel walls. Heart rate variability narrows — one of the truest signatures of a resilient nervous system, quietly stiffening.

Action discharges that state. Sitting with it does not.

The daily practice. Every morning, identify the one thing creating the most mental noise. Then take a five-minute imperfect action on it before 9 a.m.

Not a journaling session about it. Not a better plan. Not more research. A five-minute imperfect action on the actual thing.

You are not trying to solve it. You are trying to prove to your nervous system that you are a person who moves.

2. Your Energy Creates Your Reality

The Stoic principle. Marcus Aurelius wrote: "The soul becomes dyed with the color of its thoughts."

You are broadcasting a state constantly, whether or not you chose it. Your family calibrates to it. Your colleagues calibrate to it. Your children absorb it and will carry some version of it into their own adulthood.

Most people never once decide what they are transmitting. They react to whatever the morning handed them, and then they call the result their personality.

Discipline and quiet optimism are contagious in exactly the way anxiety and complaint are contagious. The difference is that one of them you have to choose deliberately, and the other arrives on its own.

The daily practice. Before you leave the house, or before you open your laptop, stand still for thirty seconds and consciously set your internal state.

Calm. Focused. Useful.

Say it out loud if it helps: "I bring order wherever I go."

Thirty seconds. It sounds absurd until you do it for two weeks and notice that the shape of your days has changed.

3. You Don't Need an Opinion About Everything

The Stoic principle. Seneca warned against being "dragged along by the crowd." He wrote that two thousand years before anyone invented a comment section, and the warning has never been more expensive to ignore.

Most of what demands your opinion sits entirely outside your control — which means engaging with it costs you something and returns nothing. Your attention. Your peace. Occasionally a relationship you can't repair.

And the modern world is engineered to convince you that silence is a moral failure. That not weighing in is a kind of cowardice.

It isn't. Discernment is not cowardice. Knowing which fights are yours is one of the highest forms of self-respect.

The daily practice. When you feel the pull to enter a debate — online, at dinner, in a meeting — pause and ask one question:

Does this strengthen my character, or does it just feed my ego?

If the answer isn't immediately obvious, stay quiet.

Practice strategic indifference once a day, deliberately, on something you genuinely wanted to argue about.

You will be astonished how much of your life comes back to you.

4. Obsess Over Who Brings Out the Best in You

The Stoic principle. For the Stoics, friendship was never primarily about comfort. It was about mutual improvement in virtue. Seneca wrote that a true friend makes you better simply by being present — not through advice, but through the standard their existence sets.

Your circle is either raising your standards or quietly lowering them. There is no neutral setting. The people around you are constantly, invisibly negotiating with your definition of acceptable.

And here is where philosophy becomes medicine. This one isn't metaphor — it is one of the most robust findings in longevity research.

Loneliness raises mortality risk comparably to smoking. The strength of your close relationships is among the most powerful predictors of how long you will live, with effect sizes that rival the risk factors we treat aggressively with drugs.

I have watched patients with pristine bloodwork decline because they were profoundly alone, and patients with frightening bloodwork thrive because they were surrounded.

Your relationships are cardiovascular medicine. I mean that literally.

The daily practice. Once a week, audit your closest five relationships. Ask one question about each:

Who leaves me more disciplined, more honest, more ambitious after we talk?

Increase time with those people. Decrease time with the rest — quietly, gradually, without drama and without announcement. You do not owe anyone a speech about it.

5. Ambition Is Highly Contagious

The Stoic principle. We are social animals, and the Stoics understood this as both our strength and our vulnerability. The people you spend the most time with shape your desires, your standards, and — most dangerously — your definition of enough.

Sit long enough among people who have settled, and you will eventually find yourself calling it wisdom. That's the trap. It doesn't feel like decline. It feels like maturity.

The daily practice. Spend at least twenty focused minutes each day around — or studying — someone further along the path you actually want.

Books count. Podcasts count. A training partner who's stronger than you counts. A conversation with someone whose life makes you slightly uncomfortable counts most of all.

Contagion works in both directions.

Make sure you're catching the right disease.

6. Someone Less Qualified Is Already Living the Life You Want

The Stoic principle. Courage is one of the four cardinal virtues, and here is the trap almost everyone falls into: waiting until you feel ready is usually fear wearing the mask of prudence.

The Stoics valued bold action guided by reason over perfect preparation, because they understood that perfect preparation is frequently just a socially acceptable form of hiding.

Somewhere right now, someone with less talent than you, less preparation than you, and considerably less right to it is doing the thing you have been researching for three years.

They are not better than you. They started.

The daily practice. Identify one thing you have been postponing because you don't feel qualified.

Today, take the smallest public or irreversible step toward it. Send the email. Post the work. Book the call. Tell someone.

The public part matters. Make it something you cannot quietly take back at 11 p.m. when the fear returns.

Courage compounds. So does its absence — and the second compounding is the one nobody notices until it's finished.

7. Procrastination Compounds Daily

The Stoic principle. Marcus Aurelius reminded himself constantly that death was not far off, and that delaying virtue was the greatest waste available to a human being.

"You could be good today. Instead you choose tomorrow."

I think about that line more than almost anything else I have ever read, and I'll tell you exactly why.

I watch tomorrow run out for people. Every week. It never announces itself, never gives notice, never waits for the list to be finished. It simply arrives — and everything the person meant to get to goes with them.

The tragedy is almost never dramatic. It's a phone call not made. A reconciliation postponed one more year. A trip planned for when things settle down.

Things do not settle down. That was never how it worked.

The daily practice. Use the two-minute rule with a Stoic edge: if something takes under two minutes and moves you toward something you genuinely value, do it immediately. No negotiation with yourself. No "later."

You are not building a habit. You are building the identity of a person who starts — and identity is what survives the days when motivation doesn't.

8. It May Not Be Your Fault, But It Is 100% Your Responsibility

The Stoic principle. This is pure Epictetus, and it is the hardest item on this list.

External events — including what other people did to you, including what was genuinely unfair — were never up to you. Your response always is.

Blame is the rejection of agency. It feels like justice. It functions like a prison.

And as a physician I have watched what it costs. Patients carrying resentment for twenty and thirty years, paying for it in their blood pressure, their sleep, their inflammatory markers, their marriages. Meanwhile the person who wronged them frequently felt none of it, and in some cases had died years earlier.

Forgiveness was never for them. It was always for you.

And to be clear about what I mean: forgiveness is not saying that what happened was acceptable. It never was. It's deciding you have worked too hard for your own peace to keep handing it to someone who isn't even in the room.

The daily practice. Each evening, take one frustration from the day and write a single sentence beginning:

"Regardless of whose fault it was, my responsibility now is to..."

Then act on that sentence the next morning.

Do this for a month and you will notice something strange: you become almost impossible to destabilize.

9. Do More of What Makes You Forget Your Phone Exists

The Stoic principle. Memento mori. Remember that you will die.

The Stoics used this not as morbidity but as clarity — a lens that instantly sorts the essential from the noise. And the present moment, they insisted, is the only place where virtue can actually be practiced. Not in your plans. Not in your regrets. Here.

A life spent staring at a screen is a life that never fully happened.

Most people give away two to four hours a day and then explain, sincerely, that they have no time for their health, their marriage, their work, or their children. That time is not missing. It is being spent — just not by them, and not on purpose.

The daily practice. Schedule one phone-free hour every day. Deep work, real conversation, training, creation, or simply your children.

Phone in another room. Not face down on the table — another room. The mere presence of a phone measurably reduces available attention even when it's silent.

Treat that hour as sacred. Then expand it.

What This Is Actually For

These nine are not a to-do list to complete. They are a character to build.

And I want to name the crucial distinction the Stoics understood that most modern self-improvement gets exactly backwards.

They never sought to feel better. They sought to be better — through small, deliberate, largely unglamorous daily action. The feeling followed. It always does, and it never arrives in the other order.

Here is what twenty years at bedsides has taught me that no philosophy book quite captures.

The people who die at peace are not the ones who accumulated the most, achieved the most, or optimized the most. In all that time, not one person has told me they wished they had worked harder.

They are the ones who said the thing. Who showed up. Who forgave someone while both of them were still breathing. Who were present for the life that was already happening instead of waiting for the better one they had scheduled for later.

The quality of your life is determined far more by what you do with what happens than by what happens.

That is Stoicism in a sentence, and it is also, I think, the closest thing to a law I have observed in medicine.

So don't try to master all nine. You won't, and attempting it is how people quit.

Pick one. Do it for a week. Then add the next.

That is not motivation. That is the only method I have ever seen actually change a person — small, repeated, deliberate action, sustained long enough that it stops being something you do and becomes something you are.

Start tomorrow morning. Five minutes. Before 9 a.m.

And forward this to one person who needs it — not someday, today. Tomorrow has a way of not arriving on schedule, and I have watched that happen more times than I can count.

Blessings.

If this resonated, share it with someone who's been waiting to feel ready.

I write every week about the things that actually determine how long and how well we live — cardiology, metabolic health, hormones, cancer screening, longevity science, and the frontier research most people never hear about until it's already standard of care. Along with pieces like this one, about the part of medicine that has nothing to do with medicine.

Completely free. No paywall. Nothing to sell you. Just a cardiologist writing what I'd want my own family to know.

Subscribe: substack.com/@afshineemrani

Blessings.

Afshine Ash Emrani, M.D., F.A.C.C.

Assistant Clinical Professor, UCLA David Geffen School of Medicine

Castle-Connolly Nationwide Top Doctor (Since 2008)

Los Angeles Magazine Super Doctor (Since 2010)

LA Style Magazine Top 100 Doctors in America (2024)

Los Angeles Heart Specialists

A cardiologist’s field manual to the technologies rewriting the human lifespan — gene editing, cellular reprogramming, senolytics, neural implants, bionics, AI-designed drugs, and the augmented body. What is real, what is coming, what will hurt you, and exactly what to do while you wait.

By Afshine Emrani, MD, FACC

I have spent more than twenty years with my hands on the human heart, and for most of that time I practiced a kind of medicine a physician from 1975 would recognize instantly.

We waited for damage. We measured it. We slowed it down. We managed decline with skill and dignity, and when the decline finished its work, we told families we had done everything we could — and we usually had.

That era is ending. I do not think most people understand how completely.

In the last twenty-four months I have watched an enzyme built by directed evolution strip seventy percent of the molecular scarring off a seventy-five-year-old human aorta — damage we called permanent for forty years. I have watched a gene therapy designed for one specific infant, manufactured in months, cure a disease that had no treatment and never would have justified a development budget. I have watched a quadriplegic man play chess with his thoughts. I have watched twelve people with type 1 diabetes receive an infusion of lab-grown islet cells, and ten of them walk out insulin-free.

And in June of this year, a patient somewhere received an injection into one eye carrying genes that reset the epigenetic clock of the cells inside it. The first deliberate attempt in human history to make a living tissue biologically younger.

None of this is science fiction. All of it happened while most of medicine was doing paperwork.

Here is the claim I want to make, and I want to be held to it: the person reading this may belong to the last cohort that experiences aging the way every human before us did — as a one-directional process we could only decorate with better management.

Not because immortality is arriving. It isn’t, and anyone selling you that is lying. But because for the first time we possess tools that go backward rather than merely slowing forward, and they are moving out of the laboratory at a pace the medical establishment has not remotely internalized.

The people who benefit most will not be the ones with the best supplement stack. They will be the ones who understood what was coming, kept their biology intact long enough to receive it, and knew how to tell the real from the sold.

This manual is my attempt to map that landscape honestly — the biology, the machines, the timelines, the traps, and the protocol you execute today so that you are still here, and still worth treating, when the rest of it arrives.

But before any of it, the single idea that organizes everything else.

PART ONE: THE IDEA THAT CHANGES THE FRAME

Aging is not damage. Aging is lost information.

For a century we assumed aging was accumulated wear — a machine grinding down, parts failing, entropy winning. If that were the whole story, aging would be essentially irreversible. You cannot un-rust a bridge.

But there is a more powerful framing, and the evidence increasingly supports it.

Consider that every cell in your body contains an identical genome. A neuron and a liver cell carry the same three billion letters. What makes them different is not their DNA — it is which genes they read. That reading is governed by the epigenome: chemical marks on the DNA and the proteins around it that tell each cell which parts of the manual to open.

Aging, in this framework, is the progressive corruption of that reading system. Your cells still possess the information. They increasingly cannot find it. Methylation patterns drift. Chromatin organization degrades. A liver cell at eighty is still a liver cell, but a slightly confused one, expressing genes it should have silenced and silencing genes it should express.

The analogy I use with patients: a scratched compact disc. The music is still encoded on the disc. The laser can no longer track it cleanly. You do not need to rerecord the album. You need to polish the surface.

This distinction is not academic. It is the difference between a condition we can only slow and a condition we might genuinely reverse.

And it explains why the same technologies keep appearing across unrelated diseases. If lost epigenetic information is upstream of heart failure, dementia, frailty, and cancer, then restoring it is not one treatment for one disease. It is a lever on the process that produces all of them.

The second idea: your body is engineerable

The mindset shift that follows is uncomfortable for some physicians and liberating for patients.

We have historically treated the body as something that happens to you. Increasingly it behaves like a system that can be read, measured, debugged, and modified — with feedback loops, failure modes, and specifications.

That does not make you a machine. It makes you a system with a control panel we are finally learning to read.

And the practical consequence is this: the most important skill in the coming era of medicine will not be knowing which therapy to take. It will be knowing your own numbers well enough to tell whether anything is working.

PART TWO: READING THE BODY

Everything downstream depends on measurement. You cannot debug a system you cannot observe.

Biological age versus the number on your license

Chronological age is a bookkeeping fact. Biological age is a physiological one, and they diverge enormously.

Epigenetic clocks read methylation patterns at specific genomic sites and estimate biological age. The first generation simply predicted chronological age accurately. The more useful modern versions — the phenotypic and mortality-predicting clocks, and pace-of-aging measures — estimate not just how old you are but how fast you are currently aging.

That second measurement is the one that matters, because it responds to what you do.

A 2026 analysis of over 164,000 people found that those born in the 1990s show a biological age gap roughly 92% larger than those born in the 1960s. Same chronological age, meaningfully older biology. And the fastest agers carried up to 15% higher risk of developing cancer before fifty-five.

Start free. PhenoAge is calculated from nine markers most people already have: albumin, creatinine, glucose, CRP, lymphocyte percentage, MCV, RDW, alkaline phosphatase, and white blood cell count. A basic metabolic panel, a CBC, and a CRP. Free calculators exist.

Then, if you want depth: commercial epigenetic clocks run roughly $200-500. A caution that the industry rarely mentions — these tests have meaningful test-retest variability. A single measurement is noisy. Trend them; do not react to one number.

Organ-specific aging

The frontier here is genuinely exciting. Your organs do not age at the same rate, and proteomic and methylation-based organ clocks can increasingly tell you which system is failing fastest.

Your liver behaving like a sixty-one-year-old’s while your calendar says fifty-two. Your kidneys tracking beautifully. Your vascular system drifting.

For a cardiologist, an early molecular signal of arterial aging would be transformative. We measure ApoB, Lp(a), and hs-CRP — all excellent, all indirect. We image plaque — but plaque is visible only after decades of silent disease. A molecular signal would let us act during the window when the process is still fully reversible.

Mitochondrial function: the energy layer

Mitochondria are not merely power plants. They are signaling hubs that influence inflammation, cell death decisions, and gene expression. Mitochondrial decline is a hallmark of aging and appears upstream of fatigue, insulin resistance, muscle loss, and cognitive decline.

What actually improves mitochondrial function, in descending order of evidence:

Zone 2 endurance training — the single most powerful mitochondrial intervention known. It increases mitochondrial density and improves the efficiency of fat oxidation. No compound competes with it.

Resistance training. Adequate sleep. Metabolic health — insulin resistance impairs mitochondrial function directly.

Then, at a lower evidence tier: NAD+ precursors and urolithin A, which promotes mitophagy — the recycling of damaged mitochondria. Both have human biomarker data. Neither has outcome data.

The panel that actually predicts your future

Metabolic: fasting insulin (under 5), HOMA-IR (under 1.0), HbA1c (under 5.4%), triglyceride:HDL ratio (under 2)

Cardiovascular: ApoB (under 80, under 60 with disease), Lp(a) once in your lifetime, hs-CRP (under 1.0), homocysteine

Hormonal: full thyroid with free T3 and antibodies; complete sex hormone panel with SHBG and free fractions

Nutrient: vitamin D (50-80), B12 with methylmalonic acid, ferritin read alongside hs-CRP, RBC magnesium, omega-3 index

Organ: cystatin C, urine albumin-to-creatinine ratio, ALT, AST, GGT

Functional: VO2 max, grip strength, gait speed, DEXA body composition, home blood pressure

The principle: one panel is a data point. Three is a trend. Direction beats position. Export everything into one spreadsheet and plot the slope.

PART THREE: THE REPAIR TOOLKIT

These technologies share a common ambition: not to slow damage, but to clear or reverse what has already accumulated.

Senolytics: killing the cells that refuse to die

Senescent cells stop dividing but resist apoptosis. They accumulate with age and secrete a continuous stream of inflammatory signals — the senescence-associated secretory phenotype — that damages neighboring tissue and spreads dysfunction outward.

The finding that launched the field is startling: transplanting even a small number of senescent cells into a young mouse causes persistent physical dysfunction and shortens lifespan. These are not inert debris. They are actively toxic.

The mechanism is elegant. Senescent cells depend on specific survival pathways to avoid dying. Disable those pathways briefly and the cells self-destruct. This permits “hit and run” dosing — two or three days, then weeks off — which dramatically limits toxicity compared to continuous exposure.

The animal data: in the landmark Mayo Clinic study, intermittent dasatinib plus quercetin in naturally aged mice increased post-treatment survival by 36% while improving walking speed, endurance, and grip strength. Subsequent work has shown systemic rejuvenation of the aging kidney.

The human data is early. Small open-label studies in idiopathic pulmonary fibrosis showed improved physical function. A diabetic kidney disease study demonstrated genuine reduction in senescent cell burden in human tissue — real proof of mechanism. Trials are running in Alzheimer’s disease, frailty, and osteoarthritis.

Now my obligation as a physician. Dasatinib is a leukemia chemotherapy drug. It carries real toxicity — cytopenias, fluid retention, pleural effusion, bleeding risk, cardiac effects, and substantial drug interactions. People are currently buying it from gray-market sources and dosing themselves from internet protocols. That is genuinely dangerous, and one liver cancer model even showed unexpected pro-tumorigenic effects.

Fisetin is the accessible alternative — a natural flavonoid with a far better safety profile, studied at roughly 20 mg/kg for two to three consecutive days monthly. Human efficacy data remains thin and absorption is poor without fat or a liposomal formulation.

My position: compelling science, genuinely early. If you want access, pursue a clinical trial where you receive monitoring and contribute to real knowledge.

NAD+ precursors

NAD+ is a coenzyme essential to energy production and to the function of sirtuins and DNA repair enzymes. Levels decline substantially with age, and that decline plausibly contributes to mitochondrial dysfunction and impaired repair.

Precursors — nicotinamide riboside and nicotinamide mononucleotide — reliably raise blood NAD+ levels in humans. That much is established.

What is not established is whether raising blood NAD+ produces meaningful clinical benefit. Human trials have shown mixed results: some improvements in specific biomarkers, inconsistent effects on physical function, and no outcome data. Tissue-level delivery remains an open question — raising the level in blood is not the same as raising it inside a neuron.

There is also a theoretical caution worth naming: NAD+ supports growth and repair pathways broadly, and whether that is uniformly desirable in a person harboring undetected malignancy is not fully characterized.

Honest assessment: biologically plausible, safe at studied doses, insufficient evidence for confident recommendation. Exercise raises NAD+ too, and it has outcome data.

Rapamycin

The most robustly validated lifespan-extending compound in animal models. It inhibits mTOR — the nutrient-sensing pathway that governs growth versus repair — and it extends lifespan in yeast, worms, flies, and mice, including when started in late life.

The mechanism connects to something you already control: mTOR is also modulated by protein intake and fasting. Rapamycin is pharmacologically doing a version of what caloric and protein restriction do metabolically.

Human longevity data does not exist. Intermittent low-dose protocols are used off-label by some physicians, and preliminary safety data in healthy adults exists. Risks include immunosuppression, impaired wound healing, mouth ulcers, and metabolic effects including glucose intolerance at higher or continuous dosing.

This requires physician supervision. It is not a supplement.

Peptides

Peptides are short amino acid chains — fragments of the same signaling language your body already speaks. Insulin is a peptide. So is the GLP-1 in the drugs transforming metabolic medicine.

That is exactly what makes them seductive and exactly what makes them risky. They are signaling molecules. They flip switches. And a molecule potent enough to accelerate tissue repair is, almost by definition, potent enough to accelerate things you do not want growing.

The regulatory landscape is shifting. In July 2026 an FDA advisory committee voted to recommend adding BPC-157 to the list of substances licensed compounding pharmacies may prepare. The vote was 8-6, over the objection of FDA’s own scientific staff, and it remains advisory and non-binding — formal rulemaking takes twelve to twenty-four months.

The honest state of evidence: the strongest published human data for BPC-157 involves roughly thirty subjects, with the longest treatment lasting about two weeks — and the routes studied barely overlap with how people actually use it. TB-500 has no completed human randomized trials. The others range from thin to nearly empty.

And the supply chain should alarm you. Over forty percent of gray-market samples fail purity testing. People are buying research-grade powder from anonymous overseas sellers and reconstituting it on kitchen counters with bootleg sterile water.

Where I land: a regulated pathway through licensed pharmacies would be a genuine safety improvement over the status quo, and I support that. But access without evidence is not liberation. It is a better-looking gamble. My specific concern as a cardiologist: BPC-157 works partly through angiogenesis. Before you inject a molecule whose job is to say grow, you should have reasonable confidence about what is already growing inside you.

Cellular reprogramming: the deepest reset

This is, in my view, the most important idea in aging biology, and it follows directly from the information framing.

Four genes — the Yamanaka factors — can reset an adult cell all the way back to pluripotency, erasing its identity entirely. That is too far; it produces teratomas. But partial reprogramming, using a subset of those factors applied transiently, appears to restore youthful epigenetic patterns while preserving what the cell is.

In animals, this has restored vision after optic nerve injury and in aged mice, improved tissue function, and extended remaining lifespan.

It is now in humans. The first-in-human partial reprogramming therapy uses an AAV vector to deliver reprogramming genes by a single injection into one eye, with a doxycycline-inducible switch — oral doxycycline activates expression for roughly eight weeks, then it shuts off. Controlled, time-limited exposure.

The Phase 1 trial targets glaucoma and ischemic optic neuropathy. FDA clearance came in January 2026; the first patient was dosed in June 2026. Approximately eighteen participants, dose escalation, follow-up up to five years.

Why the eye first: localized delivery limits systemic exposure, the eye is immune-privileged, AAV vectors are established in ophthalmology, and visual function can be measured precisely without invasive procedures.

The open questions are serious. Optimal duration and intensity of expression. Durability of the reset. And cancer risk in systemic applications — reprogramming and oncogenesis share biology, and that is not a trivial concern.

Safety readouts expected late 2026 into 2027. This is the single most important clinical readout in the entire longevity field, and almost nobody outside the field is watching for it.

Enzymatic reversal of accumulated damage

Some proteins in your body are laid down early and essentially never recycled — collagen, elastin, the crystallins in your eye lens. They are permanent scaffolding, and everything that happens to them over seventy years stays.

Sugar reacts with those proteins the way heat browns bread, leaving advanced glycation end-products that stiffen arteries, cloud lenses, and drive inflammation through the RAGE receptor. Since the 1980s this was considered irreversible.

Researchers screened forty-five thousand protein structures and ran five rounds of directed evolution across more than five hundred million variants to build an enzyme that does not exist in nature — one that strips this damage off proteins and restores the healthy amino acid underneath.

Applied to the aorta of a seventy-five-year-old donor, it removed over seventy percent of the damage, down to levels seen in a thirty-year-old artery.

Caveats: ex vivo tissue, not a living person. No functional data yet on elasticity. Delivering a large enzyme deep into tissue is unsolved.

Why I care: arterial stiffness drives systolic hypertension, heart failure, and stroke, and I have no drug that reverses it. This is the first credible claim that reversal may be possible.

PART FOUR: THE REBUILD TOOLKIT

Where the previous section clears and restores, this section replaces and rewrites.

Gene editing: from reading to writing

We spent the first genomic era learning to read. We are now learning to write.

Base editing and prime editing allow single-letter changes without cutting both DNA strands, dramatically reducing the risk of unintended rearrangements. This is the difference between a scalpel and a search-and-replace function.

The proof that changed everything: a bespoke gene-editing therapy was designed, manufactured, and delivered for a single infant with a fatal metabolic disorder — in months, not years. One patient. One custom therapy. That shatters the economic model medicine has always operated under, where a treatment must serve thousands to justify development.

In my own field: a single infusion of a base editor targeting PCSK9 has produced durable, substantial LDL reduction in early human trials. Not a daily pill. Not a monthly injection. One treatment, potentially permanent.

The open questions: durability across decades, off-target effects we have not yet detected, delivery to tissues beyond the liver, immune responses to the editing machinery, and the profound question of germline versus somatic editing — changing you versus changing your descendants.

Cell therapy: installing the factory

The distinction between peptides and cell therapy is the distinction between renting and owning.

Inject a peptide and it works brilliantly, then degrades, and you inject again. Install engineered cells and they sense what your body needs and produce it continuously, at physiological levels, responding to real signals.

The proof: stem-cell-derived islet cells infused into twelve people with type 1 diabetes. Ten were completely insulin-independent at one year, with a 92% mean reduction in insulin use. Published in the New England Journal of Medicine.

And the scalability breakthrough: hypoimmune engineering — gene-editing cells to evade immune detection — has allowed transplanted islet cells to survive and function in a patient taking zero immunosuppression. That solves the problem that has limited cell therapy for decades.

In cardiology: engineered regulatory T cells targeting oxidized LDL prevented over seventy percent of plaque buildup in animal models while preserving normal immune function. Not a statin lowering fuel — a living cell extinguishing the fire.

AI drug discovery

This is the accelerant beneath everything else.

Protein structure prediction solved a problem that consumed careers. Generative models now design binding pockets and novel proteins from scratch. The enzyme that stripped glycation from that aorta was found by screening forty-five thousand structures and five hundred million variants — that is not a wet-lab problem anymore, it is a compute problem.

AI research platforms now compress weeks of analysis into a single conversation, and major pharmaceutical companies have deployed them across tens of thousands of employees.

Why this matters more than it appears: protein design has become a search over an enormous space, and search problems get radically better with more compute and better models. Damage-repair medicine may begin to scale the way software scales.

And the economic consequence could be the most important part. If AI collapses the cost and time of discovery, the math that has left millions of rare-disease patients with no treatment gets rewritten. Diseases that were never worth a billion-dollar development budget become tractable.

Open-source biology and patient-driven medicine

Something genuinely new is happening at the edges.

A technology founder with terminal-stage cancer, told there was nothing left to try, generated twenty-five terabytes of his own molecular data — whole genome, transcriptomics, single-cell analysis, imaging, organoids grown from his own tumor. He fed it to AI as a research partner. He filed five individual-patient investigational applications with the FDA, all approved within forty-eight hours. He assembled a combination therapy from targeted radiation, checkpoint inhibition, a personalized neoantigen vaccine, and an oncolytic virus.

T-cell infiltration in his tumor went from nineteen percent to eighty-nine percent. The tumor shrank enough for surgery. He has had no evidence of disease since.

Then he published everything — the entire dataset, free and open — so anyone facing the same situation could build on it.

The uncomfortable truth in that story: he could afford it. The cost of getting a drug approved is roughly a billion dollars; the cost of dosing one person with a personalized therapy is roughly a million. That gap is where the next decade of medical ethics will be fought.

But the model is real, and the precedent matters: patient agency is becoming a legitimate medical intervention.

PART FIVE: THE AUGMENTATION FRONTIER

Here medicine stops repairing the body and begins extending it.

Brain-computer interfaces

This has moved faster than nearly anyone predicted.

In January 2024, a quadriplegic man received a neural implant and within weeks was playing chess with his thoughts. By January 2026, twenty-one people across four countries had received implants. By mid-2026, twenty-six. Zero serious device-related adverse events reported.

The implant is roughly the size of a quarter, carrying up to 3,072 electrodes. The first patient now controls a computer faster than some engineers using a mouse.

But this is not a one-company field, and the competition is instructive. An alternative approach threads a stent-mounted electrode array through a blood vessel to the motor cortex — no open brain surgery at all. Six patients, zero serious adverse events, and a pivotal trial that could produce the first premarket approval for a permanently implanted communication interface. Other companies are pursuing surface arrays that sit on the cortex rather than penetrating it.

Where it stands honestly: no motor-control brain interface has full FDA premarket approval. All remain investigational. Early engineering problems — implanted threads retracting from optimal position — required software compensation and design revision.

The near-term applications are genuinely medical and genuinely profound: restoring communication in ALS and locked-in syndrome, restoring computer control in paralysis, and decoding speech from thought. Vision restoration through cortical stimulation has breakthrough designation.

The longer-term questions are ones society has not begun to address. If a device can read motor intention, what else can it read? Mental privacy is not currently a well-defined legal category. And the line between restoration and enhancement will blur the moment these devices work well enough that healthy people want them.

Bionic limbs and neural integration

Modern prosthetics have crossed from tools to extensions.

Osseointegration anchors the limb directly to bone, eliminating socket problems and transmitting force through the skeleton. Targeted muscle reinnervation reroutes the residual nerves that once controlled the missing hand into remaining muscle, so the user thinks about moving a finger and the prosthetic responds.

And the direction that matters most: sensory feedback. Implanted electrodes stimulating sensory nerves can restore a sense of touch and limb position. Without feedback, a bionic hand is a tool you operate. With it, it begins to feel like a limb you own.

The frontier is closed-loop integration — a limb that both receives intention and returns sensation, seamlessly, without conscious effort.

Exoskeletons

Two distinct categories, and conflating them causes confusion.

Medical exoskeletons restore walking in spinal cord injury and support gait rehabilitation after stroke. Several are FDA-cleared. They are heavy, slow, and expensive — and for a person who has not stood in years, transformative regardless.

Industrial and consumer exosuits are the quieter revolution. Lightweight, often soft and unpowered or lightly powered, they reduce back and shoulder load for warehouse workers, surgeons standing for eight hours, and eventually older adults who need a little help with stairs.

The trajectory that interests me most: as these become light and cheap, they may become a mobility-preservation tool for aging. Muscle mass and balance determine independence. A device that supplements both extends the window in which someone lives in their own home.

Jet suits and the outer edge of physical augmentation

I include this because it is genuinely instructive about how augmentation actually arrives.

Turbine-powered personal flight suits exist, they work, and they have a real medical application: mountain rescue. Trials in the English Lake District demonstrated a paramedic reaching a casualty in roughly ninety seconds on terrain that would take a ground team twenty-five minutes.

That is the pattern to notice. The technology that looks like spectacle finds its first legitimate use at the extreme edge of need — trauma response, disaster medicine, remote rescue — and the engineering matures there before anything else.

Human augmentation and the Enhanced Games question

A competition has been proposed in which performance-enhancing substances are permitted and openly disclosed, with athletes medically supervised.

I want to engage this seriously rather than dismiss it, because the arguments are not stupid.

The case for: the current system is substantially a fiction. Enhancement occurs, it occurs in secret, it occurs without medical supervision, and the secrecy is precisely what makes it dangerous. Transparent, monitored use would generate genuine data on long-term effects that we currently do not have — data that would benefit patients, not just athletes.

The case against, and I find it stronger: the medical risks of supraphysiologic doses are real and include cardiomyopathy, polycythemia, thrombosis, and psychiatric effects — several of which sit directly in my specialty. Medical supervision reduces risk; it does not eliminate it. The coercive dynamics are unavoidable, because any competitor who declines enhancement is choosing to lose. And normalizing it in elite competition inevitably pressures adolescents whose developing bodies and judgment are the least equipped to absorb it.

My view: I would rather see the enormous energy in this debate directed toward legitimate therapeutic use — testosterone for genuine hypogonadism, growth hormone for documented deficiency, peptides that earn approval through actual trials. The distinction between treating deficiency and pursuing supraphysiology is medically meaningful, and it is worth defending.

But the honest observation underneath the controversy is correct: the line between therapy and enhancement is already blurred, and it will blur further. We treat low testosterone. We correct vision to better-than-normal with surgery. We are implanting devices that will eventually exceed baseline human capability. Medicine has not developed a coherent framework for this, and it needs one.

PART SIX: THE TRAPS

Every genuine revolution generates a parasitic industry. Here is how to avoid being its customer.

“It worked in mice” is the beginning of a question. Roughly ninety percent of drugs that succeed in animals fail in humans. Mouse lifespan studies are the single most over-cited category in this entire field.

Biomarkers are not outcomes. Telomere length, NAD+ levels, and epigenetic age are measurements, not results. Moving a marker is not the same as extending a life. We have been humbled repeatedly — most memorably by antioxidant supplements that improved oxidative markers and increased cancer.

Beware the person selling what they are recommending. This is not a claim of bad faith. It is a structural observation. When someone’s income depends on your believing a specific compound works, weight their enthusiasm accordingly — and notice who discloses and who does not.

The gray market will hurt someone you know. Prescription drugs purchased from anonymous sellers, dosed from internet protocols, with no monitoring. Dasatinib is chemotherapy. Rapamycin is an immunosuppressant. Peptides from unregulated suppliers fail purity testing over forty percent of the time. If a compound is powerful enough to work, it is powerful enough to hurt you.

Optimization can become its own pathology. I have seen patients so consumed by tracking that they sleep worse from anxiety about their sleep score. There is a name for it now. The goal is a life, not a dashboard.

And the deepest trap: substituting the exotic for the fundamental. The most measured man on earth — spending millions annually with a team of dozens — had an autoimmune disease quietly destroying his stomach for over a decade. It was missed not for lack of data but because a single abnormal marker was repeatedly explained away. Measurement is not interpretation. And no protocol substitutes for someone actually thinking.

PART SEVEN: THE PROTOCOL

Here is the honest allocation, and I want it stated plainly because everything above can distract from it.

Roughly ninety-five percent of the longevity benefit available to you today comes from things nobody profits from telling you.

Which is why this section is the longest in the manual. Everything before it was context. This is the part you execute.

1. EXERCISE — THE MOST POWERFUL DRUG EVER DISCOVERED

If exercise were a pill, it would be the most prescribed compound in history and the most expensive. Nothing else touches it — not for mortality, not for cognition, not for metabolic health, not for maintaining independence.

There are four distinct stimuli your body needs, and most people do one or two and assume they are covered.

Zone 2: the aerobic base

What it is. Sustained effort at roughly 60-70% of maximum heart rate, or lactate around 2 mmol/L. Practically: you can hold a conversation but you could not sing. If you can speak in complete comfortable sentences you are too easy. If you are breaking sentences to breathe, you are too hard.

Why it matters. Zone 2 is the single most powerful stimulus for mitochondrial density and fat oxidation efficiency that exists. It builds the metabolic engine that everything else runs on, and it does so without the recovery cost of high-intensity work.

The protocol. 150-300 minutes weekly. Three to five sessions of 45-60 minutes. Brisk walking uphill, cycling, rowing, swimming, or a gentle jog if your joints allow. Nasal breathing is a useful check — if you cannot maintain it, you have drifted out of zone.

A note on the trap: most people who think they are doing Zone 2 are actually in Zone 3 — too hard for the mitochondrial benefit, too easy for the VO2 max benefit. The “gray zone” gives you the fatigue of hard training with a fraction of the adaptation. Slow down.

VO2 max: the mortality lever

Why it deserves its own protocol. Cardiorespiratory fitness is arguably the strongest predictor of all-cause mortality ever measured — the least fit carry four to five times the death risk of the fittest, with no observed upper limit of benefit. Being in the bottom quartile for your age carries mortality risk comparable to smoking.

The protocol: 4x4 intervals, once or twice weekly. Four minutes at roughly 90% of maximum effort — hard enough that you are counting down the seconds — followed by three minutes of easy recovery. Four rounds. Warm up ten minutes, cool down five.

This is the protocol with the most robust evidence for raising VO2 max. Total working time is sixteen minutes. Do it on a bike, a rower, a hill, or a treadmill.

Targets to aim for:

• Men 40-50: above 42 ml/kg/min · 50-60: above 38 · 60-70: above 34

• Women 40-50: above 36 · 50-60: above 33 · 60-70: above 29

Being in the top quartile for your age is the goal. If you are in the bottom quartile, climbing out is the single highest-yield health intervention available to you — larger than any drug in this manual.

Measure it once or twice a year: a lab test, a wearable estimate, or a Cooper test (distance covered in twelve minutes).

Strength: the organ of independence

Why. Muscle is your largest glucose disposal organ, a major endocrine tissue, and the primary defense against the frailty that ends independence. After thirty, you lose roughly 3-8% of muscle mass per decade — accelerating after sixty — unless you actively resist it.

Grip strength alone predicts all-cause mortality, cardiovascular death, and cognitive decline. It is a proxy for total-body muscle and neurological integrity.

The protocol. Two to four sessions weekly. Build every session around compound movements that load multiple joints:

• Squat pattern — back squat, goblet squat, leg press, split squat

• Hinge pattern — deadlift, Romanian deadlift, hip thrust, kettlebell swing

• Push — overhead press, bench press, push-up, dip

• Pull — row, pull-up, lat pulldown

• Carry — farmer’s walk, suitcase carry. Underrated for grip, core, and real-world function.

Rep ranges. For strength and bone: 5-8 reps with a genuinely challenging load. For hypertrophy: 8-12. Both work; do some of each. The final two or three reps should be difficult.

Progressive overload is the entire point. Add weight, reps, or sets over time. Lifting the same weights for a decade produces a decade of no adaptation. Keep a log — the log is what makes progression happen.

Impact and balance: what actually prevents the fracture

This is the category almost everyone skips, and it is the one that determines whether you spend your last decade in your home or in a facility.

Bone responds to exactly two signals: heavy loading and impact. Walking, swimming, and cycling — excellent for other reasons — do not build density. The LIFTMOR trial showed postmenopausal women doing supervised high-intensity resistance and impact training twice weekly gained 2.9% spine bone density while controls lost 1.2%. Opposite directions in eight months.

Impact protocol: 10-20 jumps, hops, or heel drops daily. Rope skipping counts. Skip only if your joints or physician prohibit it.

Balance protocol, daily and free: single-leg stands, progressing from thirty seconds to a minute, then with eyes closed, then on an unstable surface. Heel-to-toe walking. Getting up from the floor without using your hands.

Falls cause the fractures. You can have excellent bone density and still shatter a hip going down hard. Balance training is the most underrated intervention in this entire manual and it costs nothing but attention.

Daily movement

Walk after meals — 10-15 minutes. This blunts post-meal glucose excursions better than almost any free intervention available. If you do one thing from this section, do this.

Break up sitting. Prolonged sitting signals bone resorption and impairs glucose handling independent of your workouts. Stand and move every 30-60 minutes.

Aim for 7,000-10,000 steps daily as a baseline, on top of structured training, not instead of it.

The weekly template

• 3-4 Zone 2 sessions (45-60 min)

• 1-2 VO2 max sessions (4x4 intervals)

• 2-4 resistance sessions

• Daily: jumps, balance work, post-meal walks

• One full rest day

If that seems like a lot, start with two: walk daily and lift twice a week. Add from there. The protocol you actually do beats the perfect one you abandon.

2. NUTRITION — OPERATIONALIZED

The Mediterranean pattern has the strongest and most consistent evidence base of any way of eating. Here is what it means in practice.

The plate architecture

Half the plate: non-starchy vegetables and leafy greens. Aim for variety and color — different phytonutrients, different benefits. Thirty different plants per week is a useful target for microbiome diversity.

A quarter: quality protein. Fatty fish two to three times weekly (salmon, sardines, mackerel, anchovies). Legumes. Eggs. Poultry. Quality red meat in moderation. Fermented dairy if tolerated.

A quarter: whole-food carbohydrate. Legumes, whole grains, tubers, fruit. Not refined flour products.

Fat: primarily olive oil, plus nuts, seeds, avocado, and the fat in fish. Extra virgin olive oil is arguably the most evidence-backed food in the entire pattern — use it liberally.

The protein question, honestly

This deserves nuance, because the internet has gotten it badly wrong in both directions.

The range: roughly 1.0-1.6 g/kg body weight daily, adjusted for age and activity. For a 75kg person, that is 75-120 grams.

The complication: a major 2026 review synthesizing over 350 studies found that protein restriction — while still meeting needs — consistently improved metabolic health and extended lifespan across species. Excess protein, particularly animal-sourced in midlife, chronically activates mTOR, the growth pathway. Traditional Okinawans ran roughly 9% of calories from protein.

The resolution: exercise appears to protect against this. Athletes consuming high protein do not develop the metabolic consequences, because the protein goes into building muscle rather than idling in growth pathways. Protein without exercise is the problem — not protein.

So, practically:

• Sedentary, under 65: stay toward the lower end, weight toward plants and fish.

• Training hard, any age: the higher end is appropriate and probably protective.

• Over 65: increase it. Sarcopenia becomes the larger threat, older adults absorb protein less efficiently, and 1.2-1.6 g/kg is the right target. Pair it with resistance training or the protein has nowhere useful to go.

Distribute it. Roughly 30-40g per meal stimulates muscle protein synthesis better than one large serving. Most people eat almost none at breakfast and then a large amount at dinner — exactly backwards.

Meal timing and the circadian dimension

Front-load your calories. Insulin sensitivity peaks in the morning and declines through the day. The identical meal produces meaningfully different metabolic consequences at 8am versus 8pm — larger insulin spike, higher glucose, lower thermogenesis in the evening.

Larger breakfast and lunch. Lighter dinner. A Lancet-affiliated analysis found that an earlier “caloric midpoint” — the time by which you have eaten half your daily calories — was robustly associated with better insulin sensitivity, independent of what or how much you ate.

Stop eating three hours before bed. Late eating disrupts sleep architecture and blunts the overnight repair window.

On fasting windows: a 10-12 hour overnight fast is achievable for nearly everyone and captures most of the benefit. Longer windows (16:8) suit some people well. But two cautions: extended fasting can be counterproductive for women’s hormonal function in some cases, and prolonged fasting worsens gallbladder stasis — relevant if you are on a GLP-1 or losing weight rapidly. Regular smaller meals stimulate gallbladder emptying; long fasts let bile sit and concentrate.

Fiber — the most underconsumed nutrient

Target 25-38 grams daily. Most of my patients get half that.

Fiber lowers LDL, feeds the microbiome that produces short-chain fatty acids, stabilizes glucose, and increases satiety. Sources: legumes (the single best), vegetables, whole grains, nuts, seeds, berries. Psyllium husk is a cheap, legitimately useful supplement if food falls short.

Increase gradually or you will be uncomfortable, and drink water alongside it.

What to cut, in priority order

Ultra-processed food. This is the single highest-yield dietary change most people can make. Engineered to be overeaten, stripped of fiber, and associated with essentially every adverse metabolic outcome studied.

Added sugar and refined carbohydrate. Sugar-sweetened beverages first — they deliver a rapid glucose and insulin load with zero satiety.

Industrial seed oils in excess, particularly from fried and packaged foods.

Alcohol. Here is the honest current picture: the old “moderate drinking is protective” finding has substantially eroded under better methodology. There is no established safe level for cancer risk, and alcohol disrupts sleep architecture — suppressing REM and deep sleep even at modest amounts. If you drink, less is better, and never within three hours of bed.

Hydration and the boring essentials

Adequate water. Salt appropriately unless you have a specific reason not to — and if you eat a low-processed-food diet, you likely need more sodium than you think, not less. Coffee is genuinely fine and likely beneficial — the AHA’s 2026 scientific statement found up to 400mg of caffeine daily was safe and associated with lower cardiovascular and metabolic risk. Paper-filter it, though: unfiltered coffee (French press, boiled, espresso in volume) delivers cafestol, which raises LDL.

3. SLEEP — THE FULL PROTOCOL

Sleep is the most underrated intervention in medicine because its benefits are invisible and its absence is catastrophic.

The non-negotiables

7-9 hours of actual sleep. Most adults need 7.5-8.5.

Regularity may matter more than duration. In 60,977 adults, the most consistent sleepers had 20-48% lower all-cause mortality — and regularity predicted survival better than total hours. A steady 6.5 may beat a chaotic 8.

Fixed bed and wake times within ±30 minutes, seven days a week. Including weekends. This is where nearly everyone fails, and it is the highest-leverage item here. Sleeping in Saturday inflicts social jet lag on a system that has no way to distinguish it from a flight to Europe.

The environment

Temperature 63-67°F. Core body temperature must drop to initiate sleep. A warm room is one of the most common and most fixable causes of poor sleep. A warm bath or shower 60-90 minutes before bed paradoxically helps — peripheral vasodilation accelerates core cooling.

Blackout dark. Cover LED indicators. Even small amounts of light suppress melatonin and disrupt sleep architecture.

Quiet, or consistent white noise.

The timing stack

Morning light within 30-60 minutes of waking. Ten to twenty minutes outdoors, no sunglasses. This is the single most powerful free circadian intervention available. Morning light anchors your clock, advances melatonin onset that evening, improves mood, and improves sleep quality that night. Cloudy days still deliver far more lux than indoor lighting.

Last caffeine before noon. Caffeine’s half-life is 5-6 hours and longer in slow metabolizers — that 4pm coffee is measurably present at midnight. Genetics matter here: CYP1A2 determines how fast you clear it, which is why your friend sleeps after an 8pm espresso and you stare at the ceiling. Neither of you is imagining it.

Last meal three hours before bed.

No alcohol within three hours of bed. It helps you fall asleep and then wrecks the second half of the night.

Dim lights and stop screens 60 minutes before bed, or use blue-blocking glasses and read on paper.

The wind-down

Build a consistent 30-60 minute routine. Dim lights, warm shower, reading, stretching, journaling. Repetition is the point — you are training a cue.

If you wake at 3am and cannot return to sleep within about twenty minutes: get out of bed, keep lights very dim, read something dull, and return when sleepy. Lying in bed frustrated teaches your brain that bed is a place of wakefulness. And know that middle-of-the-night waking is frequently driven by alcohol, a late meal, a warm room, or blood sugar instability — address those first.

The evaluation almost nobody gets

If you snore, wake unrefreshed, or your partner notices you stop breathing — get a home sleep apnea test.

Untreated sleep apnea drives hypertension, atrial fibrillation, insulin resistance, systemic inflammation, and low testosterone. It is massively underdiagnosed, and treating it can improve nearly every other marker in this manual simultaneously.

A warning

Do not chase a perfect sleep score. Orthosomnia — anxiety about sleep metrics that itself destroys sleep — is now a recognized phenomenon. Track regularity, not perfection. If the data is making you anxious, stop looking at it for a month.

4. STRESS AND NERVOUS SYSTEM REGULATION

Chronic stress is not a mood. It is a measurable cardiovascular risk factor, and I treat its consequences daily.

Sustained cortisol elevation drives hypertension, insulin resistance, visceral fat deposition, systemic inflammation, impaired sleep, and suppressed immune function. It narrows heart rate variability — one of the truest signatures of a resilient nervous system.

What actually works

Breathwork, and the specific technique that works fastest: the physiological sigh. Two inhales through the nose — one long, one short sharp top-up — followed by a long slow exhale through the mouth. Repeat two or three times. This is the fastest known method to downshift acute stress in real time, and it works because extended exhalation directly activates parasympathetic tone.

Slow breathing at roughly six breaths per minute for five to ten minutes daily improves heart rate variability and lowers blood pressure. Four seconds in, six seconds out.

Meditation or contemplative practice, ten to twenty minutes daily. The evidence for blood pressure reduction and stress-marker improvement is genuine. The tradition does not matter — meditation, prayer, or structured silence all engage similar mechanisms.

Time in nature. Japanese forest medicine research found that walking among trees for two hours increased natural killer cell activity by roughly 50%, with effects persisting for weeks. Cortisol drops, blood pressure falls, parasympathetic activity rises. Twenty minutes produces measurable cortisol reduction; two hours produces the immune effect.

Sauna. Regular use is associated in Finnish cohort data with substantially lower cardiovascular and all-cause mortality, in a dose-dependent pattern. Mechanisms likely include improved endothelial function, heat shock protein induction, and blood pressure reduction. Four to seven sessions weekly at 175-195°F for fifteen to twenty minutes is the pattern studied. Hydrate, and check with your physician if you have significant cardiac disease.

And the one that matters most: boundaries. Much chronic stress is structural rather than psychological. If your life contains a relationship, obligation, or work pattern that is grinding you down, no amount of breathwork compensates. The intervention is the conversation you have been avoiding.

Track HRV if you use a wearable — but trend it over weeks rather than reacting to single days.

5. SUPPLEMENTS — THE CONSOLIDATED LIST

Supplements are the edges, not the center. No capsule compensates for poor sleep, no training, or ultra-processed food. But several correct genuine deficiencies or have real supporting data.

Tier 1 — Take these

Magnesium glycinate, 300-400mg elemental, at night. Up to 75% of adults have inadequate intake. Supports vascular tone, cardiac rhythm, sleep quality, insulin sensitivity, and is required to activate vitamin D. Patients notice the sleep difference within one to two weeks more than with almost anything else.

Vitamin D3 with K2 — dosed to reach a blood level of 50-80 ng/mL, typically 2,000-5,000 IU with 100-200 mcg K2. Morning, with a fat-containing meal. The K2 rationale is calcium partitioning toward bone rather than arteries; the trial data on vascular calcification is genuinely mixed, and nobody has shown K2 reduces cardiac events. If you take warfarin, K2 is off the table without your physician.

Omega-3 — target an omega-3 index above 8%. If your triglycerides are elevated and you are on a statin, know that prescription purified EPA has outcome data (25% event reduction in REDUCE-IT) that supermarket fish oil does not.

Creatine monohydrate, 3-5g daily. The most well-studied supplement in existence. Supports muscle mass, strength, and increasingly, cognition — particularly in older adults and under sleep deprivation. Cheap and safe. Tell your doctor before anyone reads your creatinine, which it raises without any change in kidney function.

Protein powder if you struggle to reach your target from food. It is food, not a supplement.

Tier 2 — Consider, based on your situation

CoQ10 100-200mg — especially if you take a statin, which depletes it. The most rational supplement pairing in cardiology.

GlyNAC (glycine + N-acetylcysteine) if you are over 55 or inflamed. Trial doses approximated 100 mg/kg daily of each. Restores glutathione, with randomized data showing improvements in mitochondrial function, inflammation, strength, and cognition. Benefits fade within 12 weeks of stopping.

Vitamin B12 if you are over 60, vegetarian, or on metformin or a proton pump inhibitor. Check the level with methylmalonic acid if borderline.

Iron only with documented deficiency — never speculatively. Excess iron is genuinely dangerous.

Psyllium husk if you cannot reach fiber targets from food.

Fisetin, urolithin A, taurine, glycine — reasonable, low-risk, biologically plausible, without outcome data. Optional.

Tier 3 — Skip, or approach with real caution

Beta-carotene supplements increased lung cancer in smokers in two large trials. High-dose vitamin E increased prostate cancer risk in SELECT. Niacin failed to reduce heart attacks in two large trials while increasing diabetes and infections. High-dose fish oil carries a dose-dependent atrial fibrillation risk. Concentrated green tea extract and high-absorption turmeric have documented cases of acute liver injury — and if you take enhanced-absorption curcumin, get baseline liver enzymes and recheck at 8-12 weeks. Glucosamine did not outperform placebo for joint pain, and a 2026 analysis raised concerns in cognitively impaired populations.

And the rule underneath all of it: “natural” means nothing without evidence. Arsenic is natural.

Timing

Morning with fat: vitamin D3/K2, omega-3, CoQ10. Anytime: creatine, protein. Split through the day: GlyNAC. Evening: magnesium glycinate.

6. ENVIRONMENT AND ORAL HEALTH — THE OVERLOOKED INPUTS

Your mouth is connected to your arteries

Periodontal bacteria have been identified inside coronary plaque, and gum disease is associated with meaningfully higher cardiovascular risk. If your hs-CRP is stubbornly elevated and nobody can find why, see your dentist.

Brush twice daily, floss, and get professional cleanings on schedule. It may be the cheapest anti-inflammatory intervention in medicine, and it is almost never mentioned in a longevity protocol.

Environmental exposures

The evidence here is less mature than for exercise or sleep, but several inputs are worth addressing because the cost of doing so is low.

Air quality. Fine particulate matter is an established cardiovascular risk factor with substantial supporting data. A HEPA filter in your bedroom is inexpensive and addresses the room where you spend a third of your life.

Water. A quality filter reduces exposure to a range of contaminants. Not glamorous, and reasonable.

Plastics. Microplastics have now been identified in human arterial plaque, with early data associating their presence with worse cardiovascular outcomes. The evidence is young and I will not overstate it. But the practical steps cost nothing: avoid heating food in plastic, use glass or stainless for hot liquids and storage, and reduce single-use plastic contact with food.

Endocrine disruptors. Reducing exposure to BPA, phthalates, and certain flame retardants is sensible, particularly for those with hormonal concerns or during pregnancy.

Smoking and vaping: zero. Nothing else in this manual compensates.

7. THE SEQUENCE

Do not attempt all of this simultaneously. That is precisely how people fail.

Weeks 1-4 — Baseline and sleep. Get the full lab panel and functional testing. Buy a home blood pressure cuff. Fix the sleep schedule and get evaluated for apnea if indicated. Start magnesium and vitamin D. Begin daily walking and morning light.

Weeks 5-8 — Movement. Add Zone 2 sessions and post-meal walks. Begin resistance training, even if it is two sessions of bodyweight work. Book the dental cleaning.

Weeks 9-12 — Nutrition. Shift the dietary pattern. Start by eliminating ultra-processed food and added sugar rather than attempting perfection. Establish the protein target. Add balance and impact work.

Month 4 — Retest. ApoB, hs-CRP, fasting insulin, liver enzymes. Adjust with your physician. Do not accept “close enough” — this is where most people quietly settle for insufficient treatment.

Months 5-12 — Optimize. Add VO2 max intervals. Address hormones. Add Tier 2 supplements if indicated. Layer in stress practice. Consolidate the habits until they stop requiring decisions.

Year 2 and beyond. Re-image at one to two years. Track biological age annually. Consider experimental interventions only under genuine medical supervision, preferring clinical trials to gray-market access.

Change one variable at a time where you can, so you know what actually worked.

AND THE STRATEGIC POINT THAT GOVERNS EVERYTHING

Your job is not to guess which frontier therapy will win. Your job is to arrive at it in good enough condition to benefit.

Every technology in this manual will work better in a person with intact metabolic health, preserved muscle, a functioning cardiovascular system, and low inflammatory burden. Partial reprogramming will not rescue a body that spent the intervening decade being neglected.

You are not merely trying to live longer. You are trying to remain a candidate.

PART EIGHT: THE MEDICINE OF 2040

Let me tell you what I think a visit to your physician looks like fifteen years from now, because I believe most of the pieces already exist and are simply waiting to be assembled.

You will not go in for an annual physical. The concept will seem as primitive as an annual dental X-ray in a world of continuous monitoring. Instead there will be a continuous molecular record — a personal methylome time series, organ-resolved, updated regularly, interpreted against your own baseline rather than a population average built from sick people.

Your physician will not ask whether you have a disease. She will ask which organ is drifting, and how fast. The output will not be “you might have cancer.” It will be something closer to: your pancreatic signal is three standard deviations above your personal baseline and accelerating; here are the highest-yield interventions ranked by expected risk reduction.

Velocity rather than threshold. Direction rather than position. That single conceptual shift — from do you have it to where are you heading — will do more for human lifespan than any individual drug on the horizon.

Your treatments will not be selected from a catalog of things that work on average. They will be built. A gene therapy synthesized for your specific mutation. A neoantigen vaccine designed from your specific tumor. An enzyme engineered by a model that searched five hundred million variants to find the one that clears your specific accumulated damage. The economics that required a drug to serve a hundred thousand people to justify its existence will have collapsed, and with them the entire category of disease we currently call “too rare to treat.”

Damage will be a maintenance category rather than a destiny. Senescent cells cleared on a schedule the way you service a machine. Glycation stripped from arterial collagen. Epigenetic drift periodically reset in tissue after tissue, cautiously at first — the eye, then perhaps the liver, then the systems we are currently too frightened to touch. Not immortality. Maintenance — the thing engineers have done for every complex system except the human body, finally applied to the human body.

And the boundary of the body itself will have become negotiable. Neural implants restoring speech to people who lost it, then movement, then sight — and eventually, inevitably, offering capability to people who never lost anything. Limbs that return sensation rather than merely obeying. Exosuits light enough that an eighty-year-old climbs her own stairs.

Somewhere in that decade, medicine will stop being a discipline that responds to failure and become one that manages a system.

Which raises the question this manual cannot answer

Here is where I have to stop being a technologist and be a physician again.

I have sat with a great many people in their final hours. Not one of them has ever told me they wished they had optimized more.

They talk about people. A daughter’s laugh. The way light fell in a kitchen forty years ago. A hand they held. The reconciliation they kept postponing until there was no more until.

Nobody at the end wishes for more time in the abstract. They wish for more time with.

So I want to name three things that no reprogramming vector will ever deliver, and that the data supports as forcefully as anything else in this manual.

Energy is the real currency — not years. The capacity to be fully present, to work at what matters, to carry a grandchild up the stairs. Optimize for vitality and duration tends to follow. Optimize for duration alone and you can construct a long, anxious, joyless life spent staring at biomarkers, which is a strange thing to have fought so hard for.

Purpose is measurable medicine. People with a strong sense of purpose live measurably longer. Not metaphorically — measurably, in the longevity literature, with effect sizes that would excite a pharmaceutical company. The heart keeps beating for something, and it turns out the data agrees with the poets.

And connection is not soft science. The strength of your close relationships is among the most powerful longevity variables ever documented, comparable in magnitude to risk factors we treat aggressively with drugs. If your protocol consumes the hours you would have spent with the people who love you, it is not a longevity protocol. It is a very sophisticated way of losing.

What I actually believe

I think we are living through the hinge.

For all of recorded history, aging was weather. You could dress for it. You could not change it. Every human being who has ever lived accepted a one-directional decline as the fundamental condition of being alive, and built entire religions and philosophies around making peace with it.

We are the first generation with credible evidence that it may be an engineering problem.

Not solved. Not close to solved. But addressable — and that word has never been true before. An enzyme that strips seventy years of scarring from an artery. A therapy that reset the clock inside a living human eye this June. Cells engineered to restore a function the body permanently lost. Any one of those would have been called a miracle in 1975. We got all of them in eighteen months, and most people did not notice.

I expect to finish my career practicing a kind of medicine I could not have described when I started it.

But none of it arrives on a schedule that rescues someone who spent the intervening decade neglecting the fundamentals. The frontier will be enormously generous to people who show up with intact metabolism, preserved muscle, quiet inflammation, and a cardiovascular system still worth saving. It will have very little to offer everyone else.

So the strategy is almost absurdly simple, and it is the same strategy it has always been, with one new reason behind it:

Move. Lift. Sleep. Eat real food. Know your numbers. Protect the people you love and let them protect you.

Not because those things are the ceiling.

Because they are the ticket.

The most extraordinary decades in the history of medicine are about to happen, and the only real question is whether you will be in good enough condition to be part of them.

Take care of the body you have.

It is the one that has to make it to whatever comes next.

This manual is educational and not personalized medical advice. Many interventions discussed are investigational, off-label, or prescription-only, and several carry serious risk. Nothing here should be started, stopped, or changed without your own physician. Do not self-administer prescription medications obtained outside a physician relationship.

If this was useful, share it with someone who is drowning in longevity content and cannot tell the proven from the promised.

I write everything I know — cardiology, metabolic health, hormones, cancer screening, bone and muscle, and the frontier research most people never hear about until it is already standard of care — on this newsletter.

Completely free. No paywall. Nothing to sell you. No supplement line, no affiliate links. Just a cardiologist writing what I would want my own family to know.

Subscribe: substack.com/@afshineemrani

Blessings.

Afshine Ash Emrani, M.D., F.A.C.C.
Assistant Clinical Professor, UCLA
David Geffen School of Medicine

Join Our new website

Castle-Connolly Nationwide Top Doctor (Since 2008)
Los Angeles Magazine Super Doctor (Since 2010)
LA Style Magazine Top 100 Doctors in America (2024)

Subscribe to mynewsletter: substack.com/@afshineemrani
Explore my books: Amazon Author Profile

We say we have no discipline, no attention span, no willpower. We promise to scroll less and fail by noon. We feel the shame of the wasted hours and the empty ache after, and we assume the weakness is ours.

It is not ours. It was engineered.

There is a piece of code deciding, right now, what a billion people will see when they open their eyes. We call it an algorithm and speak of it like weather — something that simply happens to us. But it is not weather. It is a business, running billions of times a second, with exactly one goal: keep you here. Keep you scrolling. Keep your eyes on the glass a few seconds longer, because those seconds are the thing it sells.

And it learned something about us that it now uses against us every day. It learned that peace makes a person put the phone down and go live their life — and a person living their life is worth nothing to it. So it does not feed us peace. It feeds us agitation, because outrage holds us longer than calm. It feeds us envy, because the ache of not enough holds us longest of all. It discovered that a stage keeps us watching longer than a living room. And so, one small nudge at a time, it turned our lives into a stage.

We did not choose this. It was chosen for us. But we are the ones living inside the wreckage.

GET MY BOOK BEYOND THE WHITE COAT ON AMAZON

Look at what we traded for the lens

Staged grief. A child sets up a tripod beside a dying mother’s hospital bed, framing the tears, checking the light — and in recording the goodbye, misses the goodbye. The most sacred moment a human being is ever given, spent facing a lens instead of a face.

Performed mercy. A man hands a warm meal to someone sleeping on cold concrete — and angles the camera so the world can admire his kindness. The hungry man becomes a prop. The mercy becomes a commercial. What could have been holy becomes content.

The invisible table. A family gathers on a Friday night. Candles lit, food warm, everyone present — and no one is there. Each face glows from below by a small screen, each person proving their existence to an audience of strangers while the people they love most sit three feet away, quietly starving for their attention.

We are lonelier than any generation that has ever lived, and we are never once alone. That is not a coincidence. That is the design working exactly as intended.

It got inside our own thoughts

The cruelest part is how deep it reached. It did not just change what we do. It changed what we believe our own thoughts are.

We no longer feel our pain and sit with it — a feed diagnoses it for us before we’ve had the chance to understand it ourselves. We no longer wrestle with the sacred mess of loving difficult people — we flatten them into a word a fifteen-second clip handed us. A struggling partner becomes a “narcissist.” An old friend becomes “toxic.” A hard season in a marriage becomes a diagnosis, cheered on by strangers in a comment section who will never know either of you.

And almost no one asks the only question that ever heals: What was my part? It is easier to collect applause from the void than to let the truth walk into the rooms of us that need repair. Real healing asks for humility. The algorithm has never once rewarded humility, and it never will. Humility doesn’t trend.

Meanwhile everyone has become an expert in everything — fluent in every crisis, certain on every subject, master of all topics and student of none. We have never known more and understood less.

The pretend generation

Someone online named it perfectly: we have become the pretend generation.

On one app we pretend to be experts. On another, friends. On another, professionals. On another, funny, or rich, or beautiful. Everything is a simulation, and we are slowly becoming a science-fiction movie of our own making. Because when your identity is a feed tuned for engagement, you stop asking who am I and start asking what plays well. The metrics move in and quietly take over the mind. Little by little, you become an algorithm wearing a face. The performed self and the real self look alike from the outside — but only one of them is a person, and it is not the one collecting the likes.

And underneath it all sits the deepest trick of the machine: it convinced us this was connection.

But real connection never arrived like a notification. It is slow. It is awkward at first. It is built by showing up when it’s boring, when it’s hard, when no one is filming. The spark people wait for was never supposed to strike like lightning — it was meant to be grown, through consistency and time and the courage to be seen unedited. A mind trained to expect the instant hit — food delivered, shows streamed, dopamine scrolled — forgets how to wait for anything real. So we hold our ordinary lives up against everyone else’s highlight reel and conclude that our real life is the broken thing.

Our real life was never the broken thing. The machine measuring it was.

Blaise Pascal, three hundred years before the phone, wrote that nearly all of human misery comes from a single inability: we cannot sit quietly, alone, in a room. He named the exact wound the algorithm would one day be built to exploit. We are terrified of our own silence — so we fill it, endlessly, and call the fear “being connected.”

The only way home is to cut the wire

Here is the hard truth and the hopeful one at once: no app fixes this. Not a cleaner feed, not a smarter strategy, not one more performance of “authenticity.” You cannot out-scroll a machine designed to keep you scrolling. You can only step off the stage.

Every deep tradition on earth knew this long before the first notification — and now they feel like water in a desert.

The Sabbath commands one radical act each week: unplug. Put the camera down, turn the broadcast off, and sit inside the very silence you spent all week running from. Rabbi Abraham Joshua Heschel called it a palace in time — a sanctuary built not out of stone but out of hours, a day you cannot photograph your way into. You can only enter it by being fully present. It is a day the algorithm cannot reach, because you refuse to let it in.

And when the performance finally drops, something quiet returns. You stop seeing people as audiences or adversaries and start seeing them as human beings again. The Sufi mystics, and Rumi above all, taught that the heart is a mirror — that left untended it gathers so much dust it can no longer hold the light. The work of a life was never to polish your image for the crowd. It was to polish the mirror within, until something true could shine through it again. The Hasidic masters called this the real labor: not the viral hook, not the performed outrage, but the unglamorous, unwatched work of becoming humble and honest when no one is keeping score.

Simone Weil left us the truest sentence for our age: attention is the rarest and purest form of generosity. To truly look at another person — not through a lens, not while composing a caption, but fully, with your whole undivided self — may be the most radical and loving thing a human can do now. It has become nearly extinct. It is also entirely free.

Why the sacred stays hidden

Here is a thought to sit with.

Perhaps the Divine remains unseen precisely to protect us from ourselves. Because if God appeared on a screen, we would try to stream it. We would frame it, filter it, turn it into content, and argue about it in the comments. We would perform even for the holy.

So instead the sacred waits where no camera can follow — in the stillness, in the unrecorded spaces, in the ordinary Tuesday when no one is watching and there is nothing to gain. It asks nothing of your follower count. It asks only one thing:

When the stage lights go down, who are you when no one is watching?

The algorithm broke something in our generation. That much is true. We are lost, and we feel it, even when we cannot name it.

But the way home was never complicated. It was only quiet, and it was always ours to choose.

Put the phone down. Look at the person across from you. Feel the silence and let it be enough. Let the people you love see the real you — the one without the filter, the one you’ve been too afraid to show even yourself.

That person — the one no one is watching — is the only one who was ever really you.

Become real again.

Blessings.

Afshine Ash Emrani, M.D., F.A.C.C.
Assistant Clinical Professor, UCLA
David Geffen School of Medicine

Join Our new website

Castle-Connolly Nationwide Top Doctor (Since 2008)
Los Angeles Magazine Super Doctor (Since 2010)
LA Style Magazine Top 100 Doctors in America (2024)

Subscribe to mynewsletter: substack.com/@afshineemrani
Explore my books: Amazon Author Profile

In those seven minutes, your physician will likely order a lipid panel, a basic metabolic panel, a complete blood count, and perhaps a TSH. The results will come back. Someone from the office will call and say four words that mean almost nothing:

“Everything looks normal.”

Here is what that sentence actually means: nothing crossed a threshold that triggered an automatic flag.

It does not mean you are healthy. It does not mean nothing is trending in the wrong direction. It does not mean your arteries are clean, your metabolism is intact, or your hormones are where they should be. It means no red asterisk appeared next to any number in a system designed to catch disease that has already arrived.

And there is a deeper problem hiding inside that sentence.

“Normal range” was constructed from a population that is largely sick. Reference ranges are typically built as the middle 95% of people who happened to get tested at that laboratory. In a country where roughly 40% of adults are obese, over 90% have some degree of metabolic dysfunction, and heart disease remains the leading cause of death — being “within range” tells you that you resemble a population that is dying of preventable disease.

You do not want normal. You want optimal.

I have spent more than two decades as a cardiologist watching this gap kill people. Not through malpractice — through a system that was never designed to detect disease early. Every physician I know is working inside seven-minute appointments, insurance restrictions, and a standard panel that was largely designed decades ago.

So this article is the workaround.

Below is every meaningful test I believe belongs in a genuine preventive evaluation: what it measures, why it matters, what the actual target should be, how to interpret it, and the specific words to say to get it ordered.

Read it with a pen. Then print the panel and bring it with you.

PART ONE: BEFORE YOU DRAW — GETTING THE TEST RIGHT

More lab results are misinterpreted because of poor preparation than because of poor medicine. Get this part right or nothing downstream is reliable.

Fast 12 hours. Water only. Fasting insulin, glucose, and triglycerides are meaningless otherwise. Black coffee is a gray zone — it can modestly affect glucose and insulin. Skip it.

Draw before 9am. This is non-negotiable for testosterone and cortisol, both of which follow strong circadian rhythms and peak in the early morning. A testosterone drawn at 4pm can read 20-30% lower than the same man’s 8am value. Countless men have been told their testosterone is “fine” based on an afternoon draw.

No alcohol for three days. Alcohol elevates liver enzymes, triglycerides, and GGT, and disrupts glucose regulation.

Stop biotin at least three days out — ideally a week. This one is genuinely important and almost nobody knows it. High-dose biotin, common in hair, skin, and nail supplements, interferes with many immunoassays. It can produce falsely abnormal thyroid results that look like Graves’ disease, and — critically for my field — it can falsely lower troponin, the test used to diagnose heart attacks. People have had heart attacks missed because of a hair supplement.

Do not train hard the day before. Intense exercise transiently elevates CK, liver enzymes, hs-CRP, and creatinine. You will look inflamed and your kidneys will look worse than they are.

Mention creatine supplementation before anyone reads your creatinine. Creatine raises serum creatinine without any actual change in kidney function. This has sent healthy lifters into unnecessary nephrology referrals.

Same lab, same time of year, same time of day. Different laboratories use different assays and different reference ranges. Comparing a result from one lab to another is often comparing incompatible data. Vitamin D also varies substantially by season — a summer draw and a winter draw are different tests.

If you’re a woman, note your cycle day. Estradiol, progesterone, and LH vary enormously across the menstrual cycle. A single hormone level without knowing where you are in your cycle is nearly uninterpretable.

And always ask for the PDF, not the phone call. You want the actual numbers, the actual reference ranges, and the actual units. A summary of “everything’s fine” cannot be trended, cannot be compared, and cannot be questioned.

PART TWO: THE METABOLIC PANEL THAT ACTUALLY PREDICTS YOUR FUTURE

This is where the earliest warnings live, and it is where standard testing fails most completely.

Fasting Insulin — The Ten-Year Warning Bell

What it is: The amount of insulin your pancreas must produce, in the fasted state, to keep your blood sugar normal.

Why it matters more than glucose: This is the single most important test almost nobody orders.

Your fasting glucose and HbA1c can remain perfectly normal for ten to fifteen years while your pancreas works progressively harder to keep them there. Insulin resistance develops first. The pancreas compensates by producing more insulin. Glucose stays in range — and you are told you are fine — while the underlying disease advances silently.

By the time your glucose rises, you have often been metabolically ill for a decade.

Elevated insulin itself drives damage: it injures the endothelium, promotes small dense LDL particles, raises triglycerides, lowers HDL, increases inflammation, drives visceral fat deposition, and stimulates growth pathways implicated in cancer.

Target: Under 5 μIU/mL. Ideally 3-4.

Most laboratories list a “normal” range extending to 25 or higher. That range is not a health target. It is a description of a metabolically ill population.

How to interpret: A fasting insulin of 12 with a normal glucose is not reassuring. It is a pancreas working overtime. That is prediabetes years before it earns the label.

HOMA-IR — Insulin Resistance in a Single Number

What it is: A calculation from fasting insulin and fasting glucose that estimates insulin resistance directly.

Formula: (fasting glucose in mg/dL × fasting insulin in μIU/mL) ÷ 405

Target: Under 1.0. Above 2.5 generally indicates meaningful insulin resistance.

You can compute this yourself the moment you have both values.

Triglyceride-to-HDL Ratio — The Free Metabolic Crystal Ball

What it is: Simply your triglycerides divided by your HDL, both of which appear on any standard lipid panel. It costs nothing extra.

Why it is remarkable: This ratio is one of the best available proxies for insulin resistance and for the presence of small dense LDL particles — the most atherogenic kind. It frequently reveals metabolic dysfunction that total cholesterol completely conceals.

Targets:

• Under 1.0 — excellent

• Under 2.0 — good

• Over 3.0 — significant insulin resistance, and a meaningful signal for fatty liver disease

• Over 3.5 — a red flag regardless of what your total cholesterol says

How to interpret: Two people can have identical LDL cholesterol. The one with triglycerides of 180 and HDL of 38 (ratio 4.7) is in a completely different metabolic situation than the one with triglycerides of 70 and HDL of 70 (ratio 1.0). The standard panel treats them as similar. They are not.

HbA1c — And Why It Sometimes Lies

What it is: An estimate of average blood glucose over roughly three months, based on how much glucose has attached to hemoglobin.

Target: Under 5.4%. Not merely under the 5.7% prediabetes threshold — that is a disease label, not a health target.

The critical caveat nobody explains: HbA1c depends entirely on how long your red blood cells live. Anything that shortens red cell lifespan makes your A1c read falsely low.

That includes iron deficiency anemia in recovery, hemolysis, recent blood loss or donation, certain hemoglobin variants, chronic kidney disease, and — relevant to many athletes — high red cell turnover from intense training.

Conversely, iron deficiency itself can make A1c read falsely high.

This is why A1c should never be interpreted alone. Read it alongside fasting insulin, fasting glucose, and your CBC. If your A1c looks great but your fasting insulin is 15, believe the insulin.

Fasting Glucose

Target: Under 90 mg/dL. The standard cutoff of 100 for “impaired fasting glucose” is late.

Uric Acid

Why it belongs here: Uric acid is associated with hypertension, metabolic syndrome, fatty liver, kidney disease, and cardiovascular risk. It rises with fructose consumption and alcohol, and it is an underappreciated marker of metabolic strain.

Target: Generally under 6 mg/dL, and lower is often better within the physiologic range.

PART THREE: THE CARDIOVASCULAR PANEL — WHAT LDL MISSES

ApoB — The Number That Should Replace LDL

What it is: Apolipoprotein B. Every atherogenic lipoprotein — LDL, VLDL, IDL, remnants, and Lp(a) — carries exactly one ApoB molecule. So ApoB is a direct count of the particles capable of entering and damaging your artery wall.

Why it beats LDL cholesterol: LDL-C measures how much cholesterol your particles are carrying. It does not tell you how many particles you have.

Think of it as freight. LDL-C tells you the total tonnage being shipped. ApoB tells you how many trucks are on the road. It is the number of trucks that determines how many can crash into your artery wall.

Two people with identical LDL-C can have vastly different particle counts. The person with more, smaller, denser particles has far more objects capable of penetrating the endothelium — and substantially higher risk.

This is not theoretical. One analysis found that 54% of patients had dangerous ApoB levels that standard LDL testing missed entirely. The discordance is worst in exactly the people at highest risk: those with insulin resistance, metabolic syndrome, elevated triglycerides, or diabetes.

Targets:

• Low risk, no plaque: under 80 mg/dL

• Established disease, diabetes, or high Lp(a): under 60 mg/dL

• Very high risk with progressive plaque: lower still

Ask for it by name. Almost nobody runs ApoB unless the patient requests it.

Lp(a) — Test Once in Your Lifetime

What it is: An LDL particle with an additional protein, apolipoprotein(a), attached to it.

Why it is unlike every other lipid marker: It is almost entirely genetically determined, set at birth, and essentially unchanged by diet, exercise, or weight loss. Statins do not lower it and may nudge it slightly upward.

Why it matters enormously: Roughly 1 in 5 people carry elevated levels. High Lp(a) is associated with approximately a threefold increase in heart attack risk, and it drives three distinct processes simultaneously — atherosclerosis, thrombosis, and inflammation. It is also a leading cause of aortic valve calcification and stenosis.

This is why the marathon runner with perfect cholesterol has a heart attack at 47. It is why heart disease ambushes families who did everything right.

Target: Under 30 mg/dL, or under 75 nmol/L. Above 50 mg/dL (125 nmol/L) is considered elevated.

Test it exactly once. Because it is genetic, a single measurement gives you your lifetime number. Current guidelines support testing every adult at least once. The overwhelming majority never have been.

If it is high: You cannot lower it yet — but you lower everything else relentlessly. Elevated Lp(a) dramatically reduces the threshold for aggressive ApoB reduction, blood pressure control, and imaging.

And tell your first-degree relatives. It is inherited. Your result is partly their result.

What is coming: five drugs are in advanced trials achieving 80-95% reductions, with three in Phase 3 using cardiovascular outcomes as the endpoint. For four decades this was the risk factor we could measure and could not treat. That is changing.

hs-CRP — The Fire Behind the Plaque

What it is: High-sensitivity C-reactive protein, a marker of systemic inflammation.

Why standard CRP is insufficient: Ordinary CRP was designed to detect major infection and acute illness. It is far too blunt to trend at the low levels relevant to cardiovascular risk. You need the high-sensitivity version.

Why it matters: You can have flawless cholesterol and arteries actively preparing to rupture. Inflammation is what destabilizes the fibrous cap over a plaque. The JUPITER trial demonstrated that identifying and treating inflammation reduced cardiovascular events even in people whose lipids looked acceptable.

Targets: Under 1.0 mg/L is optimal. 1-3 is intermediate. Above 3 is high risk.

The essential caveat: hs-CRP rises with any acute infection, injury, or recent hard training. Never interpret a single elevated value during or shortly after an illness. Repeat it when you are well, and read the trend rather than the point.

If it is persistently elevated, inflammation always has an address: gum disease, visceral fat, untreated sleep apnea, insulin resistance, autoimmune disease, chronic alcohol use, poor sleep, or chronic stress. Find it.

Homocysteine

What it is: An amino acid that, when elevated, is associated with vascular damage and cognitive decline.

Why it is useful: It is one of the few cardiovascular markers that is often directly correctable — typically with B12, folate, and B6, particularly in people with MTHFR variants affecting methylation.

Target: Under 9 μmol/L, ideally under 7.

Standard Lipid Panel — Read Correctly

Still worth having, but read it properly: total cholesterol is nearly useless in isolation, HDL has a U-shaped relationship with risk (very high can be unfavorable), triglycerides are a metabolic marker as much as a lipid one, and LDL-C should be interpreted alongside ApoB rather than instead of it.

PART FOUR: THE HORMONE PANEL — WHERE “IN RANGE” FAILS MOST BADLY

For Men

Here is the most important thing to understand: total testosterone alone tells you essentially nothing.

The reference range problem. The lower limit of the “normal” total testosterone range has fallen substantially over recent decades — from roughly 350 ng/dL to around 264 ng/dL in commonly used harmonized ranges. That decline reflects a population whose testosterone levels have been falling, not a discovery that lower is healthier.

You should not feel reassured by a number that qualifies as normal only because the population got sicker. Men can have genuine symptoms of low testosterone at levels of 300-500 — comfortably “within range.”

The full panel to request:

Total testosterone — drawn before 9am. Non-negotiable timing.

Free testosterone — the biologically active fraction. This is what actually reaches your tissues.

SHBG (sex hormone binding globulin) — and this is the marker that explains an enormous number of frustrated men. SHBG binds testosterone and renders it inactive. A man can have a completely normal total testosterone and a free fraction on the floor because his SHBG is high — and this is never flagged, because total T looked fine.

If you have symptoms with an in-range total testosterone, pull SHBG immediately.

LH and FSH — these tell you where the problem is. Low testosterone with low LH points to a pituitary or hypothalamic origin (secondary hypogonadism). Low testosterone with high LH points to testicular failure (primary). You should not be prescribed testosterone without these, because they change the diagnosis and sometimes the treatment — secondary hypogonadism may respond to therapies that preserve fertility, which testosterone does not.

Estradiol (sensitive assay) — men need estradiol, and both too little and too much cause problems. Ask specifically for the sensitive or LC-MS/MS assay; standard immunoassays are unreliable at male concentrations.

Prolactin — an elevation can occasionally signal a pituitary adenoma, which is both treatable and important not to miss.

DHEA-S — declines roughly 10-20% per decade after 30 and reflects adrenal output.

The upstream causes to fix first: sleep apnea, visceral obesity, elevated blood sugar, heavy alcohol use, and certain medications all suppress testosterone. Address those and the number frequently rises without any prescription.

For Women

Timing is everything. Estradiol, progesterone, LH, and FSH vary dramatically across the menstrual cycle. Note your cycle day, or the results cannot be interpreted.

The panel:

Estradiol — and in perimenopause, expect volatility. A single value may not represent your typical state.

Progesterone — best drawn about seven days after ovulation in cycling women.

FSH — rises as ovarian reserve declines. Useful for characterizing menopausal transition.

Total and free testosterone, plus SHBG — this is the most overlooked panel in women’s medicine. Women produce testosterone in the ovaries and adrenals, and it is a primary driver of libido, energy, and muscle mass. It falls substantially in midlife. Assays are often poorly calibrated at female concentrations, so interpretation requires an experienced clinician — but not measuring it at all guarantees you will miss it.

DHEA-S — adrenal reserve.

Thyroid panel — see below. Thyroid disease is far more common in women and is frequently missed.

The Thyroid Panel — TSH Alone Is Not a Thyroid Panel

This is one of the most common failures in routine testing.

TSH is a pituitary hormone. It is a signal about your thyroid, not a measurement of your thyroid hormone. It can be normal in central hypothyroidism, in poor T4-to-T3 conversion, and in several other genuinely symptomatic states.

Request the full panel:

TSH — target roughly 0.5-2.0 mIU/L for most people who feel well, which is narrower than the standard range extending to 4.5 or higher.

Free T4 — the storage hormone.

Free T3 — the active hormone. Many people convert T4 to T3 poorly, particularly under stress, caloric restriction, illness, or nutrient deficiency. Free T3 is where symptoms often live.

Reverse T3 — an inactive form that rises in illness, stress, and caloric restriction and can block T3 activity.

TPO antibodies and thyroglobulin antibodies — these detect Hashimoto’s thyroiditis, which is the most common cause of hypothyroidism and often precedes abnormal TSH by years. A person with positive antibodies and a normal TSH is on a trajectory worth knowing about.

And remember the biotin warning. High-dose biotin can produce a thyroid panel that mimics Graves’ disease. Stop it a week before testing.

PART FIVE: NUTRIENT STATUS — THE CORRECTABLE DEFICIENCIES

Vitamin D (25-OH)

Target: 50-80 ng/mL.

Understand what 30 means. The commonly cited threshold of 30 ng/mL is roughly the level required to prevent overt bone disease. It is a floor for avoiding rickets and osteomalacia — not a target for optimal function.

Most people feel meaningfully better in the 55-85 range, and the associations with lower inflammation, better immunity, improved mood, and reduced cardiovascular risk sit well above the minimum.

Practical notes: dose with K2, take with a fat-containing meal, and account for season — a July value and a January value are different tests. Retest every 3-6 months until stable.

Ferritin — And Why It Fools Almost Everyone

What it is: Your stored iron.

The trap: Ferritin is an acute phase reactant. It rises with inflammation, infection, liver disease, and metabolic dysfunction — completely independent of iron status.

So you must read ferritin next to hs-CRP. A ferritin of 150 with an hs-CRP of 4 may represent inflammation masking genuine iron deficiency. A ferritin of 150 with an hs-CRP of 0.4 is real iron.

The second trap: hemoglobin drops last. Your body drains its iron stores first to keep hemoglobin normal, which means you can be profoundly iron-depleted with a completely normal hemoglobin and a normal CBC.

This is why so many women with fatigue, hair loss, and brain fog are told “you’re not anemic, you’re fine.” They are not anemic. They are iron deficient. Those are different conditions.

Bryan Johnson’s autoimmune gastritis was missed for over a decade precisely because a persistently low ferritin was repeatedly explained away rather than investigated.

Targets: For symptom resolution, many clinicians target ferritin above 50-70 ng/mL, and above 100 in the context of restless legs or hair loss. Very high ferritin with normal inflammation warrants evaluation for hemochromatosis.

Order alongside: serum iron, TIBC, and transferrin saturation for a complete picture.

Vitamin B12 — And the Test That Catches What B12 Misses

The problem with serum B12: it can appear normal while you are functionally deficient at the tissue level.

So order the confirmatory markers when B12 is borderline or symptoms are present:

Methylmalonic acid (MMA) — rises in true B12 deficiency. This is the more sensitive test.

Homocysteine — rises in both B12 and folate deficiency.

Target: Serum B12 above 500 pg/mL for most people, despite reference ranges extending down to 200. Deficiency causes irreversible nerve damage if prolonged — this is not a marker to leave borderline.

Higher risk: older adults (stomach acid declines with age, and acid is required for absorption), long-term proton pump inhibitor or metformin users, vegetarians and vegans, and anyone with autoimmune or malabsorptive conditions.

RBC Magnesium

Why not serum magnesium: Only about 1% of body magnesium is in serum, and your body defends that level aggressively by pulling from bone and tissue. Serum magnesium can be normal while you are substantially depleted.

RBC magnesium is imperfect but considerably more informative.

Up to 75% of adults have inadequate intake. Magnesium participates in over 300 enzymatic reactions, and deficiency affects sleep, blood pressure, cardiac rhythm, insulin sensitivity, and mood.

Omega-3 Index

What it is: The percentage of EPA and DHA in your red blood cell membranes.

Why it is useful: It reflects long-term intake rather than what you ate yesterday, and low levels are associated with higher cardiovascular and all-cause mortality.

Target: Above 8%. Most Americans are around 4%.

Zinc, Selenium, and Copper

Worth measuring if you have relevant symptoms — poor immunity, impaired taste or smell, thyroid dysfunction, or poor wound healing. Zinc supports testosterone production and immune function. Selenium is essential for thyroid hormone conversion. And zinc and copper compete for absorption, so long-term high-dose zinc can induce copper deficiency.

PART SIX: ORGAN FUNCTION — READ BEYOND THE FLAGS

Kidney

Creatinine and eGFR — but remember: creatine supplementation raises creatinine without any change in actual kidney function, and so does substantial muscle mass. Tell your physician before anyone panics.

Cystatin C — a superior kidney marker that is unaffected by muscle mass. If you are muscular, taking creatine, or have a borderline eGFR, request this instead.

Urine albumin-to-creatinine ratio (uACR) — and this one deserves special emphasis. Microalbuminuria is one of the earliest detectable signs of vascular damage anywhere in the body, not merely in the kidney. It reflects endothelial dysfunction systemically. It is cheap, it is a simple urine test, and it is dramatically underordered.

Target: under 30 mg/g, and lower is better.

Liver

ALT and AST — with a crucial reinterpretation. Standard reference ranges for ALT extend to 40 or higher, but those ranges were derived from populations that include enormous numbers of people with fatty liver disease.

Optimal ALT is likely under 25 in men and under 20 in women. An ALT of 35 is frequently called normal and frequently represents nonalcoholic fatty liver disease.

GGT — sensitive to alcohol intake and oxidative stress, and independently associated with cardiovascular risk and mortality. Target under 25.

And read them together with your triglyceride:HDL ratio. ALT of 33, triglycerides of 190, HDL of 40 — that combination is fatty liver until proven otherwise, and every individual value was “in range.”

Consider a FIB-4 score (calculated from age, AST, ALT, and platelets) to screen for advanced fibrosis, or elastography if metabolic risk factors are present.

Complete Blood Count — What to Actually Look At

Beyond the flags:

RDW (red cell distribution width) — variation in red cell size. Elevated RDW is independently associated with mortality and cardiovascular risk across many studies, and it is almost never discussed.

MCV — high suggests B12 or folate deficiency or alcohol; low suggests iron deficiency or thalassemia trait.

Neutrophil-to-lymphocyte ratio — a simple, free inflammation and stress marker you can calculate yourself. Generally under 2 is favorable.

Platelet count — low platelets with elevated liver enzymes can signal advancing liver fibrosis.

PART SEVEN: HOW TO ACTUALLY READ YOUR RESULTS

Normal ranges versus optimal ranges

A reference range is typically the middle 95% of people tested at that laboratory. It is a statistical description, not a physiological target.

In a population with epidemic metabolic disease, “normal” means “similar to everyone else, who is not well.” Optimal ranges are narrower, and they vary by individual.

One panel is a data point. Three is a trend.

This may be the single most useful concept in this entire article.

A single result tells you where you are. Three results across years tell you where you are going — and direction almost always matters more than position.

A fasting insulin of 8 sounds unremarkable. A fasting insulin that went 4 → 6 → 8 across four years is a trajectory heading somewhere specific, and it is far more actionable than any individual number.

Export every panel you have ever had into a single spreadsheet. Plot ten years. The slope will tell you more than any number your doctor circled in red.

The patients who correct their numbers fastest are invariably the ones who already had a panel from five years ago to compare against. Start the file this year, even if it looks boring.

Pick six markers and trend those

Most comprehensive panels contain forty rows of “fine” concealing six rows that have been drifting in the wrong direction since 2019.

My suggested core six for most people: ApoB, fasting insulin, hs-CRP, HbA1c, vitamin D, and triglyceride:HDL ratio. Add testosterone panel for men, thyroid panel for women, and ferritin for anyone with fatigue.

When symptoms and labs disagree, believe the symptoms first

This is a principle I have learned the hard way over twenty years. Laboratory reference ranges are population averages. You are not a population.

A person with genuine symptoms and “normal” labs deserves investigation, not dismissal. Symptoms frequently precede laboratory abnormalities by years — that is precisely what early disease looks like.

Retest 8-12 weeks after you change anything

Long enough for a real biological signal, short enough to stay motivated. And change one variable at a time when you can, so you know what actually worked.

PART EIGHT: BUILDING YOUR PANEL BY BUDGET

Not everyone can order everything. Here is how I would prioritize.

Tier 1 — The Essential Foundation

If you can only run a handful of tests beyond the standard panel:

ApoB · Lp(a) (once) · Fasting insulin · hs-CRP · HbA1c · Vitamin D · Complete lipid panel with triglyceride:HDL ratio

These seven will reshape your understanding of your cardiovascular and metabolic risk more than anything else you can measure.

Tier 2 — The Comprehensive Preventive Panel

Add: Full thyroid panel with antibodies · Complete hormone panel appropriate to your sex · Ferritin with iron studies · B12 with MMA · Homocysteine · Uric acid · Cystatin C · Urine albumin-to-creatinine ratio · GGT · RBC magnesium

Tier 3 — The Deep Optimization Panel

Add: Omega-3 index · Zinc, selenium, copper · Sensitive estradiol · DHEA-S · Insulin-like growth factor 1 · Apolipoprotein A1 · Fibrinogen · Coenzyme Q10 (if on a statin) · Cortisol rhythm (four-point salivary or urinary)

Beyond blood: the imaging and functional tests

Coronary artery calcium score — inexpensive, low radiation, and one of the highest-yield tests in preventive medicine. But know that zero calcium does not mean zero plaque; soft plaque is invisible to it.

Carotid ultrasound — radiation-free and repeatable; the presence of plaque matters more than intima-media thickness.

DEXA — for bone density and body composition, including visceral fat quantification.

Home blood pressure monitoring — the smartest $40 in preventive care. Morning and evening, seated quietly five minutes.

VO2 max — cardiorespiratory fitness is among the strongest mortality predictors we have.

Sleep study — if you snore or wake unrefreshed.

PhenoAge biological age — calculated free from nine markers you likely already have: albumin, creatinine, glucose, CRP, lymphocyte percentage, MCV, RDW, alkaline phosphatase, and white blood cell count.

PART NINE: WALKING INTO THE APPOINTMENT

Your physician has roughly seven minutes. Use them deliberately.

Bring the panel printed out. Not a verbal request. A printed list you hand across the desk. This changes the interaction entirely.

Bring three written questions. Prioritized. If you only get to one, make it the one that matters most.

Use specific language:

“I’d like an advanced preventive panel. Specifically: ApoB, Lp(a) once, fasting insulin, hs-CRP, a full thyroid panel including free T3 and antibodies, and vitamin D. Here’s the list.”

If you meet resistance, and you may, try:

“I understand these aren’t standard. I’m asking because I want to identify risk early rather than after an event. If ordering them isn’t possible here, could you tell me how I might obtain them?”

Understand the insurance reality. Some of these are not routinely covered without a qualifying diagnosis code. Many can be obtained through direct-to-consumer laboratory services at reasonable cost. ApoB and hs-CRP in particular are inexpensive.

And if your physician is dismissive of a symptom you know is real — that is worth a second opinion. Not because your doctor is careless, but because seven minutes is not enough time to solve a puzzle, and you deserve someone with the time and curiosity to work on yours.

PART TEN: THE SPECIAL CASES

Before accepting a statin prescription: run ApoB, triglyceride:HDL ratio, fasting insulin, and hs-CRP first. You want all four to understand your actual arterial environment — the particle burden, the metabolic driver, and the inflammatory state — rather than making a decades-long decision from LDL-C alone. Consider a calcium score as well.

Athletes and heavy lifters: creatinine and eGFR will look worse than reality — request cystatin C. CK will be elevated. Ferritin can be low from foot-strike hemolysis and increased demand. And do not test the day after a hard session.

Vegetarians and vegans: prioritize B12 with MMA, ferritin with full iron studies, omega-3 index, zinc, and vitamin D.

On a proton pump inhibitor: these impair absorption of B12, magnesium, calcium, and iron. Long-term use warrants monitoring all four — and a conversation about whether you still need the medication at all.

On metformin: check B12 at least annually. Metformin-associated B12 deficiency is common and frequently missed.

Postmenopausal women: add a full thyroid panel, DEXA, and the complete hormone panel including testosterone and SHBG.

Men over 40 with any sexual dysfunction: this is a cardiovascular workup, not merely a hormone workup. Penile arteries are small and clog before coronaries do. New erectile dysfunction can precede a cardiac event by years.

Family history of premature heart disease — a parent or sibling with an event before 55 in men or 65 in women: run the full lipid panel including Lp(a), and get imaging. Do not wait for guidelines built for average risk.

THE BOTTOM LINE

The standard physical was designed to detect disease that has already arrived. It performs that job adequately.

But nearly every disease I treat as a cardiologist announced itself in the bloodstream years — often more than a decade — before it announced itself in a symptom. Insulin resistance precedes diabetes by ten to fifteen years. Elevated ApoB precedes plaque by decades. Inflammation precedes rupture.

That window is where all the leverage lives. And the standard panel largely does not look into it.

So here is what I want you to take from this:

“Everything looks normal” means nothing was flagged. It does not mean you are well.

“Normal range” was built from a sick population. You want optimal, and optimal is narrower.

Nobody runs fasting insulin, ApoB, or Lp(a) unless you ask. So ask, by name, in writing.

One panel is a data point. Three is a trend. Start the spreadsheet this year.

When symptoms and labs disagree, the symptoms are usually early. Trust your body and keep looking.

You are not being difficult by requesting these tests. You are doing what the system, under enormous time and reimbursement pressure, is not currently built to do for you.

The most valuable hour you will ever spend on your health may be the one where you sit down, print this panel, and decide to actually find out what is happening inside your body — while there is still time to change it.

Get the numbers. Trend the numbers. Act on the numbers.

Your future self is being determined right now, in a bloodstream nobody is looking at closely enough.

If this was useful, share it with someone who was just told “everything looks normal” and didn’t know what to ask next.

This article is educational and not personalized medical advice. Interpret all results with a physician who knows your full history. Do not start, stop, or change any medication or supplement on your own.

I write everything I know — cardiology, metabolic health, hormones, cancer screening, bone and muscle, longevity science, and the frontier research most people never hear about until it is already standard of care — on this newsletter.

Completely free. No paywall. Nothing to sell you. No supplement line, no affiliate links. Just a cardiologist writing what I would want my own family to know.

Subscribe: substack.com/@afshineemrani

Blessings.

Afshine Ash Emrani, M.D., F.A.C.C.
Assistant Clinical Professor, UCLA
David Geffen School of Medicine

Join Our new website

Castle-Connolly Nationwide Top Doctor (Since 2008)
Los Angeles Magazine Super Doctor (Since 2010)
LA Style Magazine Top 100 Doctors in America (2024)

Subscribe to mynewsletter: substack.com/@afshineemrani
Explore my books: Amazon Author Profile

By Afshine Emrani, MD, FACC

I have spent more than two decades as a cardiologist, and I want to tell you what I have learned about longevity by watching thousands of people either age well or fall apart.

The people who transform are almost never the ones with the most exotic protocol.

They are not the ones taking forty supplements. They are not the ones with the cold plunge and the hyperbaric chamber and the $2 million annual spend. I have watched people do all of that and still die on schedule, because they optimized the periphery and ignored the center.

The people who transform are the ones who executed a boring hierarchy relentlessly, measured whether it was working, and adjusted.

That is the entire secret, and it is unsatisfying, and it is true.

So this is that hierarchy. Thirteen pillars, ordered roughly by the strength of evidence and the size of the effect. For each one: why it matters, exactly how to implement it, what to measure, the specific words to say to your physician, and the ways people most commonly fail.

This is not theory and it is not a wish list. It is the distilled operating system I use for myself and recommend to my own patients and my own family.

Print it. Bring the relevant sections to your appointments. Then execute.

PILLAR 1: Sleep Like It Is the Most Important Drug You Take

Why it matters

Sleep is the single most underrated intervention in all of medicine, and the reason is that its benefits are invisible while its absence is catastrophic.

During deep sleep your brain runs a cleaning cycle — the glymphatic system physically clears toxic proteins including the amyloid implicated in Alzheimer’s disease. Your body performs cellular repair. Testosterone and growth hormone are produced. Blood pressure dips. Inflammation resolves. Memory consolidates.

Skimp on it, and none of that happens properly.

And here is the finding that reframed my thinking: in an analysis of 60,977 adults tracked with accelerometers, sleep regularity predicted mortality better than sleep duration. The most consistent sleepers had 20-48% lower all-cause mortality than the most chaotic — with reductions in cancer and cardiometabolic mortality as well.

A steady 6.5 hours may genuinely beat a chaotic 8.

How to implement

Fix your bed and wake times within ±30 minutes, seven days a week. Including weekends. This is where nearly everyone fails, and it is the highest-leverage item on this entire list. Sleeping in on Saturday inflicts what amounts to social jet lag on your circadian system.

Target 7-9 hours of actual sleep — most adults need 7.5-8.5.

Bedroom conditions: 63-67°F, blackout dark, no LED indicators. Cool and dark are not preferences; they are physiological requirements for deep sleep.

Last caffeine before noon. Caffeine’s half-life is roughly 5-6 hours, and longer in slow metabolizers. That 4pm coffee is still measurably present at midnight.

Last meal three hours before bed. Late eating disrupts sleep architecture and blunts the overnight repair window.

Wind-down: dim the lights and stop screens 60 minutes before bed, or use blue-blocking glasses and read something on paper.

The test almost nobody gets

If you snore, wake unrefreshed, or your partner notices you stop breathing — get a home sleep apnea test.

Untreated sleep apnea drives hypertension, atrial fibrillation, insulin resistance, systemic inflammation, and low testosterone. It is enormously underdiagnosed. And treating it can improve nearly every other number in this article.

What to say to your doctor

“I’d like to rule out sleep apnea with a home sleep study, and review whether any of my medications may be disrupting my sleep.”

How people fail

They chase a perfect sleep score on a wearable and develop orthosomnia — anxiety about sleep that itself destroys sleep. Track regularity, not perfection. If the data is making you anxious, stop looking at it.

PILLAR 2: Train for VO2 Max and Strength

Why it matters

Cardiorespiratory fitness is arguably the strongest predictor of all-cause mortality we have ever measured.

In a Cleveland Clinic study of over 122,000 adults, the least fit had four to five times the death risk of the fittest — and there was no upper limit of benefit. Fitter was always better, at every level examined.

To put it in the terms my patients understand: being in the bottom quartile of fitness for your age carries a mortality risk comparable to being a smoker.

And muscle is not merely for movement. It is your largest glucose disposal organ, a major endocrine tissue, and the single best protection against the frailty that ends independence.

How to implement

Zone 2 cardio: 150-300 minutes per week. Conversational pace — you can talk but not sing. Roughly 60-70% of maximum heart rate. Walking briskly uphill counts. This builds mitochondrial density and the aerobic base everything else sits on.

Resistance training: 2-4 sessions per week. Prioritize compound movements that load the whole system — squat, hinge (deadlift), push, pull, and carry. Progressive overload is the entire point. If the weight never increases, the stimulus never increases.

After every meal: a 10-15 minute walk. This blunts post-meal glucose excursions more effectively than almost any free intervention available.

Once or twice a year, measure VO2 max — a lab test, a wearable estimate, or a Cooper test.

Targets

• Men over 40: VO2 max above 40 ml/kg/min

• Women over 40: above 35 ml/kg/min

• Grip strength and leg strength improving year over year

What to say to your doctor

“I’d like a baseline fitness assessment or VO2 max estimate, and clearance to begin progressive resistance training.”

How people fail

They do only cardio and lose muscle every year. Or they lift the same weights for a decade and wonder why nothing changes. The biggest single win available to most people is simply climbing out of the bottom fitness quartile — that transition carries more benefit than anything else in this article.

PILLAR 3: Eat the Mediterranean Pattern With Smart Protein

Why it matters

The Mediterranean dietary pattern has the strongest and most consistent evidence base for cardiovascular and longevity outcomes of any way of eating we have studied.

And there is a nuance most people are getting wrong right now: excess protein — particularly animal-sourced protein in midlife — chronically activates mTOR, the cellular growth pathway. A major 2026 review synthesizing over 350 studies found that protein restriction, while still meeting needs, consistently improved metabolic health and extended lifespan across species. The traditional Okinawan diet ran roughly 9% of calories from protein.

The nuance that matters: exercise appears to protect against this. Athletes consuming large amounts of protein do not develop the metabolic consequences, likely because the protein goes into building muscle rather than idling in growth pathways. Protein without exercise is the problem — not protein.

How to implement

Base every meal on: olive oil, vegetables, legumes, nuts, whole grains, and fatty fish 2-3 times weekly.

Protein: moderate, individualized. Roughly 1.0-1.6 g/kg depending on activity level and age. Shift toward plant and fish sources before 65. After 65, protect muscle more aggressively — sarcopenia becomes the larger threat, and older adults need more protein, not less.

Front-load your calories. Insulin sensitivity peaks in the morning and declines through the day. The identical meal produces meaningfully different metabolic consequences at 8am versus 8pm. Bigger breakfast and lunch, lighter dinner. Stop eating three hours before bed.

Fiber: 25-38 grams daily. It lowers LDL, feeds the microbiome, and stabilizes glucose. Most of my patients get half that.

Cut hard: added sugar, ultra-processed food, industrial seed oils, excess alcohol.

Track

Triglyceride-to-HDL ratio under 2 — ideally under 1. You can calculate it from any standard lipid panel for free, and it is one of the best available proxies for insulin resistance.

How people fail

They pursue dietary perfection, sustain it for six weeks, then abandon it entirely. You do not need perfection. You need consistency that compounds across decades.

PILLAR 4: Fix the Two Cheapest Deficiencies

Why it matters

Magnesium and vitamin D deficiencies are epidemic, inexpensive to correct, and quietly drive poor sleep, elevated inflammation, higher blood pressure, worse mood, and impaired muscle function.

Up to 75% of adults are low in magnesium. Most have no idea.

How to implement

Magnesium glycinate: 300-400mg elemental, at night. Magnesium calms blood vessels, supports normal heart rhythm, deepens sleep, and participates in over 300 enzymatic reactions. The glycinate form is highly absorbable and gentle on the stomach.

In my experience, patients notice the difference in sleep quality and baseline calm within one to two weeks — more than with almost any other single change on this list.

Vitamin D3 with K2: dose to achieve a blood level of 50-80 ng/mL — not the bare minimum of 30 that most labs accept as normal. This typically requires 2,000-5,000 IU of D3 with 100-200 mcg of K2. Take it in the morning with a meal containing fat, since it is fat-soluble.

Why these two work as a system: magnesium is required to convert vitamin D into its active form, so taking D without adequate magnesium can worsen a magnesium deficit. And K2 helps direct absorbed calcium toward bone rather than soft tissue.

An honest note on K2: the trial data on K2 and vascular calcification is genuinely mixed — one trial found no significant effect, a more recent one found roughly 29% less calcium progression. Nobody has shown K2 reduces heart attacks or deaths. The defensible rationale is calcium partitioning, not proven plaque reversal. And if you take warfarin, K2 is off the table without your physician — it directly antagonizes the drug.

Retest vitamin D every 3-6 months until stable.

What to say to your doctor

“Please check my 25-OH vitamin D. I want to optimize to 50-80 ng/mL, not simply clear the threshold of 30.”

PILLAR 5: Add GlyNAC If You Are Over 55 or Inflamed

Why it matters

Glutathione is your body’s master antioxidant. It protects mitochondria, recycles other antioxidants, and defends cells against oxidative damage. And it collapses with age — older adults are reliably deficient.

When glutathione drops, mitochondria slow, inflammation rises, insulin resistance worsens, and recovery fails.

Here is the elegant part: glutathione production has two bottlenecks, not one. Both glycine and cysteine run short with age. Supply only one and you do not fix the gap. Supply both — glycine plus N-acetylcysteine, together called GlyNAC — and the factory restarts.

In randomized trials at Baylor College of Medicine, older adults taking GlyNAC for 16 weeks improved nearly every hallmark of aging simultaneously: mitochondrial function, oxidative stress, inflammation, insulin resistance, endothelial function, strength, cognition, and gait speed. Some markers returned toward young-adult range. In aged mice, the combination extended lifespan by roughly 24%.

How to implement

Trial dose: approximately 100 mg/kg body weight daily of each compound, split into 2-3 doses. For a 70kg adult, roughly 7g glycine and 7g NAC daily.

Start lower and titrate up. Take with food if you experience GI upset.

This is maintenance, not a cure. Benefits faded within about 12 weeks of stopping in the trials. Treat it like brushing your teeth.

The honest caveats

The trials were small — dozens of participants, not thousands. The strongest effects were in older adults with documented glutathione deficiency; a young, healthy person with normal glutathione will likely see much less. The lifespan data is in mice.

Discuss with your physician first if you have kidney disease, or take nitrates or blood thinners.

What to say to your doctor

“I’d like to discuss GlyNAC based on the Baylor trials. Can we check inflammatory markers first and monitor while I’m on it?”

PILLAR 6: Measure the Fire, Not the Smoke

Why it matters

Your standard annual panel was designed to detect disease that has already arrived. The markers below detect the disease that is coming — often a decade earlier.

The labs to demand

Fasting insulin — target under 5 μIU/mL (ideally 3-4). This is the ten-year warning bell, and almost nobody checks it. Your glucose and HbA1c can look perfectly normal for a decade while your pancreas works progressively harder to keep them there. By the time A1c rises, substantial damage has accumulated.

HOMA-IR — under 1.0. Calculated from fasting insulin and glucose. The best single measure of insulin sensitivity.

ApoB — under 80 mg/dL at moderate risk, under 60 at high risk. Every atherogenic particle carries exactly one ApoB molecule, making this a direct count of the particles that can damage your artery wall. One analysis found 54% of patients had dangerous ApoB levels that standard LDL testing missed entirely.

Lp(a) — once in your lifetime. Genetically determined, essentially unchangeable, and about 1 in 5 people carry elevated levels that triple heart attack risk. Diet and exercise do not touch it. Most people have never been tested. If yours is high, tell your first-degree relatives — it is inherited.

hs-CRP — under 1.0 mg/L. Inflammation. You can have flawless cholesterol and arteries actively preparing to rupture. (Note: it rises with any acute infection — never interpret a single value while you’re ill.)

HbA1c — under 5.4%, not merely under the 5.7% prediabetes threshold.

Triglyceride:HDL ratio — under 2, ideally under 1.

Home blood pressure — under 130/80. Buy a cuff. Measure morning and evening, seated quietly five minutes, arm at heart level. Office readings mislead in both directions.

Also worth having: homocysteine, full thyroid panel, ferritin and iron studies, urine albumin-to-creatinine ratio, and uric acid.

Frequency

Baseline, then every 6-12 months while actively optimizing.

What to say to your doctor

“I’d like an advanced preventive panel including fasting insulin, ApoB, hs-CRP, and Lp(a). Here’s the list.”

If your physician declines, you’re entitled to ask why — or to find one who understands that “within the reference range” and “optimal” are not the same thing.

PILLAR 7: Quiet the Chronic Inflammation

Why it matters

Inflammation is what destabilizes plaque and causes it to rupture — even when cholesterol looks perfect. The JUPITER trial demonstrated that identifying and treating inflammation reduced cardiovascular events in people whose lipids appeared acceptable.

Chronic low-grade inflammation — “inflammaging” — is a shared root of heart disease, Alzheimer’s, cancer, and metabolic collapse. It is the fire under all of it.

How to implement

Lifestyle first, and it does most of the work: sleep, exercise, dietary pattern, visceral fat reduction, stress management, gut health.

And oral health. This is the one nobody mentions. Periodontal bacteria have been identified inside coronary plaque, and gum disease is associated with meaningfully higher cardiovascular risk. If your hs-CRP is stubbornly elevated and nobody can find why, go see your dentist. It may be the cheapest anti-inflammatory intervention in medicine.

If hs-CRP remains elevated with cardiovascular risk: discuss low-dose colchicine (0.5mg daily) with your physician. It reduced cardiovascular events in the LoDoCo2 and COLCOT trials and is now FDA-cleared for cardiovascular risk. It is dramatically underused.

On the horizon: IL-6 inhibitors are in late-stage trials for cardiovascular inflammation.

Monitor

hs-CRP every 3-6 months until consistently under 1.0.

Inflammation always has an address. Find it: gums, gut, visceral fat, sleep apnea, insulin resistance, alcohol, autoimmune disease, chronic stress.

PILLAR 8: Protect the Endothelium

Why it matters

The endothelium is the single-cell lining of every artery you own. It is not passive plumbing — it is a chemically active organ that regulates blood pressure, controls clotting, and governs what crosses into the artery wall.

Endothelial dysfunction is the first step in atherosclerosis. It precedes visible plaque by years. If you can protect it, you are intervening earlier than any imaging test can detect.

How to implement

Discuss daily low-dose tadalafil (2.5-5mg) with your physician. I take it myself, and not for the reason most people assume.

PDE5 inhibitors raise cGMP, which enhances nitric oxide signaling — the master pathway of vascular health. The data associates them with improved flow-mediated dilation, reduced arterial stiffness, and in observational cardiac cohorts, lower mortality. Sildenafil was originally developed for angina; we renamed the drug after its side effect and forgot what it was built for.

Daily low-dose tadalafil also treats BPH, so many men over 50 address two problems with one inexpensive generic pill.

Absolute safety rule: never combine with nitrates. Nitroglycerin, isosorbide, or recreational poppers. The combination can cause fatal hypotension. With tadalafil’s long half-life, that window extends 48 hours.

And a critical insight for men: new erectile dysfunction after 40 is often the earliest sign of vascular disease, because penile arteries are small and clog before the larger coronaries. It can precede a cardiac event by 3-5 years. Treating the ED without evaluating the heart is silencing the alarm and ignoring the fire.

If your ApoB is not at goal: ask about the newly FDA-approved oral PCSK9 inhibitor — a once-daily pill delivering roughly 60% LDL reduction, matching the injectable class, with reductions in ApoB and Lp(a) as well. For patients who refused injections for years, the barrier just fell.

What to say to your doctor

“Based on the endothelial data, can we discuss low-dose daily tadalafil? And is the oral PCSK9 inhibitor appropriate for me?”

PILLAR 9: Track Biological Age, Not Calendar Age

Why it matters

Your organs do not age at the same rate. Organ-specific clocks reveal which system is failing fastest — and that is where your effort belongs.

A 2026 WashU study published in Nature Medicine, analyzing over 164,000 people, found that those born in the 1990s show a biological age gap 92% larger than those born in the 1960s. Same chronological age, dramatically older biology. And the fastest agers had up to 15% higher risk of developing cancer before 55 — even after accounting for genetics.

The organ-specific findings were striking: an immune system that tested biologically older correlated with early lung cancer; fat tissue that tested older correlated with early colorectal cancer. The organs aging fastest are the ones producing disease first.

How to implement

Start free. PhenoAge is calculated from nine standard markers you may already have: albumin, creatinine, glucose, CRP, lymphocyte percentage, mean corpuscular volume, red cell distribution width, alkaline phosphatase, and white blood cell count. That is a basic metabolic panel plus a CBC plus CRP. Free online calculators exist — enter your numbers and your actual age.

Then, if you want deeper insight: epigenetic clocks such as Horvath, GrimAge, and DunedinPACE analyze DNA methylation patterns from blood or saliva. Roughly $200-500, results in weeks.

Re-measure after major lifestyle or therapeutic changes. Every marker in PhenoAge responds to the interventions in this article — CRP falls with exercise and anti-inflammatory eating, glucose improves with dietary change, immune markers normalize with better metabolic health and reduced stress.

Your birth year is fixed. Your biological age is not.

PILLAR 10: Keep the Immune System Young

Why it matters

Immune aging — immunosenescence — and the accumulation of senescent “zombie” cells drive the systemic inflammation underneath nearly every chronic disease of aging. Senescent cells stop dividing but refuse to die, secreting a stream of inflammatory signals that damages surrounding tissue.

How to implement, honestly

Pillars 1-9 are your senolytic protocol. I want to be direct about this, because the supplement industry is currently selling senolytics with almost no human outcome data.

Exercise, quality sleep, metabolic health, and maintained muscle mass are the strongest evidence-based defenses against immune aging that currently exist. Muscle is an immune organ, not merely a movement organ.

Also: avoid chronic infections, stay current on vaccines, treat gum disease and gut inflammation, and manage chronic stress, which measurably ages the immune system.

Watch this space carefully. Senolytics, thymus rejuvenation, and CAR-Treg cell therapies are advancing rapidly, and the science is genuinely exciting. But discuss emerging options only under physician supervision and only as human data matures. Do not experiment on yourself with compounds that have no trials behind them.

PILLAR 11: Hormones — The Pillar Most Longevity Protocols Skip

Why it matters

Nearly every longevity protocol I read omits hormones entirely. In my exam room, it is the subject people are most desperate to raise and least able to say out loud.

It is not vanity medicine. It is vascular, metabolic, skeletal, and cognitive medicine.

For men

Get the right labs, drawn in the morning when levels peak: total and free testosterone, plus estradiol, prolactin, and LH. Prolactin matters because an elevation can occasionally signal a pituitary issue that is treatable and important not to miss.

Chase the upstream causes first. Sleep apnea, visceral obesity, high blood sugar, and heavy alcohol all suppress testosterone. Fix those and the numbers frequently climb without any prescription.

When testosterone is genuinely low with symptoms: replacement restores drive, energy, mood, and muscle mass. The TRAVERSE trial provided reassuring cardiovascular safety data and the FDA subsequently removed the old black-box warning.

But it requires real monitoring — hematocrit (testosterone thickens blood, which matters enormously to a cardiologist), PSA, and estradiol. And if you want children, know that TRT can impair fertility; that conversation happens first.

Do not buy testosterone from a website or a pop-up clinic that hands it out without proper testing.

For women

This is where medicine has failed most spectacularly, and it is now being corrected.

In November 2025, the FDA began removing the black box warnings from hormone therapy, including vaginal estrogen. The FDA Commissioner described the original decision as one of the greatest errors in modern medicine. Roughly 50 million women were frightened away from treatment based on a misreading of the Women’s Health Initiative — in whose estrogen-only arm breast cancer risk was actually lower.

If sex has become painful, that is a diagnosis, not aging. It is called genitourinary syndrome of menopause, and local vaginal estrogen reverses it within weeks while barely entering the bloodstream. Major societies consider it highly safe — even for many breast cancer survivors, in consultation with their oncologist.

If you are on estrogen and progesterone makes you miserable — bloated, foggy, unwell — you have at least six alternatives: micronized rather than synthetic progesterone, vaginal rather than oral delivery, cyclic rather than continuous dosing, bedtime timing to harness its sedating effect, a levonorgestrel IUD, or an estrogen-SERM combination that requires no progestogen at all. Most women are only ever offered one regimen.

And if desire is gone despite loving your partner: low free testosterone is usually why. Women make testosterone too, and it plummets in midlife. Low-dose therapy — roughly a tenth of a male dose — improves desire, arousal, and orgasm in randomized trials. There is no FDA-approved female formulation in the US yet, so experienced clinicians prescribe off-label. It is the single most overlooked element of this entire conversation.

Also now available: flibanserin, FDA-approved in December 2025 for postmenopausal women with low desire; bremelanotide as an on-demand option; and fezolinetant, a non-hormonal pill that shuts off hot flashes at the brain’s thermostat.

The longevity connection

Physical intimacy raises oxytocin, lowers cortisol, improves sleep, and reinforces the single strongest predictor of how long you will live: the strength of your closest relationships. Loneliness carries mortality risk comparable to smoking.

Connection is medicine. It belongs in the protocol.

What to say to your doctor

Men: “I’d like morning total and free testosterone, plus estradiol, prolactin, and LH — and I want to rule out sleep apnea first.”

Women: “I’d like to discuss vaginal estrogen, systemic hormone therapy, and low-dose testosterone. I know the FDA has revised the warnings.”

Bring the specific words. Most clinicians will not raise these unless you do.

PILLAR 12: Protect the Skeleton

Why it matters

A woman’s lifetime risk of breaking a hip exceeds her combined risk of breast, uterine, and ovarian cancer. We screen relentlessly for the cancers and largely ignore the fracture — and the fracture is what takes her independence.

Roughly 1 in 4 people die within a year of a hip fracture. Many who survive never walk unassisted again, and a substantial portion never return home.

Men are not exempt. Men account for roughly 1 in 4 osteoporotic fractures, and when a man breaks a hip he is more likely to die from it than a woman is. Yet most men who suffer a fragility fracture are never evaluated for osteoporosis afterward.

Peak bone mass arrives in the mid-twenties. After that the trajectory declines, accelerating sharply through menopause. Most women are not scanned until 65 — by which point decades of opportunity are gone.

The good news: bone responds at any age

The LIFTMOR trial demonstrated it. Postmenopausal women with low bone mass performed 30 minutes of supervised high-intensity resistance and impact training, twice weekly, for eight months. Spine bone density rose 2.9% in the training group versus a 1.2% decline in controls — opposite directions in under a year.

How to implement

Bone responds to exactly two signals:

Heavy loading — weights genuinely challenging in the final reps. Impact — jumping, hopping, heel drops.

Walking, swimming, cycling, and yoga are excellent for other reasons. They will not build density the way heavy progressive resistance and impact will. Most women over 50 have been told to walk more and take calcium — advice that is not wrong, but is badly insufficient.

The protocol:

• Strength train 2-4x weekly with compound movements loading hips and spine — squats, deadlifts, hip thrusts, overhead press, rows

• Jump: 10-20 daily hops, skips, or rope (unless your joints or physician say otherwise)

• Protein at every meal — bone is roughly half protein by volume

• Calcium 1,000-1,200mg daily, food first, spread through the day

• Vitamin D optimized (Pillar 4) — calcium is nearly useless without it

• Train balance daily — single-leg stands and progressive work. Falls cause the fractures. This is the most underrated item here and it costs nothing.

• Move all day; prolonged sitting signals bone to resorb

Get a DEXA earlier than 65 if you have risk factors: early menopause, family history, prior fragility fracture, steroid use, low body weight, malabsorption, or — for men — low testosterone, androgen deprivation therapy, or age over 70.

When lifestyle is not enough

For established osteoporosis, recent fragility fracture, T-score at or below −3.0, or multiple risk factors, escalate without apology: denosumab (potent anti-resorptive, every six months — never stop abruptly without transitioning), teriparatide (anabolic, builds new bone, typically limited to two years then followed by an anti-resorptive), or romosozumab (dual action, note the cardiovascular boxed warning).

Sequence matters: in very high-risk patients, starting with an anabolic and then following with an anti-resorptive produces larger gains than the reverse.

PILLAR 13: Catch Disease Before It Announces Itself

Why it matters

Every pillar above is about changing your trajectory. This one is about catching what slips through anyway — because the most common sentence spoken over a preventable death is not “we had no treatment.” It is “we found it too late.”

Cancer screening — do the proven things first

It is a peculiar feature of modern health culture that people will spend thousands on frontier testing while skipping the screenings with decades of mortality data behind them.

Colonoscopy at 45. Mammography. Low-dose CT if you have significant smoking history. Cervical screening. Skin examination. These are proven to reduce death. Do them.

Then map your family history properly. Not “cancer runs in my family” — specifically which relative, which cancer, at what age. First-degree relatives and early ages of onset matter most, and this single conversation may direct your care more powerfully than any test you can purchase.

On multi-cancer blood testing: the technology is real and genuinely promising. Roughly three-quarters of the cancers it detects have no screening test in existence — pancreatic, ovarian, esophageal. But I hold it to an honest standard: the largest trial missed its primary endpoint, and mortality benefit is not yet established. It is a reasonable conversation for those over 50 or at elevated risk, with clear eyes about what positive and negative results actually mean. It supplements standard screening; it never replaces it.

Cardiac imaging — look at the artery

A coronary calcium score is cheap, fast, low-radiation, and one of the best values in preventive medicine. Zero in a low-risk person is powerfully reassuring.

But zero calcium does not mean zero plaque. In the PROMISE trial, 25% of patients who suffered a major cardiac event had a calcium score of zero. Calcification is a late stage — soft, rupture-prone plaque is invisible to it.

If your calcium is zero but you have significant risk factors, discuss CT angiography with AI plaque analysis, which visualizes soft plaque directly.

And know this: a normal stress test is not a clean bill of arterial health. It detects flow-limiting narrowing over roughly 70% and is largely blind to the non-obstructive soft plaque that causes most heart attacks.

And what to do with a positive finding

If plaque is found, that is not a verdict — it is information, and information is the only thing that ever let anyone change an outcome. Drive ApoB down aggressively, extinguish inflammation, fix the metabolic root, and re-image in 1-2 years. Plaque can be stabilized and, in imaging trials, regressed.

THE 90-DAY LAUNCH SEQUENCE

Do not attempt all thirteen at once. That is precisely how people fail.

Weeks 1-2: Fix the sleep schedule. Start magnesium and D3/K2.

Weeks 3-4: Add Zone 2 cardio and post-meal walks.

Weeks 5-6: Begin resistance training. Shift to the Mediterranean pattern — start by eliminating added sugar and ultra-processed food rather than attempting perfection.

Weeks 7-8: Get the full lab panel. Buy a home blood pressure cuff.

Weeks 9-12: Add GlyNAC if indicated. Discuss endothelial protection, inflammation, and hormones with your physician.

Day 90: Reassess labs and — just as importantly — how you actually feel.

Then change one variable at a time, so you know what worked.

THE BOTTOM LINE

Here is what twenty years has taught me.

The hierarchy matters more than the details. Sleep, fitness, muscle, and metabolic health sit at the top for a reason — they are the foundation everything else is built on, and no supplement, peptide, or frontier therapy compensates for their absence.

Measurement converts intention into progress. Vague goals produce vague results. The moment you have numbers and can watch them move, this stops being a chore and becomes something you actually want to do.

And consistency beats intensity, every single time. The person who does eighty percent of this for twenty years will outlive the person who does one hundred percent of it for eight months.

Most people will read this, feel a genuine spark, and let tomorrow look exactly like yesterday. That is not a character flaw — it is the default, and the default is powerful.

The ones who change are the ones who treat their biology the way a serious person treats a craft: deliberate, repeated action, sustained long enough that it stops being something they do and becomes something they are.

Your future self will not care how busy you were.

Execute the hierarchy. Measure it. Iterate.

Your biology will respond. It always does.

If this was useful, share it with someone who needs a plan rather than another list of hacks. And bring the relevant sections to your next appointment — the doctor scripts are there because most physicians will not raise these topics unless you do.

This article is educational and not personalized medical advice. Do not start, stop, or change any medication or supplement without your own physician, particularly if you take nitrates, blood thinners, or have kidney disease, bleeding risk, or established heart disease.

I write everything I know — cardiology, hormones and midlife intimacy, cancer screening, metabolic health, bone and muscle, longevity science, and the frontier research most people never hear about until it is already standard of care — on this newsletter.

Completely free. No paywall. Nothing to sell you. No supplement line, no affiliate links, no sponsor deciding what I am allowed to say. Just a cardiologist writing what I would want my own family to know — including the inconvenient parts, and the parts my profession gets wrong.

Subscribe: substack.com/@afshineemrani

Blessings.

Afshine Ash Emrani, M.D., F.A.C.C.
Assistant Clinical Professor, UCLA
David Geffen School of Medicine

Join Our new website

Castle-Connolly Nationwide Top Doctor (Since 2008)
Los Angeles Magazine Super Doctor (Since 2010)
LA Style Magazine Top 100 Doctors in America (2024)

Subscribe to mynewsletter: substack.com/@afshineemrani
Explore my books: Amazon Author Profile

She had been on a GLP-1 for eight months. Her A1c had normalized. She’d lost forty pounds. Her blood pressure was down, her triglycerides had fallen, and for the first time in a decade she was walking two miles a day without her knees screaming.

Then a routine blood panel showed a mildly elevated lipase. She had no pain. No nausea. No symptoms of any kind. She felt, in her words, better than she had in fifteen years.

Her medication was stopped.

Within four months she had regained a substantial portion of the weight, her A1c was climbing again, and she was sitting in my office asking what she had done wrong.

She had done nothing wrong. Neither, in fairness, had the physician who stopped it — that doctor was being cautious in the absence of clear guidance, which is exactly the problem I want to write about.

This scenario is now happening tens of thousands of times a month across the country. GLP-1 receptor agonists have become mainstream medicine at extraordinary speed. Millions of people are taking them. And a great many clinicians — reasonably, conscientiously, and in my view incorrectly — are checking pancreatic enzymes on asymptomatic patients and discontinuing therapy over numbers that do not mean what they appear to mean.

I am asked about this constantly. By patients. By colleagues. By people who read what I write. So let me lay out what I actually think, why I think it, and where I believe the field needs to go.

This is my opinion, informed by the evidence as it currently stands. Reasonable physicians will disagree with pieces of it, and I welcome that argument. But the absence of clear, widely disseminated guidance on this specific question is now actively harming patients — and that part is not an opinion.

Part One: What Actually Happens to These Enzymes

GLP-1 receptors are present in the pancreas. That is not a defect in these drugs; it is part of how they work.

When you take a GLP-1 receptor agonist, amylase and lipase commonly rise. Across the trial data, mean increases run roughly 7–38% for amylase and 22–42% for lipase, varying by agent and dose. Elevations above the upper limit of normal occur more frequently than with placebo.

Rises to three times the upper limit or higher are uncommon.

And here is the pattern that matters clinically: levels typically rise early in therapy, stabilize, and drift back toward baseline when the drug is stopped. This is a pharmacodynamic effect, not a progressive injury.

Now the number that should govern practice, and that almost nobody knows:

The positive predictive value of an isolated asymptomatic enzyme elevation for later clinical acute pancreatitis is under 1%.

Read that again. If you find a mildly elevated lipase in a patient who feels completely well, the probability that it heralds actual pancreatitis is vanishingly small.

The prescribing labels themselves state that the clinical significance of isolated enzyme elevations, in the absence of symptoms, is unknown.

We are stopping effective, life-extending therapy over a finding the manufacturers explicitly describe as being of unknown significance.

Part Two: The Analogy Every Physician Already Understands

We have been here before, and we solved it.

When statins first became widespread, we checked liver enzymes obsessively. Mild transaminase elevations turned up constantly, and countless patients were taken off statins because of them.

Then we learned what those elevations actually meant: mostly nothing. Mild, asymptomatic transaminitis on a statin is common, usually benign, frequently transient, and rarely reflects genuine hepatic injury. Guidelines evolved. Routine periodic liver monitoring was abandoned in favor of baseline testing and symptom-driven evaluation.

We stopped treating a lab value and started treating a patient.

GLP-1 enzyme monitoring is in exactly the position statin liver monitoring occupied twenty years ago — and I believe the resolution should be the same, for the same reasons.

The difference is that this time the cost of getting it wrong is larger, because the drugs are more consequential. When you stop a statin unnecessarily, you lose lipid lowering. When you stop a GLP-1 unnecessarily, you lose glycemic control, weight management, cardiovascular protection, and renal protection simultaneously — and the metabolic regression is often rapid.

Part Three: What Actual Pancreatitis Requires

This is where the diagnostic confusion lives, so let me be precise.

The American College of Gastroenterology and American Gastroenterological Association criteria require at least two of three features:

1. Characteristic pain — severe, persistent epigastric or upper abdominal pain, classically radiating to the back.

2. Lipase (preferred) or amylase at least three times the upper limit of normal.

3. Compatible imaging on CT or MRI.

An isolated enzyme elevation, with no pain, does not meet the diagnostic criteria for acute pancreatitis. It is not a mild case. It is not “early” pancreatitis. It does not satisfy the definition at all.

And many things other than pancreatitis raise these enzymes modestly: renal impairment, salivary gland conditions, celiac disease, inflammatory bowel disease, macroamylasemia, certain medications, and simple biological variation.

Meanwhile, adjudicated acute pancreatitis in the large GLP-1 randomized trials has consistently been uncommon — typically in the range of 0.1–0.3%, and often statistically similar to placebo.

The labels do warn about pancreatitis, including rare severe and fatal cases, and the instruction is clear and appropriate: discontinue if pancreatitis is suspected, and do not restart if it is confirmed.

Suspected means symptoms. It has never meant a number on a routine panel in a patient who feels fine.

Part Four: The Gallbladder — Where the Real Signal Lives

Here is the part of this story that deserves more attention than it gets, because I think a meaningful portion of whatever excess pancreatitis risk exists with these drugs is biliary in origin rather than direct pancreatic toxicity.

GLP-1 receptor agonists genuinely promote biliary sludge and gallstone formation, through several converging mechanisms:

Suppression of cholecystokinin. CCK is the hormone that tells your gallbladder to contract and empty after a meal. GLP-1 reduces postprandial CCK release, which means weaker, delayed gallbladder contraction.

Altered gallbladder kinetics. Maximum emptying volume is often preserved — but the time to reach maximal contraction can be prolonged substantially, sometimes nearly doubled, and refilling is delayed. Bile simply sits longer.

Changes in bile composition. Effects on bile-acid receptor pathways — TGR5 and FXR/FGF19 — can increase cholesterol saturation of bile and alter gallbladder smooth muscle tone, favoring crystallization.

Neural effects. GLP-1 receptors in the brainstem influence vagal signaling, potentially producing less coordinated gallbladder contraction.

And rapid weight loss itself. This one is not unique to GLP-1s at all. Fast mobilization of adipose tissue floods the liver with cholesterol, which is then secreted into bile and supersaturates it. Add smaller, less frequent, lower-fat meals — which happen naturally when appetite falls — and you further reduce the stimulus for gallbladder emptying.

This is precisely the physiology we have long observed with very-low-calorie diets and after bariatric surgery. It is the biology of rapid weight loss, expressing itself through a drug that causes rapid weight loss.

The pathway is: biliary stasis → sludge and microliths → gallstones → possible duct obstruction → biliary colic, cholecystitis, or gallstone pancreatitis.

The magnitude, honestly stated: meta-analyses of randomized trials show elevated risk of gallbladder and biliary disease — overall relative risk around 1.37, cholelithiasis around 1.27, cholecystitis around 1.36. Cholecystectomy risk was elevated at a relative risk of roughly 1.70.

Relative risks always sound alarming, so here is the absolute picture: roughly 1 to 3 additional events per 1,000 patients per year. Risk is higher with higher doses, longer duration, and weight-loss indications. Real-world observational data is more variable, with some cohorts showing elevated cholecystectomy rates and others finding smaller or non-significant differences.

This is a real effect. It is also a modest one, and — importantly — it is one we can partially mitigate, which almost nobody discusses.

Part Five: What I Actually Recommend

This is my practice, offered as opinion rather than guideline, because no adequate guideline currently exists.

Do not order routine amylase and lipase in asymptomatic patients

FDA prescribing information does not recommend it. The American Diabetes Association Standards of Care do not recommend it. Major endocrine and gastroenterology societies do not recommend it.

We are doing it anyway, largely out of understandable caution — and every unnecessary test we order generates a certain number of abnormal results, each of which generates a decision, and a meaningful fraction of those decisions are wrong.

You cannot be harmed by a test you did not need and should not have had. But you can absolutely be harmed by what happens next.

Baseline testing: optional, and risk-stratified

Reasonable in higher-risk individuals — prior unexplained pancreatitis, known gallstones, markedly elevated triglycerides, heavy alcohol use. Not necessary for everyone.

During dose escalation

Clinical assessment focused on symptoms, tolerability, rate of weight loss, and patient education. No automatic enzyme bloodwork.

Ongoing monitoring

Standard metabolic monitoring at usual intervals — A1c, renal function, lipids, roughly every three months once stable. Enzyme testing only if symptoms suggest pancreatitis or biliary disease.

If you find an incidental elevation

Continue the medication. Investigate alternative causes if the rise is marked or progressive. Recheck only if clinically indicated.

Stopping effective therapy over a trivial asymptomatic change is, in my view, the single most common avoidable error in GLP-1 prescribing right now.

When to stop, without hesitation

Stop immediately and evaluate if pancreatitis is suspected: persistent severe upper abdominal pain, often radiating to the back, with or without nausea and vomiting. Do not restart if pancreatitis is confirmed.

Temporary interruption for severe gastrointestinal intolerance is entirely reasonable, with cautious restart at the lowest dose after resolution.

Prior pancreatitis is not an absolute contraindication, but it warrants genuine caution and shared decision-making.

Part Six: What to Tell Every Patient Before They Start

This is the education I believe should accompany every GLP-1 prescription, and it takes about ninety seconds.

Explain the difference between an enzyme elevation and pancreatitis. If a patient understands in advance that mild rises are expected pharmacology, they will not panic — and neither will the covering physician who sees the result on a Saturday.

Teach the pancreatitis warning signs. Severe, persistent upper abdominal pain radiating to the back, especially with nausea and vomiting. This is a call-your-doctor-now symptom.

Teach the biliary warning signs, which almost nobody mentions: right upper quadrant pain, particularly after fatty meals; pale stools; dark urine; yellowing of the eyes or skin; persistent nausea. Consider ultrasound if these appear, or if weight loss is very rapid and symptomatic.

And give the practical mitigation advice, which I think is genuinely underused:

• Encourage regular, smaller meals rather than prolonged fasting. Every meal stimulates gallbladder contraction. Long fasting windows let bile sit and concentrate. If your gallbladder is already contracting sluggishly on a GLP-1, extended fasting compounds the problem.

• Do not eliminate dietary fat entirely. Fat is the primary trigger for CCK release and gallbladder emptying. Extremely low-fat eating during rapid weight loss is a recipe for sludge.

• Maintain adequate hydration.

• Aim for a sustainable rate of weight loss. Very rapid loss — sustained beyond roughly 1.5 kg per week — meaningfully increases gallstone risk. Faster is not better, and this is one of the clearest examples of why.

• Address modifiable risk factors: triglycerides and alcohol in particular.

Part Seven: Why We Need Guidelines, Urgently

Here is my central argument.

These drugs are no longer niche. They are mainstream medicine, prescribed by endocrinologists, cardiologists, primary care physicians, obesity specialists, telehealth platforms, and increasingly by clinicians with varying levels of familiarity with the pharmacology.

In that environment, the absence of clear, explicit, widely disseminated guidance on enzyme monitoring is not a neutral gap. It is an active source of harm — because in the absence of guidance, the default clinical instinct is to test, and then to react to what you find.

That instinct is admirable. It is also, in this specific situation, producing the wrong outcome at scale.

What I believe the major societies should state explicitly:

1. Routine surveillance amylase and lipase testing is not recommended in asymptomatic patients on GLP-1 receptor agonists.

2. Isolated asymptomatic enzyme elevation is not a diagnosis and is not an indication to discontinue therapy.

3. Acute pancreatitis is a clinical diagnosis requiring symptoms; enzyme thresholds alone do not establish it.

4. Biliary risk should be addressed proactively through patient education, attention to meal patterns and dietary fat, and a sustainable rate of weight loss — not through laboratory surveillance.

5. Clear criteria for when to stop, when to interrupt, and when a cautious restart is appropriate.

This is not a call for less caution. It is a call for caution aimed at the right target — symptoms, not surveillance labs.

The Bottom Line

For the large majority of appropriate candidates, the benefits of these medications substantially outweigh the small absolute risks of pancreatitis and gallbladder disease. That is not a close call.

We are talking about drugs that reduce major cardiovascular events by roughly 20% in the right population, reduce serious kidney events, reduce mortality, resolve fatty liver inflammation, and transform metabolic disease — against an absolute biliary risk measured in a few events per thousand patient-years.

Asymptomatic enzyme elevations are expected pharmacology. They are not a warning. They are not early pancreatitis. They are the drug doing what the drug does.

True pancreatitis is uncommon, and it is diagnosed at the bedside — by a patient in genuine pain — not on a routine panel in someone who feels the best they have felt in years.

Gallbladder effects are real, mechanistically well understood, largely driven by motility and rapid weight loss, and partially preventable with advice that costs nothing.

So: focus on symptoms. Educate thoroughly. Reserve testing and interruption for clear clinical indications.

And to my colleagues — I say this with genuine respect, because I understand exactly why the reflex exists — when you find a mildly elevated lipase in a patient who feels wonderful, please look at the patient before you look at the number.

My patient regained the weight. Her A1c climbed. She lost eight months of momentum and a great deal of confidence, over a laboratory value that, by the manufacturer’s own labeling, has unknown clinical significance in the absence of symptoms.

She is back on therapy now, doing well.

But she should never have had to stop.

This article represents my clinical opinion, informed by current evidence, and is not personalized medical advice. Do not start, stop, or change any medication without your own physician. If you develop severe abdominal pain on a GLP-1 receptor agonist, seek medical attention.

If this was useful, share it — particularly with a physician colleague. The clinicians ordering these tests are being careful, not careless, and the fix is information rather than blame.

I write everything I know — cardiology, metabolic health, cancer screening, hormones, longevity, and the frontier research most people never hear about until it is standard of care — on this newsletter. Completely free. No paywall, nothing to sell you. Just a cardiologist writing what I would want my own family to know.

Subscribe: substack.com/@afshineemrani

Blessings.

Afshine Ash Emrani, M.D., F.A.C.C.
Assistant Clinical Professor, UCLA
David Geffen School of Medicine

Join Our new website

Castle-Connolly Nationwide Top Doctor (Since 2008)
Los Angeles Magazine Super Doctor (Since 2010)
LA Style Magazine Top 100 Doctors in America (2024)

Subscribe to mynewsletter: substack.com/@afshineemrani
Explore my books: Amazon Author Profile